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 CHAPTER I: INTRODUCTION  
Due to the great advances in recombinant DNA technology in the mid 1970s 
nowadays approximately 20 % of new drug applications involve a protein as active 
compound [1]. Unfortunately, proteins generally require parenteral administration for 
systemic delivery and the plasma half-lives of proteins are often very short, which is 
associated with frequent injections or administration via infusions. One way to 
overcome the related problems like poor patient compliance, increased occurrence of 
side effects, or cost consuming hospitalisation is the development of sustained 
release systems which should allow prolongated systemic or local delivery of the 
protein drug with the therapeutically desired dosing rate [2-3].  
For that purpose research has been focused on the embedding of peptides and 
proteins in microspheres, or solid or in-situ forming implant systems based on 
synthetic biodegradable polymers, mainly poly(D,L-lactic acid) (PLA) and poly(lactic-
co-glycolic acid) (PLGA). However, despite the early success of such systems for the 
delivery of small peptides no controlled release device for proteins is on the market. 
This limited success can be explained with the fragile, three-dimensional 
macromolecular protein structure rendering proteins susceptible to a variety of 
chemical and physical degradation pathways during the manufacturing, storage and 
release [2, 4]. In order to overcome this restriction lipid derived drug delivery systems 
have been proposed as an alternative [5-8]. Apart from matrix-like solid systems like 
lipid micro-particles and solid lipid implants liposomal drug carriers gained great 
interest offering the benefit of transporting the drug to certain target sites. However, 
especially traditional liposomes, such as unilamellar vesicles or multilamellar vesicles, 
often reveal an insufficient retention of the incorporated drug due to leakage of the 
phospholipid membrane. For instance, multilamellar liposomes loaded with 
granulocyte-macrophage colony stimulating factor (GM-GCSF) provided a sustained 
release of the cytokine over only 24 hours after subcutaneous administration [8]. 
Another potential problem might be that the generation of liposomes with a 
homogeneous size often comes along with low encapsulation efficiencies for 
hydrophilic drugs. Above these hurdles liposome processing methods often involve 
conditions that might induce protein denaturation and/or aggregation [5]. In order to 
prolong the release period very large (100µm), multivesicular liposomes or liposome 
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clusters have been proposed [9]. A further promising delivery concept, which has up 
to now not been evaluated for protein delivery, is the encapsulation of a 
macromolecular drug into vesicular phospholipid gels (VPGs). These gels display 
highly concentrated, semisolid, aqueous phospholipid dispersions, generated by a 
‘forced hydration’ of phospholipids in the presence of relatively low amounts of water. 
The inner structure of the obtained semisolid pastes can be described as a matrix of 
tightly packed phospholipid vesicles. Depending on the phospholipid content and the 
preparation method the size and the morphology of these vesicles varies from small 
and unilamellar to large multivesicular or multilamellar [10-11]. 
So far it has been shown in literature that VPGs can serve as sustained release 
systems for various low molecular weight drugs, especially in the field of anticancer 
treatment [11-12]. First important success was achieved by loading of VPGs with the 
small peptide hormone cetrorelix: in vitro release experiments showed a wide range 
of cetrorelix release periods, ranging from 24 hours to a predicted sustained release 
of over more than 3 months [13]. However, still it was unclear if VPGs might be 
suitable for the delivery of high molecular weight drugs. 
Compared to traditional liposomal formulations VPGs have been shown to facilitate a 
more sustained drug release and furthermore, difficulties associated with the low 
encapsulation efficiencies can be overcome, since even the fraction of drug which is 
not liposomally encapsulated during the preparation process is localized in-between 
the vesicles of the phospholipid matrix and thereby also retained in the gel. Moreover 
the manufacturing protocols are not only rather straightforward and easy to up-scale 
but also advantageous with regard to protein stability and safety as they avoid the 
usage of organic solvent. 
1. GENERAL CONSIDERATION ON PHARMACEUTICAL PROTEINS 
Peptides and proteins are polymers formed by amino acids’ joining with each other 
when the carboxyl group condenses with the amino group to eliminate water [14]. 
There are twenty natural amino acids to construct all physiological peptides and 
proteins. The distinction between proteins and peptides is normally defined by the 
number of amino acids and molecular weight. The proteins typically contain 50 or 
more amino acids resulting in a molecular weight above 5kD. For instance, Insulin 
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has a molecular weight of 5800, and is one of the smallest pharmaceutically relevant 
proteins available. Four levels of protein structure are principally described as the 
primary, secondary, tertiary, and the quaternary structures. Because proteins have 
higher numbers of amino acids within one molecule, only proteins can form the 
tertiary and quaternary structures, but not peptides.  
Proteins have a uniquely important place in therapeutics for various physiological 
purposes due to the high specificity. Advances in biotechnology have led to 
significantly increasing production of biologically active proteins. However, the 
number of pharmaceutical proteins that reached the market is still limited despite the 
continuing trend of proteins to act as therapeutic agent. One of the most challenging 
tasks in the formulation of proteins into pharmaceuticals is to ensure the protein 
stability. Physical and chemical instabilities of proteins are broadly classified as 
shown in Table I-1. In most cases, protein degradation involves more than one 
pathway of physical or chemical instabilities, which are tied to each other [14-16].  
Table I-1. Instability of proteins [14-16] 
 Physical Instability Chemical Instability 
Referred to Loss of secondary, tertiary, or quaternary 
structure 
Covalent modification of the protein via 
bond formation or cleavage 
Including 
Denaturation 
Aggregation 
Precipitation 
Adsorption to surfaces 
Hydrolysis 
Deamidation 
Oxidation 
Disulfide exchange 
B-elimination 
Racemization 
 
2. ADMINISTRATION ROUTES AND EXISTING PROBLEMS 
Proteins and peptides play a very important role in replacement therapy and are now 
well accepted for systemic treatment of certain diseases in medical practice. 
Parenteral injection is the most common route for proteins’ administration since the 
bioavailability of these therapeutic agents is poor when administered nonparenterally. 
Many other administration routes have been tried out, and various degrees of 
success have been achieved [14, 17]. 
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2.1. PARENTERAL DELIVERY 
The therapeutic peptide and protein drugs are mostly available for parenteral 
administration in the market [14]. However, frequent administration is normally 
required due to the often short half life for the delivery of peptides and proteins 
parentally. It results in poor patient compliance and high cost of the health care 
system.  Intravenous injection or infusion is preferred when the peptide or protein 
drugs show significant degradation at the subcutaneous or intramuscular injection 
site. Thus intravenous injection may allow a smaller dosage as the drug is not lost by 
proteolytic degradation. However, high peak drug concentration occurs after 
intravenous injection, which might lead to local or systemic side effects [14, 18-19]. 
The intramuscular and subcutaneous routes of drug injection are often used when 
drugs cannot be injected intravenously because of their low aqueous solubility and/or 
when the high peak concentration creates a problem. Compared with intravenous 
injection, intramuscular and subcutaneous routes have fewer problems associated 
with the compatibility of the injection components with full blood in the circulation. A 
relatively longer duration of action is permitted resulting in less frequent 
administration. In addition, the subcutaneous route are mostly preferred by patients 
due to the feasibility of self administration and consequently improved compliance. 
However, these administration routes are also more problematic in terms of 
immunogenicity and local irritation. Moreover, the drug release after subcutaneous 
injection or intramuscular is known to be affected by many variables (e.g. drug 
lipophilicity , drug solubility. initial drug concentration, injection depth, body 
movement, blood supply at the injection site) [18]. Thus non parenteral formulations 
have been widely investigated to address these problems.   
2.2. ORAL DELIVERY  
Oral delivery of therapeutic proteins is theoretically the most preferable 
administration route due to its accompanying advantages of patient comfort, ease of 
administration, decreased medical costs, and improved patient compliance, but has 
been a challenge for decades. The relatively large size and hydrophilic nature of 
proteins limit the absorption of these molecules in the gastrointestinal tract. The 
gastrointestinal tract is rich in proteolytic enzymes, which are designed by nature to 
digest dietary proteins as well as therapeutic proteins with the same efficiency. Thus, 
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the major barriers for oral delivery of therapeutic proteins include poor intrinsic 
permeability, luminal and cellular enzymatic degradation, rapid clearance, and 
chemical and conformational stability of proteins [20-21].  
Consequently, the bioavailability of therapeutic proteins by oral administration is poor. 
Conventional pharmaceutical approaches to address these barriers, which have 
been successful with traditional organic drug molecules, have not been effective for 
peptide and protein formulations. Meanwhile, various specific approaches are under 
investigation for oral delivery of proteins and peptides. 
The adsorption of proteins and peptides varies from different regions of the intestine. 
For example, the preferred adsorption site is the duodenum for cyclosporine, and the 
upper GI tract for octreotide [22-23]. Hence site specific delivery may offer a solution 
to improve the drug transport and absorption. The stomach has harsh conditions for 
protein drugs due to the acidic environment and enzymatic activity while the colon 
offers a high population of bacteria and largely anaerobic species. Enteric coating is 
typically exploited to avoid dissolution in stomach and to target the proteins and 
peptides to the colon [24-25].  Saffran [25] has coated peptide drugs with polymers 
cross-linked with azoaromatic groups to form an impervious film to protect orally 
administered drugs from digestion in the stomach and small intestine. 
Chemical modification is another approach to improve the oral absorption of proteins. 
In Milstei’s study [26], low molecular weight compounds have been attached to 
protein molecules to form a conjugated molecule. The interaction of these carrier 
molecules with the proteins reversibly destabilizes the native state of the molecule 
favouring a partially unfolded conformation. These intermediate protein 
conformations are transport competent and are able to be absorbed through the 
intestinal tissue and into the bloodstream. However, this approach is generally more 
suitable for peptides than for proteins due to the structural complexity of proteins. 
Protease inhibitors can reduce the proteolytic breakdown of therapeutic proteins in 
the GI tract, and may consequently promote oral adsorption [14, 27]. For example, 
the pancreatic trypsin inhibitor protected insulin in the intestine of rats. Some 
inhibitors that inhibit insulin-degrading enzymes, including N-ethylmaleimide, 1, 10-
phenanthroline and pchloromercuribenzoate dramatically improved insulin transport 
across the ileum. The drawbacks of inhibiting agents, such as the risk of toxic side 
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effect, might be eliminated with advanced drug delivery systems. The introduction of 
delivery system containing mucoadhesive polymers with immobilized protease 
inhibitor, which provides associative binding contact with the mucosa, reduced drug 
degradation between the delivery system and the absorbing membrane [28]. 
The use of carrier systems such as nano-particles, microspheres and liposomes can 
also offer promising approaches to enhance protein oral delivery. Normally a 
combination of two or more approaches is required with the goal to improve the oral 
bioavailability of therapeutic proteins from less than 1% to 10% or higher. Kimura [29] 
has reported a formulation with insulin and protease inhibitor encapsulated in 
polymeric hydrogel spheres. In this case, insulin and inhibitor are released from the 
gel and provide a significant and prolonged reduction of blood glucose level.  
2.3. ALTERNATIVE ROUTES 
Because of the shortcomings of the parenteral and oral dosage forms, alternatively 
delivery routes are under active investigations.  
The transdermal route of delivery is particularly attractive because it avoids protein 
degradation via the gastrointestinal tract and the hepatic first-pass effect, and the 
delivery can be interrupted by simply removing the device. However, the major 
problem is the low permeability of proteins across the skin which is an excellent 
barrier to hydrophilic, polar macromolecules [30]. The use of ultrasound energy can 
be applied to enhance the systemic delivery of protein molecules. In addition, other 
promising enhancement techniques have been developed, such as that applying 
micro-needles and jet propulsion can bypass the stratum corneum barrier to permit 
direct access to the viable epidermis [14]. For the topical delivery, growth factors 
have been applied for post surgery wounds showing accelerated healing effect [31]. 
Moreover, application of delivery systems, such as hydrogels [32]and liposomes [33] 
are tried to enhance the topical delivery of proteins.  
The use of the pulmonary route may soon become one of the most promising routes 
for local and systemic delivery of therapeutic proteins. For non-invasive delivery of 
biologics, it was discovered that the large highly absorptive surface area of the lung 
could be used for local and systemic delivery of proteins such as insulin. Promising 
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results with an absolute bioavailability > 56% were achieved for alpha-Interferon by 
the pulmonary route [34].  
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) has been 
prepared in powder formulations for inhalation [35]. The protein retained in vitro and 
in vivo bioactivity using rabbits as animal model. The market product Exubera® was 
developed for inhalation of insulin. Moreover, liposomes and microspheres have 
been widely investigated as the pulmonary delivery carrier for the controlled release 
of drugs to the lung. However, the major problem is that the lungs are capable of 
metabolizing proteins, of which the metabolic pathways may be different from those 
observed in the intestine. Thus, case-by -case investigations might be necessary to 
test the feasibility of the pulmonary administration.  
In addition, other mucosal routes such as vaginal administration have been 
investigated for therapeutic proteins. Systemic delivery of insulin across the vaginal 
mucosa was studied in ovariectomized rats given subsequent estrogen treatment. 
Enhancers were necessary to achieve decreased blood glucose levels. However, 
variable and often severe histological changes were observed in the vaginal 
epithelium after treatment with the enhancer systems [36]. 
2.4. CONTROLLED DRUG DELIVERY SYSTEM 
There are many challenges to develop an efficient controlled-release drug delivery 
system. Normally a high drug loading efficiency is desired and the delivery system 
should have the feasibility in drug release at various rates to meet different treatment 
schedules. Moreover, the formulation components should meet some basic biological, 
physical, and technological requirements as summarized in Table I-2 [37]. 
Table I-2. Optimal features of materials for protein delivery   
Biological properties Physical properties Technological properties 
Non-cytotoxic Injectable scalable 
Non-immunogenic Mechanical strength Easy production or purification 
Non-infectious Suitable Viscosity Retaining full protein stability 
Biodegradable with non-toxic products Suitable Elasticity  
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Besides, for the therapeutic proteins, retention of biological activity is a big issue 
since the proteins are susceptible to proteolysis, chemical modification, and 
denaturation during formulation production, storage, administration, and release [38].  
The research on synthetic biodegradable polymer systems such as poly(D,L-lactide) 
(PLA), and Poly(Lactic-co-glycolic acid) has gained first interests for sustained 
release formulations for therapeutic proteins [39].  However, limited success was 
achieved due to the inherent drawbacks of the polymeric systems. Protein instability 
occurs in the manufacturing process, as well as during the release and storage [4, 
40]. Alternatively, hydrogels have been investigated for protein delivery, which exhibit 
more hydrophilic property and appear more suitable for proteins than the other 
polymeric system.  
Recently, more interests were raised in the biocompatible natural materials (e.g. 
lipids [41]) as alternative to synthetic polymers. Lipids such as triglycerides and 
monoglycerides can be formulated into implants simply by compressing or extrusion. 
Importantly beside the good biocompatibility and easy manufacture process, lipid 
implants cause less detrimental effect on the incorporated proteins [42-43].  
Besides the traditional use of liposomes as drug carriers which circulate in the blood 
stream upon intravesicular administration, some attempts have been made to 
establish liposome-based local depots for sustained drug delivery. One of these 
novel liposome based systems is the multivesicular vesicles which have a bi-liquid 
foam structure with a large particle size ranging from 1–100μm [44].  Multivesicular 
liposomes can be administered by subcutaneous, intramuscular, intra-tumoral or into 
cavities injection for sustained delivery of proteins and anticancer agents [45-49].  
Moreover, vesicular phospholipid gels consisting of phospholipid vesicles were 
introduced as an intermediate to enhance the storage stability of liposomes. First 
investigation on small compounds and peptides showed its potential application as a 
depot for the controlled delivery over a prolonged period [50-51].  
3. POLYMERIC SYSTEM 
The desirable characteristic of polymer systems for drug delivery are: minimal effect 
on biological systems after introduction into the body, in vivo degradability at a well-
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defined rate to nontoxic and readily excreted degradation products, absence of toxic 
impurities or residual chemicals e.g. cross-linking agents. Synthetic and naturally 
occurring polymer based systems have been developed in various forms, including 
nano-particles, micro-particles, films, and matrix devices, etc [52-53].   
3.1. POLY (LACTIC-CO-GLYCOLIC ACID) SYSTEM 
A frequently investigated polymeric system for controlled release is based on 
poly(lactic-co-glycolic acid) (PLGA) especially in the form of injectable micro-particles. 
PLGA is a linear polyester that hydrolyzes by an acid or base catalyzed reaction to 
form the natural metabolites, glycolic and lactic acids [54-55]. Thus these polymeric 
systems are biocompatible, biodegradable, and considered safe. Until now, liquid 
drug-polymer formulations generating (semi-) solid micro-particles (in situ forming 
micro-partices, ISM) on subcutaneous or intramuscular injection have grown 
exponentially. There were some market products developed with these PLGA 
systems, e.g. Nutropin Depot® developed by Genetech and Alkermes jointly as once 
or twice a month injection formulation by loading recombinant human growth 
hormone (hGH) into PLGA micro-particles.  
The capability of the system in releasing therapeutically useful proteins in a 
controlled manner have been widely investigated [38, 55-56]. However, protein 
instability during preparation, storage and release resulting in incomplete release of 
native protein has become recognized as a major problem [4, 57-58]. 
In most cases organic solvents have to be utilized to prepare the polymeric system. 
Protein was loaded either by emulsifying an aqueous protein solution with the organic 
polymer phase or suspending the solid protein powder in the organic polymer phase. 
Denaturizing stresses were associated with this emulsion and the suspension loading 
[57, 59-60]. Moreover, the incorporated proteins are faced to a completely altered 
microenvironment [4, 58, 61] inside the matrix during degradation. The generated 
degradation products are accumulatively entrapped within the matrices and might 
consequently result in a low pH [62], an increased osmotic pressure [63], and 
accumulation of reactive species [64]. As a result, the structural integrity of the 
protein to be delivered can be adversely affected.  
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The use of various stabilization approaches has rendered some success in 
increasing protein stability, but, still, full preservation of the native protein structure 
remains a major challenge in the formulation of protein-loaded PLGA micro-particles 
[3, 65-70]. Moreover, individual proteins exhibit unfortunately large differences in 
sensitivity to stress factors. For a rational optimization of protein stability, one must 
first establish the stage at which degradation occurs and identify the stress factors 
compromising the stability of the particular protein. Then, a rational stabilization 
approach can be followed to ensure the safety and efficacy of these protein-loaded 
PLGA micro-particles [4].  
3.2. HYDROGEL 
As an alternative to the PLGA systems hydrogels were developed for protein delivery. 
Hydrogels are defined as cross-linked polymer matrices that exhibit the ability to 
swell in water without dissolving and to retain a large amount of water within its three-
dimensional structure. Hydrogels have been proposed for local, sustained delivery of 
proteins and other biological pharmaceuticals because of their soft tissue 
biocompatibility, the ease with drug loading and the high degree of feasibility 
achieved by selecting the physical and chemical properties of the polymer network 
[71]. Moreover, the cross-linked polymeric networks can also protect proteins from 
the potentially harsh environment in the vicinity of the release site, such as the acidic 
environment of the stomach [38, 71-73].   
Hydrogels are formulated by chemical cross-linking or physical cross-linking. 
Chemical linking results in a high mechanical strength of gels, while the incorporated 
drug or protein might be affected by the chemical reactions or by the cross-linking 
agents and loses the bioactivity consequently. Thus physical cross-linking gained 
more and more interests, which can be established by e.g. ionic, hydrophobic, or 
coiled-coil interactions [74]. 
A variety of synthetic or natural polymeric hydrogels (e.g. collagen) have been 
employed as the controlled release systems for drug delivery [72, 75-76]. Among the 
wide investigations, in situ forming hydrogels gained considerable interests. The in-
situ cross-linking mechanisms render the system injectable and so that an invasive 
surgical placement can be avoided [77-78]. An aqueous mixture of gel precursors 
and bioactive agents were administered using a syringe into bodies. Cross-linking of 
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the gel precursors can happen either induced by the change in temperature or pH, or 
chemically by Michael type addition reaction or disulfide bond formation in the body 
environment [74, 79]. A temperature-sensitive and in-situ forming hydrogel system 
was developed by Chung [80-81] for the delivery of human growth hormone (hGH). A 
sustained release in a zero-order fashion was observed for 13 days controlled by a 
diffusion/erosion coupled mechanism.  
However, the major drawback of the system is the slow gelation which is caused by 
the time lag between injection of a liquid mixture of gel precursors and protein drugs 
and the formation of a cross-linked gel network[38]. Thus, rapid initial burst and drug 
overdose were observed since a large amount of drugs diffuse away from the 
injection site after injection and before the hydrogels formed. Hence, injectable 
hydrogel systems were developed with a tunable gelation rate to achieve better 
therapeutic output [74, 82]. Delgado [82] has prepared a N,N-dimethylacrylamide-
based hydrogels for the controlled release of bioactive agents including lysozyme, 
bovine serum albumin, and rabbit IgG. The rate of protein release showed a 
dependence on both the molecular weight of the protein and the amount of cross-
linker utilized to prepare the hydrogels. Neither the toxicity against human dermal 
fibroblasts nor the immunogenicity in mice was observed for the hydrogels. 
4. LIPIDIC SYSTEMS 
Lipids are referred to a group of naturally-occurring molecules which includes fats, 
waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E and K), as well as 
mono-glycerides, triglycerides, phospholipids. Lipids may be broadly defined as 
hydrophobic or amphiphilic small molecules; the amphiphilic nature of some lipids 
allows them to form structures such as liposomes, or membranes in an aqueous 
environment [83].   
Bangham [84] was probably the first to recognize the potential of the lipid shells for 
delivering soluble materials for extended periods. In the past few decades, research 
into conventional liposomes with unilamellar and multilamellar vesicles played a 
major role in the area of injectable drug delivery systems.  Significant efforts in basic 
and applied research institutions led to the clinical development and ultimate 
approval by regulatory agencies for human use of a lipid complex (AbelcetTM, 
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AmphotecTM) and three liposome formulations, AmbiSomeTM, DaunoXomeTM and a 
Stealth liposome DOXILTM [85-86]. These products have been developed for 
intravascular administration. The advantages conferred by the lipid complex, 
liposome and stealth liposome technologies include enhancement of circulation times, 
and reduced toxicity by lipid encapsulation. For protein delivery, incorporation of IL-2 
into liposomes seemed to prolong of the local (intra-and/or peritumoral) residence 
time of the cytokine and thereby to improve the antitumor effects [87-88]. However, 
an insufficient retention of the incorporated drug was often observed due to a 
leakage of the phospholipid membrane.  
                               
Figure I-1. Structures of some common lipids. 
In order to address the issue, the most novel lipidic systems for protein delivery, e.g. 
lipid implants, multivesicular liposomes, vesicular phospholipid gels, will be discussed 
in detail below.  
4.1. LIPID IMPLANTS  
Lipophilic materials including cholesterols [89] as well as fatty acids, glycerides, and 
waxes can be used to form lipidic implant systems. In contrast to polymeric implants, 
the high compressibility of lipids allows the formation of solid matrices by traditional 
compression at mild conditions. Different techniques can be applied to generate the 
lipid protein blend: the protein in the solid form can be physically mixed with either 
the lipid powder or with the precipitated lipid powder, or alternatively the protein can 
be co-precipitated with the lipid powder [41, 90-96]. 
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In the working group of Winter et al, many successes has been achieved on the 
study of this novel model depot system for the controlled release of proteins.  
A promising platform for the delivery of rh-interferon-2α based on tristearin implants 
was developed by Mohl [90, 92, 97].  Polyethylene glycol 6000 was incorporated into 
the implants as release modifier. Varying amounts of polyethylene glycol 6000 and 
tristearin were mixed with the lyophilized protein and subsequently compressed to 
form the implants. Over 90% of the entrapped protein was released from the implants 
for over 1 month in virtually monomeric form in vitro. The implants using the 
preparation technique maintained the protein integrity both in the formation process, 
and in the release tests. The addition of hydroxypropyl-β-cyclodextrin (HP-β-CD) was 
applied to stabilize the protein and improve the storage stability of the matrix.  
Herrmann [98-101] has further investigated the role of PEG on the protein release 
from the implants. Implants containing 5-20% PEG showed significantly changed 
release profiles of the entrapped protein. The underlying mass transport mechanisms 
were investigated by monitoring the release of IFN-α, HP-β-CD and PEG into 
phosphate buffer pH 7.4 simultaneously and fitting the results to Fick's second law of 
diffusion.  It was suggested that the release of IFN-α from PEG-free implants was 
purely diffusion controlled while in contrast the reduced protein solubility and a 
reversible IFN-a precipitation during release in PEG-containing matrices were shown 
to control the protein release.  
The in vivo release of the IFN-α implant was performed by Schwab [102] using 
rabbits as the animal model. Protein serum concentrations with the therapeutically 
relevant level maintained nearly constant for 9 days after implantation. However, the 
serum protein level abruptly weared off from the tenth day. It was assumed that IFN-
α was continuously released from the implant after 9 days but the released protein in 
the serum was quantitatively captured by the rabbit antibodies. Good biocompatibility 
and little matrix erosion were observed for the implants. Moreover, a close in vivo–in 
vitro release correlation was revealed by computer modelling in the work.  
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4.2. MULTIVESICULAR LIPOSOMES 
Multivesicular liposomes (MVLs, Trade name DepoFoamTM) are spherical lipid 
vesicles with a size range of several micrometers. The particles are composed of 
multiple non-concentric aqueous chambers bound by a network of lipid bi-layers 
which appears like foam under microscopic examination (Figure 4) [103]. Compared 
with conventional liposomes, the unique structure of MVLs renders a higher aqueous 
volume-to-lipid ratio, which facilitates loading of water-soluble drugs and improves 
their encapsulation. The active ingredient is encapsulated within the non-concentric 
internal aqueous chambers so that a single breach in the external membrane will not 
result in a total release of the internal aqueous content. Moreover, MVLs are not 
rapidly cleared by tissue macrophages due to their large size [104-109]. 
MVLs can be applied as a drug depot, which has efficient entrapment of hydrophilic 
molecules including a variety of therapeutic proteins, providing slow release of drugs 
delivered through different routes of administration. Further, these particles are more 
stable than conventional liposomes due to the higher mechanical strength of the 
unique structure [103, 110-111].    
                
 
Figure  I-2. Microscopy images of Multivesicular Liposomes [103, 110-111]   
4.2.1. PREPARATION METHOD 
In order to prepare MVLs, one neutral lipid (e.g. triglyceride) and at least one usual 
membrane forming lipids (e.g. phospholipids) must be included in the lipid 
compositions. When the neutral lipid is omitted, conventional multilamellar vesicles or 
unilamellar vesicles are formed instead of multivesicular liposomes [46]. The neutral 
lipid acts as hydrophobic space filler at bilayer intersection points and stabilizes these 
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junctions, and is also present as oil droplets dispersed in the encapsulated aqueous 
compartments.  
Kim [44, 103, 112] has evaluated the influence of triolein and other lipid compositions 
on the capture volume and drug encapsulation efficiency of MVLs. In a mixture with 
phosphatidylcholine, cardiolipin and cholesterol (4.5:1:4.5 in mole ratio) maximal 
capture volume and encapsulation efficiency are obtained in the triolein mole fraction 
range of 0.01–0.08. At lower triolein content the capture efficiency is reduced 
markedly. 
A two step emulsification process is critical to form MVLs whereas other types of 
smaller liposomes rather than MVLs are formed if other methods are used even with 
the same required mixtures of phospholipids and triglycerides The first step is making 
a ‘‘water-in-oil’’ emulsion: the lipids in one or more volatile organic solvents are 
emulsified with drug containing water phase under input of high mechanical energy. 
This emulsion is then mixed with a second immiscible aqueous component at less 
mechanical energy so that a water-in-oil-in-water (w/o/w) double emulsion is formed. 
The organic solvent is removed generally by evaporation, by reduced pressure or by 
passing a stream of gas over or through the suspension. Cross filtration is used to 
remove the un-entrapped drugs. The characteristics of prepared MVLs, such as 
particle size, viscosity, and conductivity are affected by many factors including mixing 
speed, mixing time, energy input, and temperature in the double emulsification 
process [46, 103, 113]. However, the preparations can not undergo terminal 
sterilisation and are too big for filtration through microbe-retentive filters. Therefore a 
GMP-conform process for commercial scale production was established with aseptic 
processing techniques containing a set of four sequential unit operations namely first 
emulsion, second emulsion, solvent extraction, and microfiltration [46]. 
4.2.2. INFLUENCE FACTORS ON THE RELEASE   
The release rate of the biologically active compound from MVLs can be modified by 
utilizing a suitable neutral lipid component (triglycerides) in the preparation. Slower 
release rates are observed by incorporating long chain triglycerides in MVLs. 
Triglycerides having mono-unsaturated fatty acids containing about 14–18 carbons in 
the acyl chain and those with saturated fatty acid ester moieties containing about 10–
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12 carbons in the acyl chain generally lead to slow release, among which triolein or 
tripalmitolein are mostly utilized. The neutral lipids inducing fast release are selected 
from triglycerides having saturated fatty acid ester moieties containing from about 6 
to 8 carbons in the acyl chain with a molecular weight from about 387 to 471. 
Tricaprylin, and mixtures of tricaprylin and tricaproin, or mixed chain C6 to C8 
triglycerides are most preferred. However, the use of neutral lipids with less than 6 
carbons (e.g. tricaproin) in the acyl chain results in a rapid release of the 
encapsulated compound. The reason is assumed that the stabilizing effect on the 
structure of the particle by longer chain length is then missing. In mixtures, the 
concentration of the shorter versus longer chain triglycerides determines the release 
rate [111, 114-115]. 
The osmolarity of the aqueous phase containing the drug that is mixed with the 
immiscible solvent phase containing lipids is an important determinant of in vivo rates 
of release. The rate of release of the active substance into the surrounding in vivo 
environment can be decreased by increasing osmolarity of this solution. The decay 
half-life of the amount of cytarabine MVLs containing higher amount of cytarabin 
showed slower in vivo release rate than those containing lower content. Since the 
concentration gradient of drug between the inside of the particle and the peritoneal 
fluid for MVLs containing more drug is greater than those containing less,  it is 
assumed that increased osmolarity of the drug containing aqueous solution (first 
aqueous solution) decreases the in vivo release rate of the active compound from 
MVLs [116]. Thus the in vivo release is suggested to be dominated by mechanisms 
other than simple diffusion [111]. 
 Acids in the first aqueous solution are shown to have profound effect on the in vivo 
release rates. The half-life of cytarabine MVLs ranged from for 1.6 to 37.2 h 
depending on the acid added to a solution of cytarabine at a constant concentration, 
which consequently suggests the permeation of the salt complex is an important 
determinant of drug release in vivo [114]. 
It was suggested that the overall release mechanism of MVLs is composed of at least 
three components namely, diffusion, erosion and attrition [117-118]. For the diffusion 
component, particle number (measured by hemocytometry) remains constant but the 
amount of drug retained within the MVL particles decreases over time. Particle size 
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remains essentially constant, except when the particles act as osmometers sensing 
the loss of solute. For the erosion component, both particle concentration and 
internal drug concentration remain constant while particle size decreases. When the 
attrition part of the mechanism is operative, particle concentration decreases while 
internal drug concentration and size remain constant. 
4.2.3. MVLS FOR  CONTROLLED DRUG DELIVERY 
Several hydrophilic molecules including a variety of therapeutic peptides and proteins 
have been efficiently entrapped in MVLs which offers a novel approach to sustained-
release drug delivery [107, 119-121]. MVLs formulations can be administrated 
through injection into body cavities including intrathecal, epidural, intraperitoneal, 
subcutaneous, intramuscular but due to the particle size of up to 5μm, MVLs are not 
suited for intravascular injection [122-123]. 
The MVLs’ particles are retained at the injection site and thus serve as a depot 
releasing the entrapped drug in a sustained manner over several days to weeks after 
non-vascular administration while drugs entrapped in conventional small liposomes 
normally last several hours to a few days after intravascular administration.  
4.2.3.1. APPLICATION FOR SMALL COMPOUNDS 
TOLIYAT [108] has reported MVLs for the delivery of desferrioxamine which is 
normally administered by the parenteral routes due to the poor absorption efficiency 
in the gastrointestinal tract. The results showed not only triolein in the lipid containing 
organic phase but also lysine in the second aqueous solution played significant 
effects on the captured volumes of the vesicles whereas cholesterol content in lipids 
has no significant effect. The effective concentration range for triolein is between 1.7 
to 3.4 mg/ml and for lysine is is between 20 and 40mM. Large MVLs particles were 
obtained with a size between 15-35μm and a capture volume of about 27%. The in 
vitro studies in 0.9% NaCl at 37 ºC showed that 57% of desferrioxamine has released 
from MVLs in 9 days without a rapid initial burst.  
Cisplatin [cis-dichlorodiamine platinum (II)] is one of the most effective antitumor 
agents in the treatment of testicular, ovarian, head and neck, and lung cancer. Due to 
the hydrophobic property, the loading efficiency of cisplatin was limited for 
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conventional liposomes (with unilamellar or multilamellar vesicle structure) and the 
pegylated liposomes [124-125].  Xiao [126] has investigated the cisplatin entrapped 
MVLs. The drug loading capacity of MVLs was improved to 0.148–0.444 mg per mg 
of lipid in contrast a drug to lipid ratio of 0.014 for pegylated liposomes. In vitro 
release of MVLs encapsulated cisplatin was over 7 days. The encapsulated drug 
showed much higher drug concentration in plasma as well as at the tumour site 
compared with unencapsulated drug after subcutaneous injection into mice 
inoculated with the murine carcinoma 180 (S180) tumour. Moreover, a longer 
circulation time was observed resulting in higher therapeutic efficiency to decrease 
tumor growth for MVLs cisplatin than uncapsulated cisplatin solution. 
US FDA has approved two MVL formulations for clinical use. DepoCytTM is the first 
clinically available MVL formulation, which contains the antineoplastic agent 
cytarabine for the treatment of malignant lymphomatous meningitis via intrathecal 
injection. MVLs encapsulated cytarabine is released in a sustained manner with 
cytotoxic concentrations in cerebrospinal fluid over 2 weeks after intrathecal injection. 
DepoCytTM has good tolerability from the early efficiency data.The use of MVLs 
encapsulated cytarabine was expected to reduce the dosing frequency from twice a 
week to once every other week and improves the outcome compared with frequent 
intrathecal injections of unencapsulated cytarabine [127-129] . 
DepoDurTM is a morphine loaded MVL formulation and it has heen approved for its 
single epidural injection in the treatment of postoperative pain. Animal experiments 
have confirmed the saftty, efficiency of encapsulated morphine after epidural 
administration. The half time in plasma and CSF were prolonged by different factors 
when administrating encapsulated morphine. However, no clinical studies suggest 
that the use of DepoDurTM decreases the amount of systemically administered 
analgesics needed for adequate postoperative pain control in humans. Due to the 
sustained release fashion of MVLs, it may provide superior pain control during the 
first 1-2 postoperative days compared with epidural administration of unencapsulated 
morphine or intravenous administration of an opioid.  However, three to four times 
lower peak plasma concentrations were observed for the encapsulated morphine 
compared with administrating the same dose of unencapsulated drug. Moreover, 
some safety concerns remain because it is impossible to predict how long patients 
may be at risk of experiencing serious adverse effects [130-132]. 
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4.2.3.2. APPLICATION FOR PEPTIDES AND PROTEINS 
The versatility of the MVLs technique has also been demonstrated using peptide and 
protein drugs [49, 107, 110, 121, 133]. In general, as a sustained-release formulation 
of therapeutic proteins and peptides, MVLs have many advantages including high 
drug loading efficiency, low content of free drug in the suspension, little chemical 
change in the drug caused by the formulation process, narrow particle size 
distribution, and spherical particle morphology. Drug release assays of various 
protein loaded MVLs have been conducted in vitro in biological media such as 
human plasma. The results indicate that these formulations provide sustained 
release of encapsulated drug over a period from a few days to several weeks, and 
that the rate of release can be modulated. In vivo pharmacodynamic studies in rats 
also showed a sustained therapeutic effect over a prolonged period.  
Progenipoietin is a dual receptor agonist of fetal liver tyrosine kinase-3 and 
granulocyte colony-stimulating factor receptors. The novel chimeric protein was 
entrapped into MVLs to develop a sustained delivery formulation. Various 
phospholipid blends containing DOPC, DEPC, and DPPG and two kinds of 
triglcerides including triolein and tricaprylin have been used to modulate the delivery 
profile. Examined by RP-HPLC, the encapsulated protein remained intact in the 
MVLs formulation. Pharmacodynamic studies were performed in rats using 
subcutaneous injection with a single dose of 1mg/kg (either the free protein or the 
MVLs entrapped protein). The same dose of progenipoietin doubled the count of 
neutrophil granulocytes in peripheral blood for 9 days after administering 
encapsulated drug, while the count was back to baseline within 3 days of injecting 
unencapsulated drug. Encapsulation of progenipoietin in MVLs led to retention of its 
structural integrity and maintenance of its biological activity in vivo over several days. 
Thus, a single dose of MVLs encapsulated progenipoietin was expected to improve 
hematopoietic recovery time after chemotherapy, and for other indications that 
require multiple daily doses of progenipoietin [134]. 
Langston [114, 135] has examined the efficiency of entrapped myelopoietins, a 
therapeutic grow factor, after subcutaneous injection in rats. A single injection of 
MVLs encapsulated myelopoietins results in elevated neutrophil counts for 10 days, 
which is a 5-fold increase in contrast to only 2 days for un-encapsulated drugs. The 
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duration of the pharmacodynamic effect of encapsulated drug can be modulated by 
varying the triglyceride (tricaprylin) content of the matrix from 10 days to 4 days, 
which offers the flexibility for controlled delivery of cytokine therapeutics. No increase 
in the extent of deamidation was observed during encapsulation and in vivo release.  
A sustained release MVLs formulation of interferon (IFNα-2b) for subcutaneous 
administration was developed by Qiu [136]. Encapsulation efficiency of interferon 
was enhanced to about 60% by optimizing the protein-lipid ratio. Both the SDS-
PAGE and HPLC analyses showed that the proteins were chemically intact. ELISA 
was performed and showed that the antibody binding affinity for the protein after 
encapsulation was only slightly reduced, indicating that substantial native structure 
remained after preparation. There was considerable protein detected in the 
circulation for more than 5 days using rats as animal models. The serum half-life was 
estimated to be approximately 30 h. Moreover, the in vivo release profile could be 
modified by varying the size of the MVL preparations. By the work of Bonetti [137],  a 
linear release of encapsulated interferon was observed with a half-life time of 384hrs 
in human plasma.  
In Katre’s [107] work, Insulin-like Growth Factor I was entrapped into MVLs to 
achieve sustained therapeutic blood levels which would replace repeated 
administration. IGF-I was encapsulated in this system with good efficiency. The 
median size of MVLs particles ranged from 18 to 20µm.  The integrity of the 
encapsulated protein was maintained, as characterized by physiochemical (HPLC, 
SDS-PAGE) and by biological methods (mitogenic activity). The in vitro studies in 
human plasma at 37 °C showed that the MVLs released 70-80% of the entrapped 
protein in 6-7 days without initial burst. In a pharmacokinetic in vivo study, after 
subcutaneous injections in rats, IGF-I levels were sustained for 5-7 days with 
entrapped protein formulation, whereas the free IGF-I was cleared in 1 day. 
Importantly, the full biological activity of the entrapped protein was maintained over at 
least 5 days at 37 °C, both for the protein released from the MVLs particles and for 
the drug retained in the particles. The protein in the MVLs and the lipid vesicle itself 
are assumed to have long-term shelf life stability at 4 °C for at least 12 months. 
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As a summary, MVL system was shown to be capable of efficiently encapsulating 
therapeutic proteins and peptides and effectively providing controlled delivery of 
these biologically active macromolecules.  
4.3. VESICULAR PHOSPHOLIPID GELS  
Vesicular phospholipid gels were first described as highly concentrated lipid 
dispersions, which normally consisted of 300mg/g-600m/g lipids [11, 138-140]. VPGs 
have a gel-like consistency formed by numerous densely packed vesicles. The 
aqueous compartments are both within the cores and in-between the vesicles so that 
the system is suitable for entrapping hydrophilic compounds including peptides and 
proteins. The gels are formulated by high-pressure homogenisation or dual 
asymmetric centrifugation. First investigations have shown that small water soluble 
compounds could be retained by vesicular phospholipid gels over extended periods 
of hours up to several weeks within an in-vitro set-up. 
4.3.1. PREPARATION METHODS 
4.3.1.1. HIGH PRESSURE HOMOGENIZATION 
High pressure homogenization is basically used for preparing VPGs of small and 
unique vesicle sizes. The preparation approach is based on the one-step technique 
as originally described by Brandl, in which no organic solvent is involved [139, 141]. 
Briefly, dry lipids are mixed with water or buffer with gentle shaking. After a period of 
swelling, the raw lipid dispersions were processed with a high-pressure homogenizer.  
The device APV micro lab 40 can be normally used for lab scale production (with a 
batch size of 40ml).   
A pressure of 70MPa with 10 processing times is usually appropriate to obtain finely 
dispersed gels which are available for spontaneous hydration (dispersion) leading to 
the formation of small liposome in the size range below 100nm. 
The size distribution of the liposomes depends on the applied pressure, the number 
of homogenisation cycles, as well as the lipid type and content. Adding of cholesterol 
results in a slightly increased vesicle size of redispersed VPGs [123, 142-144].  
4.3.1.2. DUAL ASYMMETRIC CENTRIFUGE 
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Dual asymmetric centrifugation has been known as a convenient technology for the 
rapid mixing of viscous components [145-146]. For example, by application of the 
mixer nano-CaCO3 can disperse uniformly in polymer-composites (nano-CaCO3 is 
dispersed as filler between the polymers. By adding a lower content of the fillers, the 
mechanical properties of the composites can be improved significantly) [145-146]. 
The working principle of this special centrifugation technique is that the sample is not 
only rotated around a central axis but also around a second axis in the centre of the 
sample container as shown in Figure I-3. The main rotation arm of the DAC forms an 
angle of about 40° with the rotation plane. At this angle, the rotating arm forces the 
content of the vial into the corner between the bottom and the vial wall [147]. The vial 
holder rotates in the opposite direction with approximately one fourth of the rotating 
arm's frequency. The combination of these two contra-rotating movements makes 
efficient homogenization of viscous materials possible [148-149].   
 
Figure I-3. Schematic drawing of the dual asymmetric centrifuge, SpeedMixerTM DAC 150 FVZ, 
Hauschild GmbH & Co KG, Hamm, Germany  [147].   
DAC was recently applied for production of Vesicular phospholipid gels, which have 
previously been formulated by phospholipid/water blends using high pressure 
homogenizer. In contrast to the preparation technique with high pressure 
homogenizer, DAC is a fast, easy and straight forward method without specific need 
of know-how. Moreover, a small scale production for lab scale study is feasible using 
DAC, which directly lowers the cost. In addition, aseptic production is easily achieved 
with the method using a hermetically sealed sample vial.  
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In Massing’s [147] study, the lipid blends consisting of hydrogenated egg 
phosphatidylcholine and cholesterol of a ratio of 55:45 (mole/mole) was 
homogenized with aqueous solution (Batch size: 0.25g-3.7g) by DAC (150 FVZ, 
Hauschild GmbH & Co KG, Hamm, Germany) using brown injection vials as sample 
container. In their study, glass beads or stainless steel beads were added to the 
sample mixture as homogenizing aid.  Multiples of 5 min-runs were performed until 
the desired mixing time was reached.  After production, the VPGs were redispersed 
with a double volume of 0.9% sodium chloride solution to produce a liposome 
dispersion. The liposome size was used to evaluate the process parameters. When 
the lipid concentration in the blends varied from 350mg/g to 450mg/g, the liposome 
size did not significantly differ while an even higher lipid concentration of 500 mg/g 
led to a slightly higher mean liposome size and variability. Both the duration of DAC-
homogenization and DAC-speed had influence on the size and the size distribution. 
A mixing period over 30 minutes at the speed of 3540 rpm was found necessary to 
obtain smallest liposomes and the lowest variability in mean size. Comparably small 
particles can be obtained from VPGs produced by High pressure homogenizer within 
a much shorter processing period. This contrast offered the hint that DAC generated 
a gentler shear force compared to High pressure homogenizer, which might be more 
applicable for entrapping sensitive compounds, e.g. proteins.  Adding glass beads or 
stainless steel beads, regardless of the amount and size, all seemed to improve the 
mixing efficiency resulting in smaller liposome sizes (less than 100nm) and more 
homogenous distributions. Without adding the beads, the particle size was in the 
range from about 110nm to160nm. Moreover, the influence of the batch size (from 
0.25g to 4g) was also evaluated and no significant influence on the liposome sizes 
was found.  Hence, they have concluded an optimized process (Table. I-3) to prepare 
small liposomes (around 60nm) in a highly reproducible manner. However, a broad 
particle distribution was observed for VPG’ dispersions prepared by DAC which was 
the same situation with those prepared by High pressure homogenizer. The trapping 
efficiency of the model compound calcein was higher in the case of VPGs prepared 
by DAC compared with HPH.  
Table. I-3 Optimized parameters for VPGs’ production with DAC process[147] 
Lipid contwnt Batch size Duration of DAC DAC-speed Homogenizing aid 
400 mg/g 0.5 g 30 min or longer
3540 rpm 
(maximum) 
 
glass beads 1 mm, amount: 100% 
(equal amount as compared to 
batch amount) 
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As mentioned above, VPGs can been utilized as storage-stable intermediates for 
liposomes, as well as semisolid depot formulations for sustained release of 
entrapped drugs [143]. For the former purpose of developing a VPGs based 
liposomal formulation, DAC was fully demonstrated as a suitable method beside high 
pressure homogenizer for production of small liposomes which are applicable for 
parenteral administration. Moreover, autoclaving is no longer necessary since using 
hermetically sealed sample vial in addition with inert gas can easily provide a sterile 
production environment for entrapping sensitive compounds e.g. proteins in VPGs. 
The lysophosphatidylcholine generated in the sterile process conditions of DAC was 
lower compared with the process of High pressure homogenizer plus autoclaving 
(0.23% vs. 1.2%). In contrast to the High pressure homogenizer where a relatively 
large batch size is normally necessary, various batch sizes from below a gram up to 
several kilo grams can be processed by using different sizes of sample vials and 
DACs.   
Moreover, it was predicted that sensitive drugs and bioactive compounds e.g. 
peptides, proteins could be entrapped within VPGs by DAC without significant 
degradation since the processing temperature could be maintained low by dividing 
the mixing into a series of short DAC-runs combined with sample cooling in between 
[147].  
In summary, major problems for the VPG production by HPH and further liposome 
preparation (including overly large batch sizes, sterility and safety issues or the harsh 
conditions which limit the entrapment of sensitive compounds) may be overcome by 
using DAC.  
4.3.2. CHARACTERIZATION OF VPGS 
The morphology of VPGs was revealed by freeze-fracture electron microscopy [150-
151]. The inner structure was described as a matrix of densely packed vesicles within 
the semisolid pastes. The influence of the mechanical stress, lipid content, and lipid 
type on the morphology was studied. When magnetic stirring was used for 
processing, very heterogeneous multilamellar vesicles are found whereas after high 
pressure homogenization, the pastes predominantly consist of homogenous small 
and unilamellar vesicles as long as the lipid content is less than 450mg/g (Figure I-4). 
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However, the characteristics of the vesicles within homogenized pastes depend on 
the lipid content. When a higher lipid content is applied, large multilamellar vesicles 
and planar lamellar stacks are found beside small unilamellar vesicles which leads to 
more heterogeneous in size extending to a range of several 10μm (Figure I-5) [140]. 
The gel pastes prepared with lipid blends containing DMPC, DPPC or mixtures 
thereof showed domains of ripple phases beside areas of vesicular character, which 
indicated incompletely hydration.  
 
Figure I-4. Freeze-fracture electron micrograph of vesicular phospholipid gel based on 450mg/g lipids, 
soy PC, prepared by high pressure homohenization (10 cycles at 70MPa). Predominantly small 
unilamellar vesicles (SUVs) in the size range below 100nm, with some larger vesiclesin the several 
hundred nanometer range [50, 140, 143]. 
 
Figure I-5. Freeze-fracture electron micrograph of vesicular phospholipid gel based on 500mg/g lipids, 
soy PC, prepared by high pressure homohenization (10 cycles at 70MPa). Partly small unilamellar 
vesicles (SUVs) in the size range below 100nm, as well as larger vesicles in the micrometer-range [50, 
140, 143]. 
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4.3.3. APPLICATION OF VPGS FOR DRUG DELIVERY 
4.3.3.1. VPGS BASED LIPOSOMES 
VPGs have emerged both as intermediates for liposome production and as semisolid 
depot formulations for loco-regional sustained release of drugs upon implantation or 
injection.  
By mixing with excess aqueous medium and mechanical agitation, VPGs can be 
transferred into conventional liposome dispersions [152]. Redispersing the VPGs by 
using a ball mill, the occurrence of larger particles could be widely suppressed, as 
indicated by photon correlation spectroscopy.  
With the technique of VPGs based liposomes, encapsulation efficiencies of 
hydrophilic compounds into small unilamellar liposomes are improved compared with 
other liposome preparation techniques so that removal of unencapsulated drug may 
be avoided. Moreover, small and uniform vesicle sizes could be achieved at the 
same time. Improved storage stability is expected for the liposomes prepared this 
way.  
Autoclaved VPGs have already been used in first animal experiments [153]. In 
general, steam sterilisation is considered applicable for VPGs which maintained their 
vesicular structure but showed a slight increase of vesicle size. This size drift was 
deemed irrelevant for safety despite the influence on the pharmacokinetics of 
liposomes redispersed from VPGs. For the application of VPGs as local-depot 
formulation, the bigger vesicle sizes and corresponding increase in packing density 
were assumed to slow down the erosion of the matrix and therefore lead to a slower 
release of the hydrophilic marker [11, 140, 154]. 
 A liposomal formulation of gemcitabine based on VPGs was reported as a highly 
effective gemcitabine delivery system through intravenous administration [153]. The 
hydrophilic anticancer agent Gemcitabine can be entrapped in a stable manner into 
small liposomes through the VPG approach with a satisfactory drug entrapment 
efficiency and sufficient storage stability for potential clinical use. Redispersed VPGs 
consisted of 33% liposomally entrapped and 67% free gemcitabine. In vivo 
pharmacokinetics and antitumor activity showed efficiency compared to the 
conventional formulations due to the sustained release and passive tumor targeting 
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of the liposomes. Using the VPG concept, another antitumor agent Vincristine [155] 
was passively entrapped in small liposomes with efficient entrapment and good 
retention without using deleterious acidic pH values. Furthermore, such a liposomal 
formulation allowed application without removing non-entrapped drug, and provided a 
prolonged shelf-life of the liposomes. By redispering VPGs, it was possible to 
develop liposomal formulation of Bendamustine [156] which was difficult with 
conventional liposome preparation techniques because of the insufficient stability of 
Bendamustine in aqueous solutions. A sterile DAC process with optimized 
processing parameters was performed to achieve small particles within VPGs. The 
gel pastes were subsequently redispersed into liposomes with an average size of 
about 62.5 nm and an entrapment efficiency of around 41.5%. Entrapped 
Bendamustine showed a better stability in aqueous solution.  Moreover, an enhanced 
antitumor efficacy was observed in cell culture for liposomal Bendamustine. 
4.3.3.2. VPGS AS LOCAL DEPOT SYSTEMS 
Local delivery is frequently the only feasible strategy to achieve locally high 
concentrations of therapeutic substances. Some proteins, such as chemokines, 
cannot be delivered systemically because their mode of action requires a 
concentration gradient. Local rather than systemic delivery may be the preferred 
route of protein delivery in the case of that: (i) the protein can not reach the site of 
action; (ii) the protein acts undesirably on other organs; (iii) high local concentrations 
are needed; or (iv) local concentration gradients need to be established [157-158]. 
The use of the undiluted VPGs as implants for the local administration of drugs was 
applied to meet the requirement. The multivesicular morphology of VPGs offers the 
potential as local depot as the pastes appeared to retain entrapped drugs when in 
contact with excess aqueous medium [50, 138, 143].  
Tardi [11] has used Calcein (Mw 623) as a hydrophilic model to evaluate the in vitro 
release behaviour of VPGs. The small water-soluble compound could be retained 
within the matrix over extended periods of hours up to several weeks depanding on 
the lipid content within the various formulations of VPGs. The released calcein and 
released phosphatidylcholine were both quantified so that two mechanisms 
controlling the release were found occurring at the same time: (1) erosion of the 
matrix with release of liposomal compounds and the compounds trapped in between 
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(2) diffusion through the matrix. In addition, increasing the lipid content of lipids 
decreases matrix erosion rate and consequently slows down the release of the 
entrapped model, whereas no influence was observed of the entrapped calcein.  
Kaiser [159] has prepared different formulations of 5-fluorouracil loaded VPGs with 
hydrogenated soy phosphatidylcholine and cholesterol by high pressure 
homogenization. The entrapment efficiency of liposomal 5-fluorouracil redispersed 
from VPGs was around 40%.  A prolonged half-life time of the antitumor agent 
released from VPGs was found to be in the order of 4–5 h and the kinetics was 
typical for matrix-controlled drug diffusion. Thus it was suggested VPGs were 
applicable as implants with controlled release properties or, after redispersion, as 
intravenously injected liposomal formulations.  
Another potential application concerns prolonged systemic delivery of peptide 
hormones after implantation [13, 160-161]. VPGs were prepared with 300mg/g-500 
mg/g egg phosphatidylcholine and 0.5–10 mg/g cetrorelix acetate (CXA) using High 
pressure homogenization. The in vitro release behaviour of the peptide loaded VPGs 
were influenced by the lipid content, the drug content within the formulations, and 
also the interactions between the two factors. A fast complete release within 24hrs 
was observed for the formulation consisting of 0.5 mg/g CXA and 400 mg/g lipids 
while a sustained release of therapeutically relevant CXA doses over up to 6 weeks 
also appeared feasible with the formulation containing 8.5 mg/g and 360 mg/g lipids. 
Erosion of the phospholipid matrix was found to be the main release mechanism, 
following zero order or first order kinetics depending on the composition of the VPGs. 
CXA-concentration dependent drug–drug or drug–lipid interactions were assumed to 
be responsible for the change in release kinetics and the decrease of CXA release at 
high concentrations of the peptide. VPGs were thus considered as a promising new 
approach for the sustained release of peptide hormones. 
In addition, Farkas [162-163] has incorporated β-sitosterol into VPGs of 
hydrogenated phospholipids and chlorhexidin digluconate, which led to the phase 
transition of the gels to the less ordered fluid vesicular state. The membrane 
deformability and the system dispersity were increased as a result of increasing the 
β-sitosterol ratio in the lipid blends. Moreover, the release extent of chlorhexidine 
from the matrix was significantly increased.  
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As a summary, current work has shown promising results of VPGs as controlled 
delivery system. The feasibility of the system has been demonstrated by varying the 
components of VPGs to modulate the in vitro release behaviour. 
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 CHAPTER II: AIM OF THE THESIS 
Lipid based carriers have attracted increasing scientific and commercial attention 
during the least few years for controlled delivery of proteins concerned with stability 
issues [164]. 
Vesicular phospholid gels have emerged as a novel lipid based formulation with a 
three-dimensional network. The gel formulations can be applied both as 
intermediates for liposome production and as semisolid depot formulations for loco-
regional sustained release of drugs upon implantation or injection [50, 123, 143, 152]. 
As a loco-regional application, the sustained release character of vesicular 
phospholipid gels has been demonstrated using the small water soluble compounds 
[152, 165]. First important success was achieved by loading of VPGs with the small 
peptide hormone cetrorelix: in vitro release experiments showed a wide range of 
cetrorelix release periods, ranging from 24 hours to a predicted sustained release of 
over more than 3 months [13]. However, still it was unclear whether VPGs might be 
suitable for the delivery of proteins due to the inherent instabilities of the 
macromolecules. Therefore, the first major aim of the present work was to develop 
various protein-loaded VPGs.  
Second, dual asymmetric centrifuge was introduced as an alternative for the 
traditional preparation method of VPGs with high pressure homogenisation [147]. 
Thus lab scale preparation became feasible. Our second part of work was to develop 
a suitable preparation method for loading protein into VPGs.  
Moreover, morphology and rheological behaviour of VPGs have been investigated in 
previous work [151-152]. For the intro release tests, Grohganz [160, 166] has 
developed a RP-HPLC method to quantify released cetrorelix from the gel matrix. 
Various organic solvents and surfactants have been tried out to extract the peptide 
from the release fractions since liposomes in the release fractions got strong 
interference if they are not disrupted.  However, for the protein loaded VPGs, we 
have to develop suitable characterization methods both for the gel matrix and for the 
entrapped protein.       
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As a brief, the project was to focus on: 
 
• Preparation of VPGs with various phospholipid contents and compositions, to 
evaluate their influence on the physical character of VPGs, as well as the 
influence on the in vitro release behaviour.  
• Preparation of VPGs with various proteins, for each protein to evaluate the 
influence of protein concentration on the physical character of VPGs, as well 
as the influence on the in-vitro release behaviour.  
• Establishment of analytical methods for various proteins and phospholipids. 
• Adaption of the release system. 
• In vitro release tests of the various VPG formulations and analysis of the 
released fractions. 
• Investigation on the in vitro release kinetics of the formulations. 
• Establishment of an ELISA method for the in vivo experiment. 
• Preparation of VPGs for intra-articular application in the animal models. 
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CHAPTER III: MATERIALS AND METHODS 
1. MATERIALS 
1.1. FLUORESCEIN ISOTHIOCYANATE-DEXTRAN (FITC-DEXTRAN) 
FITC-dextran (FD-40, with an average molecular weight of 40kDa) was supplied from 
Sigma-Aldrich, Steinheim, Germany. The molecular structure is shown in Figure III-1 
[167]. FITC-dextran is a water-soluble yellow powder. It has good stability at pH 4-10 
at room temperature and excellent biocompatibility in vivo. FITC-dextrans have been 
used as tracers for studying microcirculation or membrane permeability in vivo [168-
170]. Besides, FITC-dextrans were also applied as hydrophilic macromolecular 
models to evaluate drug delivery systems [171-172].  
 
Figure III-1. Structure of FITC-dextran. 
1.2. ERYTHROPOETIN (EPO) 
EPO is a glycoprotein with a molecular weight of 30.4kDa, 40% of which is ascribed 
to carbohydrates [172]. The protein molecule contains a single-chain with 165 amino 
acids [173]. EPO is produced primarily by the kidney and to a lesser extent in the 
liver. The physiological function of EPO is to regulate the red blood cell production 
[174-176].  Besides, the protein is also involved in the wound healing process [177] 
as well as the brain’s response to neuronal injury [178]. The iso-electric point of EPO 
is around a pH value from 4.2 to 4.6 [179]. 
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The protein bulk used in this work had a concentration of either 0.65 mg/ml or 
0.75mg/ml in 20 mM phosphate buffer pH 7.2, containing 20 mM sodium chloride. 
However, further concentrating of these protein bulks was needed for the study.  
1.3. GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) 
Recombinant human (rh-) G-CSF was provided with a concentration of 4.04 mg/ml.  
The protein buffer consisted of 10mM sodium acetate buffer, 0.004% Tween and 5% 
Sorbitol with a pH of 3.9. 
Mouse granulocyte colony-stimulating factor (G-CSF) was first recognized and 
purified by Rafael Duarte in 1983 [180]. and the human form was cloned later in 1986 
[181]. G-CSF is a single, non-glycosylated, polypeptide chain containing 175 amino 
acids and having a molecular mass of 18.8 kDa. G-CSF is a cytokine which naturally 
regulates the survival, proliferation, and differentiation of hematopoietic cells [182-
183]. rh G-CSF has been therapeutically utilized to increase the production of 
neutrophils, as well as to mobilize the hematopoietic stem cells [183]. However, due 
to the short human plasma life (ca. 3.5hr) and limited therapeutic efficiency, multiple 
injections are normally required to achieve the desired therapeutic outcome [184]. 
1.4. MONOCLONAL ANTIBODY IMMUNOGLOBULIN G (MAB) 
The antibody used in the study is a monoclonal recombinant human IgG antibody. 
The monoclonal antibody is produced by a type of immune cells that are all clones of 
a single parent cell. The IgG antibodies are composed of 4 peptide chains with 
molecular weight of about 150 kDa. There are two identical heavy chains (ca. 50kDa) 
linked to each other and to a light chain (ca.25kDa) each by disulfide bonds. The 
resulting tetramer forms the Y-like antibody. Each IgG has two antigen binding sites. 
IgG is the most abundant immunoglobulin constituting 75% of serum 
immunoglobulins in humans. IgG antibodies are predominately involved in the 
secondary immune response. The presence of specific IgG generally corresponds to 
maturation of the antibody response [185-188]. 
The monoclonal IgG antibody bulk was provided with a concentration of 17.6mg/ml in 
50 mM phosphate buffer pH 6.4, containing 150mM sodiudm chloride and 0.1% BSA.  
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1.5. PHOSPHOLIPIDS 
The following phospholipids were kind gifts from Lipoid GmbH (Ludwigshafen, 
Germany): Egg lecithin (E 80) containing 80%-85% phosphatidylcholine (PC) was 
used as the basic liposome forming phospholipid. The other major compounds in E 
80 are specified (certificate of analysis) as: phosphatidylethanolamine (7.0–9.5%), 
lysophosphatidylcholin (less than 3%), sphingomyelin (2–3%) and triglycerides (less 
than 3%). DOTAP (1, 2-dioleoyloxy-3-trimethylammonium propane chloride) was 
used as a cationic, DPPA (dipalmitoylphosphatidic acid) as an anionic phospholipid. 
The other phospholipids used in the work were generously provided by 
PHOSPHOLIPID GmbH (Cologne, Germany).  
1.6. CHEMICALS  AND REAGENTS 
Acetic acid (100 %), p.A., VWR International GmbH, Darmstadt, Germany 
Acetonitril, CH3CN, gradient grade, VWR International GmbH, Darmstadt, Germany 
Basic fibroblast growth factor, bFGF, PROSPEC, Israel 
Chloroform, CHCl3, p.A., Merck KGaA, Darmstadt, Germany 
Dipotassium hydrogen phosphate, K2HPO4, p.A., VWR International GmbH, Darmstadt, Germany 
Disodium hydrogen phosphate dihydrate, Na2HPO4 x 2 H2O, p.A., VWR Int. GmbH, Germany 
Ethanol, p.A., Merck KGaA, Darmstadt, Germany 
FLuorescamine, Sigma-Aldrich, Steinheim, Germany  
Hexane, p.A., Merck KGaA, Darmstadt, Germany 
Lyophilised bovine serum albumin, 66kDa, Fraction V, Sigma-Aldrich, Steinheim, Germany 
Methylene blue, VWR International GmbH, Darmstadt, Germany 
N, N-Dimethylformamide, DMF, Merck KGaA, Darmstadt, Germany 
Octyl ß-D-glucopyranoside, ODG, Sigma-Aldrich, Steinheim, Germany  
Potassium chloride, KCl, p.A., VWR International GmbH, Darmstadt, Germany 
Sodium azide, NaN3, p.A., VWR International GmbH, Darmstadt, Germany 
Sodium borate, Sigma-Aldrich, Steinheim, Germany  
Sodium chloride, NaCl, p.A., VWR International GmbH, Darmstadt, Germany 
Sodium deoxycholate, DOC, Thermo Fischer Scientific Inc 
Sodium dihydrogen phosphate monohydrate, NaH2PO4 x H2O, p.A., VWR Int. GmbH, Germany 
Sodium dodecyl sulphate, C12H25NaO4S, VWR International GmbH, Darmstadt, Germany 
Sodium hydroxide, NaOH, p.A., VWR International GmbH, Darmstadt, Germany 
Trifluoroacetic acid, TFA, p.A, Merck KGaA, Darmstadt, Germany 
Triton X-100, Sigma-Aldrich, Steinheim, Germany 
Tween®80, Polysorbate 80, Serva, Heidelberg, Germany 
Ultra pure water, taken from Purelab Plus®, USF GmbH, Ransbach-Baumbach, Germany 
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2. METHODS 
2.1. UP-CONCENTRATION OF PROTEINS  
The protein bulk solutions were concentrated to the desired concentrations by 
ultrafiltration using Vivaspin tubes (Sartorius Stedim Biotech GmbH, Goettingen, 
Germany). According to the molecular weight of the proteins, various Vivaspin tubes 
were used as shown in Table III-1. 
The concentrated proteins were quantified by UV photometry at 280nm and 
calculated with the extinction co-efficiency. For each protein, the integrity proved to 
be maintained from the ultrafiltration process by HPLC.   
Table III-1. Concentrating of proteins with Vivaspin tubes 
Protein Concentrating fold  Centrifugal concentrators 
Centrifugal 
conditions 
Extinction coefficiency 
at 280nm. 
EPO Ca. 10 x Vivaspin 20ml, 5kDa membrane cut-off. 0,743ml/mg.cm [189] 
G-CSF Ca. 2-8 x Vivaspin 2ml, 3kDa membrane cut-off. 0,860ml/mg.cm [190]  
mAb-IgG Ca. 2-4 x Vivaspin 20ml,100kDa membrane cut-off. 
Swing Bucket Rotor, 
Centrifugation at 
3000rpm, 15°C, 
multiple runs of 
30minutes till 
desired 
concentration 
achieved 1,499ml/mg.cm  
 
2.2. PREPARATION OF VESICULAR PHOSPHOLIPID GELS 
In the first steps, FITC-dextran loaded VPGs were formulated either by High pressure 
homogenization or Dual asymmetric centrifugation to compare the preparation 
methods. Proteins were loaded into VPGs by DAC.    
2.2.1. PREPARATION BY HIGH PRESSURE HOMOGENIZATION 
The preparation method of VPGs using High pressure homogenization was first 
described by Brandl [50, 139, 143, 151-152]. FITC-Dextran was used as the 
macromolecular model instead of proteins to evaluate the suitability of the 
preparation method. Briefly, FITC-dextran was dissolved in destilled water. 
Phospholipids were subsequently added to the FITC-dextran solution. The blends 
Chapter III: Materials and methods 36
 
were allowed to swell for 10 minutes and then fed into the high-pressure 
homogeniser (APV Micron Lab 40, APV Homogeniser, Luebeck, Germany). The 
mixture was homogenised 2-7 times at 70 MPa at room temperature. The batch size 
was between 40 and 45 g. After homogenization the gels were stored in capped 
glass vials at 2–8°C.  
2.2.2. PREPARATION BY DUAL ASYMMETRIC CENTRIFUGATION 
The preparation of VPGs using Dual asymmetric centrifugation was based on the 
method described by Massing et al [191]. Modifications were made in order to avoid 
potential heat-stability problems with the proteins. Briefly, FITC-dextran or proteins 
were incorporated by direct loading, i.e. EPO solution (formulated in 20mM PBS 
buffer, pH 7.2) was added to the accurately weighed lipids and homogenized by 
means of a dual asymmetric centrifuge (SpeedMixerTM DAC 150 FVZ, Hauschild 
GmbH & Co KG, Hamm, Germany) (Figure III-2.) in a 25ml cylindrical container (PP, 
Duerrmann GmbH, Hohenlinden, Germany). For homogenization a process speed of 
3500 rpm was utilized in all experiments. According to the first report on the 
utilization of DAC and the fact that a continuous long-time centrifugation run causes a 
significant temperature increase in the product, multiple centrifugation steps of 1.5-
minutes were added up to a total mixing time of 45 mins with interrupts for cooling at 
2-8°C. In addition, methylene blue loaded VPGs were prepared to demonstrate the 
homogeneity distribution of VPGs.  
 
 
Figure III-2. The dual asymmetric centrifugation, SpeedMixerTM DAC 150 FVZ 
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2.3. MICROSCOPIC STUDIES 
Microscopic studies of protein loaded VPGs were carried out using an Olympus 
microscope. Magnifications at 400 x was applied in order to visualise the surfaces of 
the VPGs. Microscopic pictures were collected with a TK-C1380 colour video camera 
(camera digital – ½ inch CDD, JVC Professional Products GmbH, Friedberg, 
Germany) coupled with Lucia software. 
2.4. RHEOLOGY  
The rheologic behavior of VPGs was studied on the rotational rheometer (Physica 
MCR 100, Anton Paar GmbH, Ostfildern, Germany) with cone and plate geometry. 
The shear rate was set to 10-100 s-1. About 1g of VPGs were used for each 
measurement. The temperature was set to 25°C. The viscosity of VPGs was 
compared at the fixed shear rate of 37.9 s-1.  
2.5. TEXTURE ANALYSIS 
Texture analysis was performed to evaluate the gel strength of VPGs. The 
measurement was performed on a texture analyzer (TA.XT plus, Stable Micro 
Systems, UK) with a micro-probe of 4mm in diameter. The test speed was set to 
0.50mm/sec. A gel volume of 1.5ml (in u-bottom eppendorf tubes) was used for each 
measurement. The value given by the texture analyzer is the gel strength expressed 
in gram versus time plot according to the standard “Bloom test” for determination of 
the gelatine’s gel strength. 
2.6. DISPERSIONS OF VPGS 
VPGs were accurately weighed and dispered with excess aqueous buffer solutions to 
form the liposomes. Vigorous vortex (Heidolph REAX Top, Heidolph GmbH, 
Germany) was applied to offer a mechanical agitation.  
2.7. PARTICLE SIZE ANALYSIS AND ZETA POTENTIAL MEASUREMENT 
Particle size analysis and zeta potential measurement was conducted on the 
Zetasizer nano ZS (Malvern Instruments, UK). The vesicle size of liposomes 
dispersed from VPGs and from release fractions were analyzed and represented as 
intensity-weighted averages. 
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The Zeta potential is the electric potential at the shear plane of a particle [191]. The 
ionic interaction between proteins and lipids was evaluated by measuring the zeta 
potential of dispersed VPGs. The test temperature was set to 25 °C.  
2.8. TURBIDITY 
The turbidity of the release fractions was determined to reflect the release degree of 
the VPGs matrix. The Nephla turbidity photometer (Dr Lange GmbH-Berlin, Germany) 
used in the study has a measurement range of 0.001-1000 FNU at the working 
wavelength of 860 nm.  
2.9. EXTRACTION OF PROTEINS FROM THE VPG MATRIX 
Liposomes in the dispersions of VPGs or in the release fractions from VPGs were 
found to have strong interference with the entrapped proteins in characterization and 
quantification. Therefore, extraction processes had to be applied, which allows the 
quantitative recovery of the proteins from the liposome fractions without having 
detrimental effects on the protein integrity. Since individual proteins exhibit. large 
differences in extraction process, a case-by-case investigation was performed testing 
several organic solvents and surfactants.  
2.9.1. EXTRACTION OF EPO 
Chloroform was found suitable for EPO extraction. For disperions or release fractions 
containing uncharged and negatively charged lipids, 0.3 ml of chloroform were added 
per ml of release medium sample volume. In the case of samples containing cationic 
lipids, 200mM sodium chloride was added to reduce the ionic interaction between 
EPO and cationic lipids before 0.3ml chloroform was added per release sample 
volume. Afterwards the mixtures were vortexed and centrifuged (at 3000rpm, 15°C, 
30 mins). The upper aqueous phase was analyzed by reverse phase-HPLC to 
quantify the EPO content. The protein stability was evaluated by gel electrophoresis 
(SDS-PAGE). 
2.9.2. EXTRACTION OF G-CSF 
In order to extract G-CSF from liposome containing samples, the following steps 
were performed: 1.5mg/ml phospholipids (E 80) were added to the sample solutions. 
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The pH was adjusted to 3.5. 0.4ml/ml DMF was then added to the dispersions. Lipids 
were removed by centrifugation (3000rpm, 15°C, 30mins).  Protein concentration was 
determined by using a Reverse phase-HPLC, and protein stability was evaluated by 
gel electrophoresis (SDS-PAGE).  
2.9.3. EXTRACTION OF MAB IGG 
0.015% sodium deoxycholate (DOC) was added first to reduce the interaction 
between the antibody and lipids. After incubating at 37°C for 20mins, 1ml/ml 
chloroform was added to dissolve the lipids. The protein remains in the aqueous 
phase after centrifugation at 3000rpm for 30mins (15°C). Protein concentration was 
determined by using a micro BCA assay (Pierce, Bonn, Germany). 
2.10.  SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS 
The integrity of proteins after incorporation was analyzed by SDS-PAGE with non-
reducing conditions. The proteins were extracted by applying the suitable method as 
described in 2.10. The protein containing samples were diluted with Tris-buffer pH 
6.8 containing 2% SDS and incubated for 20min at 90 °C. Unstained molecular 
standard (Mark12 TM, Invitrogen, Groningen, Netherlands) was used as the molecular 
weight marker. For EPO and G-CSF, 20µl of the samples were loaded into the 10% 
Bis-Tris gel wells (NuPAGE® Novex 10 % Bis-Tris Pre-Cast Gel 1.0 mm, Invitrogen, 
Groningen, Netherlands). Electrophoresis was performed at a constant current mode 
of 40 mA in a MES running buffer (Invitrogen Groningen, Netherlands). The gels 
were stained either with silver staining kit (SilverXpress® Stain Kit, Invitrogen) or a 
coomassie blue kit (Colloidal Blue Staining Kit ® Stain Kit, Invitrogen) , and dried 
using a DryEase ® Gel Drying System (Invitrogen). For the monoclonal antibody, the 
electrophoresis was performed on the 7% Tris-acetate gels (NuPAGE® Novex 7% 
Tris-acetate Pre-Cast Gel 1.0 mm from Invitrogen, Groningen, Netherlands) in a 7% 
Tris-acetate/SDS running buffer (Invitrogen Groningen, Netherlands).  
2.11.  IN VITRO RELEASE TESTS 
Flow-through release cells were made of Teflon material (Figure III-3, by the 
workshop of the Department of Chemistry and Pharmacy, LMU, Munich) based on 
the design described by Tardi [11]. The donor compartment (lower compartment) had 
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a rectangular cross-section in order to ensure a relatively constant contact area even 
if some portions of the VPG were lost due to erosion. The acceptor compartment 
(upper compartment) on the other hand showed a semicircular cross-section, which 
was beneficial for the facilitation of a laminar flow. 
 
 
 
 
 
 
 
Figure III-3. The custom-made release cells for the in vitro tests, made by the workshop of the 
Department of Chemistry and Pharmacy, LMU, Munich 
Teflon tubing was used in order to minimize the surface adsorption of the released 
proteins. In order to study the erosion of VPGs, no membrane was used between the 
donor and acceptor compartment. The cells were filled with 1g accurately weighed 
VPGs and kept at 37°C by a water bath (Thermomix; B. Braun Biotech International). 
The pumping rate was set to 1ml/hr by using a multi-syringe pump (KDS 220, KD 
Scientific Inc). For EPO and mAb IgG, 40mM PBS buffer pH 7.4 containing 80mM 
sodium chloride was used as acceptor medium while 20mM PBS buffer pH 7.4 was 
used for G-CSF release.  
2.12. QUANTIFICATION OF RELEASED DRUGS 
2.12.1. DETERMINATION OF FITC-DEXTRAN CONCENTRATION BY FLUORESCENCE 
PHOTOMETRY 
The FITC-dextran concentration upon release fractions was determined by using 
Varian fluorescence spectrometer Cary eclipse. 1.8ml ethanol was added to 2ml 
samples to dissolve the liposomes. The excitation wavelength was fixed at 488 nm, 
and the emission was collected at 517nm.   
Buffer flow in  
Donor compartment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Buffer flow out  
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2.12.2. QUANTIFICATION OF PROTEIN BY HPLC 
Size exclusion-HPLC (SE-HLC) and Reverse phase-HPLC (RP-HPLC) are the two 
standard methods for protein analysis. SE-HPLC is often used in protein 
quantification and aggregation monitoring. RP-HPLC can be applied to assess the 
protein concentration and the amount of chemically modified protein e.g. oxidized 
species 
2.12.2.1. SE-HPLC OF EPO 
SE-HPLC of EPO was performed on a TSKgel size exclusion column (G3000SWXL, 
7.8mm x 30.0mm, Tosoh Biosep, Stuttgart, Germany). The mobile phase consisted 
of 100 mM disodium hydrogen phosphate dihydrate and 200mM sodium chloride with 
a pH of 7.0. The flow rate was set to 0.7 ml/min and the injection volume was 100µl. 
EPO was detected at 215nm (UV detector, Spectra Series 1100, San Jose, CA, USA) 
with a retention time of about 12.5mins. 
2.12.2.2. RP-HPLC OF EPO 
RP- HPLC of EPO was performed on a Spectra-Physics HPLC system (San Jose, 
CA, USA), equipped with a ternary gradient pump (Spectra-Physics SP 8800), an 
autosampler (Spectra Series AS 100) and a UV detector (Spectra Series 1100). The 
system was controlled by HPLC ChromQuest software. The analysis was conducted 
on Phenomenex C18 Jupiter columns (5µm, 250 x 4.6mm, Aschaffenburg, Germany) 
with a flow rate of 0.5ml/min. The UV detector was operated at 215nm. The injection 
volume was 100µl. The eluents were: (A) 0.1% TFA in ultrapure water and (B) 84% 
CH3CN (in ultrapure water) with 0.08% TFA. The gradient started with 80% eluent  A, 
over a period of 10min decreased to 40% A and then lasted for 5min. Afterwards, 
eluent  A decreased to 0% in 5 min, and finally returned to 80% over a 5min period.  
2.12.2.3. RP-HPLC OF G-CSF 
The ProSwiftTM RP-2H column (ProSwiftTM, 4.6 x 50mm, Dionex) was used for RP-
HPLC of G-CSF. The UV detector was operated at 215nm. The injection volume was 
100µl. Gradient elution was performed as shown in Table III-2. The eluent A 
consisted of 0.12% TFA in destilled water, and the eluent B consisted of 90% CH3CN 
(in ultrapure water) and 0.1% TFA.   
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Table III-2. Gradient elution for RP-HPLC of G-CSF 
Time/min 0 5 10 25 30 35 40 45 
Eluent A% 100 80 60 60 40 20 0 100 
Eluent B% 0 20 40 40 60 80 100 0 
Flow rate 1.5ml/min 
2.12.3. QUANTIFICATION OF PROTEIN BY PROTEIN ASSAYS 
2.12.3.1. FLUORESCAMINE PROTEIN ASSAY 
Fluorescamine assay was assessed for the quantification of G-CSF in the lipid 
containing samples. The assay was based on the principle that fluorescamine reacts 
rapidly with primary amines in proteins, to yield highly fluorescent products [192-193].  
A modified process using the 96 well-microplate as described by Lorenzen [194] was 
performed. Briefly, 150µl of the protein containing samples (in PBS buffer pH 7.4) 
and standards were pipetted into microplate wells (Nunc MaxiSorp™, Roskilde, 
Denmark). Fluorescamine was dissolved in acetone resulting in a concentration of 
3mg/ml. The microplate was placed on a microplate shaker and 50µl of the 
fluorescamine solution was added to each well. After shaking for a minute, the 
fluorescence was determined by using an excitation wavelength of 400nm 
(bandwidth: 20nm), and an emission wavelength of 460nm (bandwidth: 20nm). 
2.12.3.2. CBQCA ASSAY 
The CBQCA Protein Quantitation Kit (Molecular Probe, Invitrogen) was evaluated for 
the quantification of MAB. The assay utilizing the ATTO-TAG CBQCA reagent (3-(4-
carboxybenzoyl)quinoline-2-carboxaldehyde) has proven a rapid and highly sensitive 
method for quantitating amines in solution, including the accessible amines in 
proteins [195-197].The protein samples were diluted into 0.1 M sodium borate buffer 
pH 9.3. 5 µL of 20 mM KCN (supplied in the kit) was added and the reaction was 
started by adding 10µl of 5mM CBQCA (in 0.1 M sodium borate buffer pH 9.3). After 
incubating for 1 hour (room temperature, protected from light), the samples were 
measured with the FLUOstar Omega multifunctional micro-plate reader (BMG 
LABTECH GmbH. Offenburg, Germany). The excitation wavelength was set to 
485nm, and the emission was collected at 580nm. 
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2.12.3.3. MICRO  BCA ASSAY 
The micro BCA protein assay is based on the following reactions: First, the working 
reagent (Cu2+) is reduced by protein in an alkaline environment [198-199]; 
Bicinchoninic acid (BCA) subsequently chelates with the reduced (Cu1+) cation to 
form the intense purple-colored reaction product. The water-soluble product exhibits 
a linear behaviour with increasing protein concentrations.  
The procedure for microplate mode followed instructions from the manufacture. 
Briefly, 150µl of the working reagent was added to 150µl sample solutions in the 
microplates (Nunc MaxiSorp™, Roskilde, Denmark). After incubating at 37°C for 2hrs, 
the samples were measured at 562nm.  Prior to assay the lipids containing samples, 
protein extraction (as described in 2.10) was needed to eliminate the interference of 
lipids. The concentration of the mAb IgG from release fractions or from VPGs’ 
redispersions was determined by using this micro BCA assay. It was a major 
consideration in developing the extraction method for the antibody that some often 
used organic solvents and surfactants including Triton, DMF, and Tween were 
reported to have interference with the assay at a certain amount [200-201]. The 
micro BCA assay was used for the quantification of MAB in absence and in presence 
of lipids in the context.  
2.13. QUANTIFICATION OF PHOSPHATIDYLCHOLINE BY THE ENZYMATIC ASSAY 
An enzymatic assay (LabAssay Phospholipid, Wako, Neuss, Germany) was used to 
quantify the phospholipid content in the release medium following the manufacturer’s 
instruction [202]. Shortly, phospholipids in the samples are hydrolyzed to choline in a 
reaction catalyzed by phospholipase D. The subsequent reaction of choline produces 
hydrogen peroxide, which causes the quantitative production of a blue pigment. The 
assay was performed in 96-well microplates (Nunc MaxiSorp™, Roskilde, Denmark). 
The amount of phospholipids E 80 in the samples were determined by measuring the 
absorbance at 600nm using the Fluostar Omega multimode microplate reader (BMG 
LABTECH, Offenburg, Germany).  
2.14. ENZYME-LINKED IMMUNOSORBENT ASSAYS OF G-CSF 
In order to assess the protein concentration in the serum/plasma samples, G-CSF 
was assayed by the enzyme-linked immunosorbent assays (ELISA). For example, 
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the Quantikine (DCS50, R&D Systems) Human G-CSF Immunoassay used in the 
study was a solid phase ELISA designed to measure G-CSF in cell culture 
supernates, serum, and plasma. It contains E. coli-expressed recombinant human G-
CSF and antibodies raised against the protein. It has been shown to accurately 
quantitate recombinant human G-CSF without obvious cross reactivity with rabbit 
serums [203]. The detailed steps of the assay followed the manual by the supplier. 
Another two ELISA kits: RayBio Human G-CSF ELISA from RayBiotech., Human G-
CSF Instant ELISA Kit from Bender MedSystems, have also been assessed in the 
work, but were not chosen finally due to insufficient results.   
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 CHAPTER IV: TENTATIVE EXPERIMENTS 
In a first approach, FITC-dextran (40KDa) was applied as hydrophilic 
macromolecular model to establish the preparation and characterization methods. 
1. PREPARATION OF VPGS USING FITC-DEXTRAN AS DRUG MODEL 
The preparation of VPGs can be performed either by high pressure homogenization 
(HPH) [11, 140] or by dual asymmetric centrifugation (DAC) [147]. Using a HPH, it is 
suitable for the production of VPGs which can be redispersed into very small (less 
than 100nm) and homogeneous liposomes [139, 143, 151-152].  However, a 
relatively large batch size is necessary (tens of grams) even for a lab scale HPH.  In 
the early stages of development of VPGs formulations there is a clear need to 
produce batch sizes of about several grams or even less.  
With the introduction of the DAC, production of VPGs with small batch sizes (about 
several grams) has become feasible, which is especially useful for entrapment of 
expensive biological materials such as proteins [147].  
1.1. HIGH PRESSURE HOMOGENIZATION 
The HPH method to prepare VPGs was first described by Brandl [10]. Briefly, FITC-
dextran (40KDa) was dissolved in destilled water. Phospholipids were subsequently 
added to the FITC-dextran solution. The blends were allowed to swell and then fed 
into the high-pressure homogeniser (APV Micron Lab 40, Luebeck, Germany).  
Based on the previous findings [11, 152], a lipid content of 400mg/g (egg PC, 
PHOSPHOLIPON) was used for VPGs’ preparation by HPH. The concentration of 
FITC-Dextran was 2mg/g for basic research. The mixture was homogenized at 
70MPa for 2-7 cycles. The batch size was between 40g and 45g. 
All the obtained VPGs showed a semi-solid consistency. The viscosity of the VPGs 
increased with the increasing homogenization cycles judged by visual examination. 
The gel strength of VPGs was determined by texture analysis (The texture analysis 
method used here is according to the “Bloom test”  for determination of the gelatine’s 
gel strength which is normally expressed in the mass values).  
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The gel strength value of VPGs was increased from 18g to 86g as the 
homogenization cycles increased from 2 to 7 times (Figure IV-1). 
VPGs were redispered with excess aqueous buffer solutions (PBS buffer pH 7.4) to 
form the liposomes by applying vigorous vortex. Over 90% of the particles were in 
the range of 87nm-129nm for all the VPGs prepared by HPH. The vesicle size was 
slightly decreased when the process cycle was increased from 2 to 6 times while the 
particle size was much smaller for the VPGs homogenized after 7 cycles (Figure IV-
2).  
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 Figure IV-1. Gel strength (mean±SD, n=3) of 
VPGs prepared by high pressure homogenization. 
VPGs were processed by various homogenization 
cycles (as indicated in the figure). 
Figure IV-2. Particle size of VPG dispersions 
(mean±SD, n=3), influence of homogenization 
cycles (as indicated in the figure). 
 
 
 
1.2. DUAL ASYMMETRIC CENTRIFUGATION 
As described in the Chapter I, dual asymmetric centrifugation (DAC) is a double 
DAC (SpeedMixerTM150 FVZ, Hauschild) was used for the preparation of VPGs. 
centrifugation technique where the sample is not only rotated around a central axis 
but also around a second axis in the centre of the sample container. Due to this 
combination of two contra-rotating movements efficient homogenization of viscous 
materials is possible. Compared with HPH, the manufacturing process using DAC 
can be easily modulated to control the system temperature which might be an 
essential factor for protein entrapment. Moreover, sterile production can be easily 
realized by performing the centrifugation with a hermetically sealed sample container 
[147].  
The preparation process was based on the method described by Massing et al [147]. 
FITC-dextran was incorporated by direct loading: the FITC-dextran solution was 
added to accurately weighed lipids resulting in a semisolid dispersion. 
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Homogenization was performed with a centrifugation speed of 3500rpm. In previous 
studies, glass beads were used as homogenization aid. However, in our work we 
omitted the use of beads in order to avoid potential heat-stability and protein 
adsorption problems. Since a long time run of centrifugation causes the temperature 
increasing of the system which might have interference on the bioactivity of the 
protein, multiples of 1.5-minute runs were set up to a total mixing time of 45 minutes. 
Using this procedure an average process temperature of below 40°C could be 
maintained during the production, which appeared appropriate for the incorporation 
of sensitive proteins. 
The VPGs were prepared with various contents of lipids (egg PC, PHOSPHOLIPON) 
in the range from 400mg/g to 550mg/g. The concentration of FITC-dextran was 
2mg/g in all the formulations. The gel strength was determined by texture analysis. 
As it can be seen in Figure IV-3, increasing the lipid content resulted in higher gel 
strength. The gel strength value was 5g for VPGs based on 400mg/g lipids while it 
was 60g for VPGs containing 550mg/g lipids.  
VPGs were also loaded with various contents of FITC-Dextran in the range from 
1mg/g to 3mg/g with the lipid content of 550mg/g in all the formulations. In general, 
the gel strength was increased as incorporating more FITC-Dextran within the VPGs. 
The gel strength value was 46g for VPGs containing 1mg/g FITC-Dextran while 
VPGs with 2mg/g FITC-Dextran got a value of 60g and VPGs with 3mg/g FITC-
Dextran had a gel strength value of 70g (Figure IV-4). 
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 Figure IV-3. Gel strength (mean±SD, n=3) of 
VPGs formulations with various lipid contents 
(as indicated in the figure). All gels were based 
on egg PC and loaded with 2mg/g FITC-
Dextran. 
Figure IV-4. Gel strength (mean±SD, n=3) of 
VPGs formulations with various FITC-Dextran 
contents (as indicated in  the figure). All gels 
were based on egg PC. 
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Comparing the VPGs prepared by HPH with the VPGs prepared by DAC, the VPGs 
prepared by HPH had a higher gel strength valule (ranging from 18g to 86g 
depending on the homogenization cycle) than the VPGs prepared with DAC (5g) 
based on the same contents of lipids (400mg/g egg PC) and FITC-dextran (2mg/g). It 
was assumed that the difference between the properties of VPGs prepared by HPH 
and those by DAC were due to the preparation technology of the different devices. In 
agreement with previous report [147], this comparison clearly shows that the shear 
forces generated by DAC are much lower than those generated by HPH, which on 
the other hand might be advantageous when sensitive compounds are entrapped 
within VPGs.   
2. HOMOGENEITY OF VPGS  
It might be argued that a non-uniform drug distribution of the VPGs could be caused 
by the manufacture process by dual asymmetric centrifugation. Consequently 
variations of drug loading could be possible.  
Methylene blue was used as model drug compound for homogeneity evaluations of 
the manufactured VPGs due to its colour enabling a convenient visual control. 
Methylene blue was dissolved in destilled water and subsequently added to the lipids 
in a cylindrical container (Figure IV-5a-5b). VPGs were formulated with dual 
asymmetric centrifugation as described previously. No obvious darker or lighter areas 
were visible (Figure IV-5c), being a result of homogeneous methylene blue contents 
in the gels. 
 
 
      (a)                                     (b)                                     (c) 
 
 
 
Figure IV-5. Images of VPGs loading with methylene blue: (a) the addition of lipids in the cylindrical 
container; (b) methylene blue and lipid mixture before dual asymmetric centrifugation; (c) VPGs with 
loading of methylene blue (the mixture after dual asymmetric centrifugation). 
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3. IN VITRO RELEASE TESTS 
Flow-through cells were made of Teflon material based on the design described by 
Tardi (Figure IV-6a) [11] for in vitro release tests. The donor compartment (lower 
compartment) had a rectangular cross-section in order to ensure a relatively constant 
contact area of about 250 mm2 (50mm x 5mm) even when portions of the VPG were 
lost due to erosion. The acceptor compartment (upper compartment) on the other 
hand showed a semicircular cross-section, which was beneficial for the facilitation of 
a laminar flow [3, 9]. 
Teflon tubing was used in order to minimize the surface adsorption of the released 
protein. In order to allow the erosion of VPGs, no membrane was used. The cells 
were filled with 1g accurately weighed VPG and kept at 37°C by a water bath. PBS 
buffer (40mM, pH 7.4) was used as acceptor medium and the flow rate was set to 
1ml/hr by using a syringe pump (Figure IV-6b). The concentration of FITC-Dextran 
upon release fractions was determined by fluorescence photometry (Excitation 
wavelength: 488nm, Emission wavelength: 517nm). 0.2ml of a release fraction was 
diluted to 2.0ml by adding ethanol to dissolve the lipids. The results were represented 
as the average of triplicates.  
 
 
                                              
 
  (a)                                                                 (b) 
Figure IV-6. In vitro release set-up: (a) Schematic drawing of the release cell; (b) Release system. 
 
VPGs were prepared with various concentrations of lipids (egg PC, 
PHOSPHOLIPON). The concentration of FITC-Dextran was 2mg/g in all the 
formulations. As it can be seen in Figure IV-7, the release behavior could be adjusted 
by the variation of the phospholipid concentration. Slower release rates were 
observed with increasing the lipid concentrations. For instance, the release of VPGs 
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prepared with 550mg/g lipids lasted more than 288hrs, whereas the release of FITC-
Dextran was terminated after 50hrs for VPGs based on 400mg/g lipids. This 
confirmed that it should be possible to achieve a desired release profile for 
proteinaceous substances by optimizing the formulation of VPGs with respect to its 
gel properties. Moreover, it was importantly found that the release of the 
macromolecules from various VPG-formulations all followed a close to zero-order 
kinetics.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV-7. Cumulative release of FITC-Dextran from VPGs based on various concentrations of egg 
PC (Mean± standard deviation, n = 3 each).  
 
The turbidity of the release fractions was determined to reflect the erosion of the 
VPG-matrix. It was found that the turbidity of the release fractions was in parallel with 
the release content within the whole release period (Figure IV-8 showed the VPGs 
based on 550mg/g lipids and 2mg/g FITC-Dextran for example). Since the turbidity of 
the release fractions was mostly from the lipids eroded from the matrices, it was 
assumed that erosion of VPGs is the controlling mechanism for the release of FITC-
Dextran as a macromolecular weight model. This is in agreement with former 
observations which showed that mainly matrix erosion governed the delivery of small 
molecular weight drugs [11] and peptides [51] from VPGs. 
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Figure IV-8. Release percentage of FITC-Dextran (left Y-axis) and turbidity of the release fractions 
(right Y-axis) at each time point. VPGs were based on 550mg/g lipids (egg PC, PHOSPHOLIPON) 
and 2 mg/g FITC dextran. 
 
The vesicle size of the release fractions was also determined at each time interval by 
PCS. As summarized in Table IV-1, the release fractions from various VPG-
formulations mainly consisted of small liposomes,  
 
Table IV-1. Particle size of release fractions from VPGs based on various contents of lipids.       
VPGs Based on 400mg/g lipids 
Based on 
450mg/g lipids 
Based on 
500mg/g lipids 
Based on 
550mg/g lipids 
Particle size of 
release fraction 170nm-232nm 185nm-258nm 184nm-250nm 199nm-290nm 
4. SUMMARY AND CONCLUSION 
In this chapter, FITC-Dextran was used as drug model for the loading of 
macromolecules. Various VPG-formulations were prepared using high pressure 
homogenization and dual asymmetric centrifugation respectively. Texture analysis 
was performed to characterize the gels. The gel strength was also found influenced 
by the variation of lipid content and drug content within the VPGs prepared by DAC.  
In order to demonstrate the homogeneity of the drug distribution, methylene blue was 
entrapped within the VPGs. Upon visual and quantitative examination, a sufficient 
homogeneity was revealed of the drug loading.  
In vitro release tests were set up using flow-through cells as described by Tardi[11]. 
Sustained release of FITC-Dextran from various VPG-formulations was observed 
following a close to zero-order kinetics. Moreover, the release rate can be modified 
by incorporating various amounts of lipids within VPGs. Slower release was observed 
by the addition of more lipids within the system. Turbidity of the release fractions was 
determined, which reflect the erosion of the matrices. Accordingly, it was 
consequently found erosion is the controlling mechanism for the release of the 
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macromolecular drugs as the determined turbidity was in parallel with the released 
amount of FITC-Dextran at each sample point. This result was in agreement with the 
previous work that matrix erosion governed the delivery of small molecular weight 
drugs [11] and peptides [51] from VPGs. The vehicle size was determined and was 
shown small liposomes (less than 300nm) released from the matrices. As summary, 
based on the obtained results it could be stated that VPGs possessed great potential 
as alternative system for the controlled delivery of proteins. 
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CHAPTER V: DEVELOPMENT OF EPO LOADED VESICULAR 
PHOSPHOLIPID GELS 
VPGs represented a promising approach for the sustained in-vitro release of peptide 
drugs [13]. As shown in Chapter IV, we used FITC-dextran as a drug model to 
demonstrate the suitability of VPGs for sustained delivery of macromolecular 
compounds. However, due to the sensitivity of the three dimensional structure and 
inherent instability of proteins, it was still unclear whether the system can be applied 
to proteins.   
Therefore, it was the aim of the following work to assess the potential of Vesicular 
phospholipid gels as alternative delivery system for therapeutic proteins. 
Erythropoietin, the first model protein, was incorporated into various VPGs 
formulations by using dual asymmetric centrifugation. The protein stability and in vitro 
release behaviour were used as main criteria to evaluate the suitability of the system. 
In order to characterize and to quantify the incorporated protein, different extraction 
protocols were investigated. Physicochemical characterizations were performed for 
the EPO loaded VPGs. 
1. PREPARATION OF EPO LOADED VPGS 
In this work production of protein loaded VPGs was performed with a DAC 
(SpeedMixerTM150 FVZ, Hauschild GmbH & Co KG, Hamm, Germany). The 
preparation process was based on the method described by Massing et al [147]. In 
previous studies, glass beads were used as homogenization aid. However, in our 
work, we omitted the use of beads in order to avoid potential heat-stability problems 
with the protein. Then, EPO was incorporated by direct loading, i.e. EPO solution 
(formulated in 20mM PBS buffer, pH 7.2) was added to the accurately weighed lipids 
and homogenized by means of a dual asymmetric centrifugation in a cylindric 
container of 25 ml total volume. The phospholipids’ (egg phosphatidylcholine, E 80) 
content ranged from 300mg/g to 550mg/g in total weight of the gels. The formulation 
contained a total protein drug load of 3.8 mg/g gel. Lipid blends consisting of egg 
phosphatidylcholine and charged lipids (egg PC: DPPA/ 9:1; egg PC: DOTAP/ 8:2, in 
total 500mg/g) were used to evaluate the influence of the lipid charge. For 
homogenization a process speed of 3500 rpm was utilized in all experiments. 
According to the first report on the utilization of DAC [147] and the fact that a 
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continuous long-time centrifugation run causes a significant temperature increase in 
the product, multiple centrifugation steps of 1.5-minutes were added up to a total 
mixing time of 45 mins with interrupts for cooling at 2-8°C. Using this procedure 
aprocess temperature of below 40°C could be maintained during the production, 
which appeared appropriate for the incorporation of temperature sensitive proteins. 
The inner structure of VPGs has been revealed by freeze-fracture electron 
microscopy in previous work [151, 165], which was described as a matrix of densely 
packed vesicles within the pastes. Upon visible examination it was observed that all 
the VPGs obtained exhibited a viscous semi-solid consistency. With increasing the 
lipid content in the formulations, the obtained VPGs showed increased viscosity and 
behaved less fluidity.  Upon optical microscopic inspection all the formulations 
exhibited a homogeneous appearance (Figure V-1). Increased packing density was 
observed for the VPGs containing more lipids which might lead to the decreased 
fluidity. 
 
  20µm        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            (d). VPGs containing 500mg/g lipids; (e). VPGs containing 550mg/g lipids            
 (a). VPGs containing 300mg/g lipids; (b). VPGs containing 400mg/g lipids;  (c). VPGs containing 450mg/g lipids     
 
Figure V-1.  Light micrograph of VPG formulations based on various contents of egg PC (LIPOID E80) 
and 3.8mg/g EPO at 400X magnification. (a). 300mg/g, (b). 400mg/g, (c). 450mg/g, (d). 500mg/g, (e). 
550mg/g.   
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2. RHEOLOGY AND TEXTURE ANALYSIS 
Bender [150] has investigated the complex viscosities of VPGs formulated with 
various types of lipids with oscillation rheometry. The viscoelastic character in the gel 
state increased due to decreased fluidity in the membrane bilayers and in the VPG 
structure. 
In our study, the rheologic behavior of VPGs was studied by a rotational rheometry 
(Physica MCR 100, Anton Paar). The measurement was performed at 25°C. The 
viscosities of VPGs were compared at a fixed shear rate of 37.9 s-1 (Figure V-2). 
Increasing the lipid content resulted in increased viscosity whereas adding a certain 
amount of charged lipid DOTAP or DPPA had little influence on the gel viscosity 
(Figure V-3). 
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 Figure V-2. Viscosity (mean±SD, n=3) of VPGs 
formulations with various lipid contents (as 
indicated in the figure). All gels were based on 
egg PC (LIPOID E80) and loaded with 3.8mg/g 
EPO (formulated in PBS buffer 20mM).  
Figure V-3. Viscosity (mean±SD, n=3) of 
VPGs formulations with various lipid 
compositions (as indicated in the figure). All 
gels were based on 500mg/g lipids or lipid 
blends and loaded with 3.8mg/g EPO 
(formulated in PBS buffer (20mM). 
 
 
 
Texture analysis was performed with the TA.XT plus texture analyzer (Stable Micro 
Systems, UK) to determine the gel strength (represented as the maximal force value). 
More rigidity of VPGs was observed by increasing the lipid content of the 
formulations (Figure V-4). Incorporating charged lipid DOTAP or DPPA slightly 
increased the gel strength compared with the VPGs containing egg PC only (Figure 
V-5).  
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 Figure V-4. Gel strength value (mean±SD, n=3) 
of VPGs formulations with various lipid contents 
(as indicated in the figure). All gels were based 
on egg PC or and loaded with 3.8mg/g EPO 
(formulated in PBS buffer (20mM). 
 
Figure V-5. Gel strength value (mean±SD, n=3) 
of VPGs formulations with various lipid 
compositions (as indicated in the figure). All gels 
were based on 500mg/g lipids or lipid blends 
and loaded with 3.8mg/g EPO (formulated in 
PBS buffer (20mM). 
 
 
 
3. EVALUATION OF PROTEIN STABILITY BY SDS-PAGE 
SDS-PAGE was performed to determine whether the manufacture process e.g. the 
mechanical shear force on the protein integrity. Since organic solvents or surfactants 
were applied in the protein extraction process from VPGs’ dispersions or release 
fractions, it was also necessary to evaluate their effect on the protein integrity. The 
samples were analysed by non-reducing SDS-PAGE with subsequent coomassie 
blue staining or silver staining. Electrophoresis was performed on the Bis-Tris Pre-
Cast Gel (Invitrogen, Groningen, Netherlands) in the MES running buffer (Invitrogen). 
Since the presence of lipids had a strong interference with the protein in SDS-PAGE 
analysis (data not shown), it was necessary to apply extraction agents. As the first 
step various extraction agents (as indicated in Table V-1) were applied to the lipid-
free EPO samples. The protein solutions were emulsified with organic solvents by 
vortex, and EPO was subsequently recovered from the aqueous phase after 
centrifugation. If Triton X-100 was applied, incubation with the protein solutions was 
needed at 37°C for 30 minutes.  
Table V-1.  Organic solvents and surfactants applied for EPO extraction 
 Organic solvents Surfactants 
Extraction agent Ethanol Dichloromethane Chloroform Triton X-100 
Applied amount to 1ml VPGs’ 
dispersions 1ml/ml 1ml/ml 1ml/ml 5% 
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The obtained protein samples were analysed by gel electrophoreses with subsequent 
coomassie blue staining (Figure V-6). Only the band of monomer EPO was 
detectable irrespective of the extraction agents. Hence it can be stated that applying 
the extraction agents induced no instability of EPO.  
 
                                    
 
 
 
 
 
 
 
  
 
Figure V-6. Influence of extraction agents on the EPO stability. Lane 1/ lane 5, adding ethanol to EPO; 
lane 2 / lane 6, adding Triton X-100 to EPO; lane 3 / lane 7, adding dichloromethane to EPO; lane 4 / 
lane 8, adding chloroform to EPO; lane 9, EPO standard solution; lane 10, molecular weight  maker. 
SDS-PAGE with subsequent blue staining. 
 
Further investigations applied these organic solvents and surfactants to extract EPO 
from freshly prepared VPGs (500mg/g egg PC and 3.8mg/g EPO). The formulation 
process was performed with DAC as described above in Chapter III. The protein had 
a concentration of 3.8mg/g in the final VPGs formulations. Aliquots of 0.2 g gel were 
dispersed in 10ml PBS buffer with vigorous vortex. EPO was extracted and analysed 
by SDS-PAGE with subsequent coomassie blue staining. No band was observed 
when ethanol was used to dissolve the lipids (Figure V-7, lane 1/ lane 5) indicating 
low protein recovery from extraction. As shown in lane 2 and lane 6, adding Triton X-
100 caused bands’ tailing, which was probably caused by the lipids remained in the 
samples. Only monomeric bands were detectable by applying chloroform (as 
indicated in lane 4/ lane 8) or dichloromethane (as indicated in lane 3/ lane 7) for lipid 
extraction and subsequently recovering EPO from the aqueous phase. Due to the 
higher protein recovery chloroform was used in the further investigations for 
extraction of EPO from lipid containing samples for the SDS-PAGE analysis.   
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Figure V-7. Extraction of EPO from VPGs. Lane 1/ lane 5, applying ethanol to extract EPO from VPGs; 
lane 2 / lane 6, applying Triton X-100 to extract EPO from VPGs; lane 3 / lane 7, applying 
dichloromethane to extract EPO from VPGs; lane 4 / lane 8, applying chloroform to extract EPO from 
VPGs; lane 9, EPO standard in PBS buffer 20mM; lane 10, molecular weight maker. SDS-PAGE with 
subsequent blue staining. 
 
However, it was important to exclude the possibility that the protein aggregates or 
fragments which were probably induced either in the manufacture process or in the 
extraction process might not be extracted and then not detected by the SDS-PAGE 
analysis. Further investigations were carried out by stressing the protein to generate 
aggregation or degradation products. In brief: EPO solutions were incubated at 60°C 
for 24hrs and on the other hand the protein was oxidized with hydrogen peroxide. 
Lipids (egg PC, 1.5mg/ml) were dispersed into these stressed-protein solutions. 
Chloroform was applied and the extracted proteins were analysed by SDS-PAGE 
with subsequent silver staining (To improve the sensitivity of the PAGE method, 
silver staining was used instead of coomassie blue staining in further work). 
Denatured protein samples without adding lipids or applying extraction process were 
analysed directly as the control. As shown in Figure V-8, it could be concluded that: (I) 
Denatured EPO could be extracted from lipids using chloroform and detected by the 
SDS-PAGE (lane5, lane 6, and lane 8); (II) Applying chloroform for EPO extraction 
did not create more denatured protein fractions (No additional band was observed for 
extracted proteins, see: lane 3 and lane 5; lane 4 and lane 6; lane 7 and lane 8); (III) 
As expected, the detection of aggregate and fragment fractions was dependant on 
the loading content of the protein. Some denatured fractions became invisible at 
lower concentrations (comparing lane 3/ lane 5 with lane 4/ lane 6). Consequently, it 
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could be stated that the developed extraction protocol with chloroform and the SDS-
PAGE were suitable for evaluation the stability of entrapped EPO from VPGs.  
                                       
  
 
 
 
 
 
 
 
 
 
 
 
Figure V-8. Analysis of denatured EPO samples. SDS-PAGE with subsequently silver staining:  
 
 
 
 
 
 
 
 
 
Lane 1, molecular weight marker 
Lane 2, EPO standard in PBS buffer 20mM 
Lane 3, denatured EPO by incubating at 60°C for 24hrs with a total protein concentration of 750µg/ml.  
Lane 4, denatured EPO by incubating at 60°C for 24hrs with a total protein concentration of 50µg/ml.  
Lane 5, denatured EPO (by incubating at 60°C for 24hrs) extracted from lipids containing samples, with a total 
protein concentration of 750µg/ml. 
Lane 6, denatured EPO (by incubating at 60°C for 24hrs) extracted from lipids containing samples, with a total 
protein concentration of 50µg/ml. 
Lane 7, oxidized EPO, with a total protein concentration of 150µg/ml. 
Lane 8, oxidized EPO extracted from lipids containing samples, with a total protein concentration of 150µg/ml.
 
 
 
 
 
 
 
 
 
 
 
 
Figure V-9. Proof of EPO integrity within VPGs formulations. Lane 1, molecular weight maker; lane 2 
to 5: EPO extracted with chloroform from various VPG formulations based on 500mg/g egg PC and 
3.8mg/g EPO, lane 6 to 9, EPO standard in PBS buffer 20mM. SDS-PAGE with subsequently silver 
staining. 
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Consequently, the influence of the manufacturing process on the integrity of EPO 
was studied by SDS-PAGE with subsequent silver staining. Chloroform was applied 
to extract EPO from freshly prepared gels (containing 500mg/g egg PC and 3.8mg/g 
protein). As shown in Figure V-9, no aggregation or fragmentation bands of EPO 
were observed. It could be concluded that EPO was maintained stable within VPGs 
after production, which encouraged further investigation of the in-vitro release tests. 
4. DEVELOPMENT OF QUANTIFICATION METHOD OF EPO  
As described previously, VPG formulations offer the unique property that drug 
incorporation is achieved either within the tightly packed lipid vesicles or in-between 
them. Consequently, it can be expected that EPO is released from the gel matrix 
both in free form and in liposomal form. Therefore it is essential to develop an 
extraction method that allows the quantitative recovery of the protein from the 
liposome fraction without having detrimental effects on the protein integrity. In 
previous work, Qi [172, 204] used chloroform to extract EPO from liposome solutions 
prior to quantitative analysis by RP-HPLC. In a comparative study on the extraction 
efficiency of the decapeptide cetrorelix from liposome dispersions 2.5% Triton X-100 
and hexane were the best choices among several detergents and organic solvents. 
However, it should be also noticed that the Triton X-100 containing samples featured 
creation of multiple peaks [160]. Also the detergent 30 mM octyl ß-D-glucopyranoside 
(ODG) has been suggested for protein extraction [205].  
4.1. SAMPLE PREPARATION  
Since the released amount of VPGs at each time interval was unknown, it was 
important to develop an extraction protocol and a subsequent quantification method 
which featured a high robustness against variations of the lipids as well as against 
variations in the protein amount which make this method suitable for protein 
quantification during in-vitro release studies.  
Initial screening of the extraction methods was done with a constant EPO 
concentration of 10µg/ml. The extraction agents and analytical methods for initial 
screening were used as in Table V-2. Surfactants were accurately weighed and 
added to lipid containing EPO samples and incubated for a short period before 
Chapter V: Development of EPO loaded Vesicular Phospholipid Gels 61
 
injection to HPLC. Alternatively, the lipids were extracted by organic solvents and 
EPO was subsequently recovered from the water phase.  
To investigate the influence of variation in the lipid content on the analysis method, 
various amounts of lipids were dispersed by applying vigorous vortex in PBS buffer 
pH 7.4 (release medium) and diluted to the concentration of 0.5mg/ml, 1.5mg/ml and 
5.0mg/ml respectively (These concentrations were assumed to be around the 
concentrations which would be expected in the release fractions during the release 
tests.).  
Table V-2.  Extraction and quantification protocol   
Applied surfactants or 
organic solvents Volume/Concentration HPLC-Method Reference 
Triton X-100 1.25%- 5.0% SEC, RP Grohganz, 2004 [160] 
Tween 80 0.03% SEC, RP Hermeling, 2003 [206] 
ODG 10 mM - 50 mM SEC,RP Gonzalez, 1981[205] 
Hexane 0.3 m l – 4 ml per 1 ml sample RP Grohganz, 2004 [160] 
Chloroform 0.3 ml – 4 ml per 1 ml sample RP Qi,1995[172] 
Acetonitrile 1 ml per 1 ml sample RP - 
 
4.2. SE-HPLC METHOD 
A classical size exclusion HPLC approach using SEC column (TSK-Gel G3000Wxl, 
7.8 mm x 30.0 cm) with a flow rate of 0.7 ml/min and UV detection at 215 nm was 
applied for EPO analysis as the start point. The mobile phase consisted of 100 mM 
disodium hydrogen phosphate dehydrate and 200 mM sodium chloride, adjusted with 
hydrochloric acid to a pH of 7.0. EPO solutions of known concentrations (3.0 – 37.5 
μg/mL) were used to generate the calibration curve (Figure V-10). As shown in 
Figure V-11a, dimers (5.7± 0.4%) were detected in the protein bulk solutions.  
The next step under investigation was to evaluate possibilities for protein 
quantification in the presence of various amounts of phospholipids. 
Applying Triton X-100 caused generation of additional peaks and baseline shift. 
Moreover, EPO could not be totally separated from the Triton (Figure V-11b) Adding 
0.03% Tween 80 produced a peak around the retention time of EPO, which could not 
be baseline separated from the EPO peak (Figure V-11c). It caused problems in 
quantification especially for the proteins with low concentrations. Applying either 
30mM (Figure V-11d) or 50mM ODG no protein peak could be identified. Whether 
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there possibly occurs aggregation or degradation of EPO could not be clarified. 
Consequently, judged by the obtained results no suitable extraction protocol for SE-
HPLC could be developed and it could be stated that a SE-HPLC method might not 
be suitable for the determination of EPO in presence of lipids due to the lack of 
sensitivity and high cost. 
 
 
Figure V-10. Response curve of EPO standard solution by SE-HPLC, n=3 
The next step under investigation was to evaluate possibilities for protein 
quantification in the presence of various amounts of phospholipids. 
Applying Triton X-100 caused generation of additional peaks and baseline shift. 
Moreover, EPO could not be totally separated from the Triton (Figure V-11b) Adding 
0.03% Tween 80 produced a peak around the retention time of EPO, which could not 
be baseline separated from the EPO peak (Figure V-11c). It caused problems in 
quantification especially for the proteins with low concentrations. Applying either 
30mM (Figure V-11d) or 50mM ODG no protein peak could be identified. Whether 
there possibly occurs aggregation or degradation of EPO could not be clarified. 
Consequently, judged by the obtained results no suitable extraction protocol for SE-
HPLC could be developed and it could be stated that a SE-HPLC method might not 
be suitable for the determination of EPO in presence of lipids due to the lack of 
sensitivity and high cost. 
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(a)    EPO Bulk                                               (b) EPO extracted with Triton X-100               
(c)  EPO extracted with Tween 80                           (d) EPO extracted with ODG 
 
 
Figure V-11. SE-HPLC chromatograms of EPO. (a) EPO bulk, detection of aggregated specimen; (b) 
EPO extracted from lipids containing samples by applying 2.5% Triton; (c) EPO extracted from lipids 
containing samples by applying 0.03% Tween 80; (d) EPO extracted from lipids containing samples by 
applying 30 mM ODG.  
 
4.3. RP-HPLC METHOD 
Compared with SE-HPLC, reverse phase HPLC method has many advantages in our 
case, such as the flexibility in choosing extraction agents and robustness against the 
variation of lipids in the samples from the release fractions.     
4.3.1. VALIDATION OF THE HPLC METHOD 
For EPO quantification a RP-HPLC method using a Phenomenex C18 Jupiter column 
(5 µm, 250 x 4.6 mm) together with UV detector (215nm) was developed. Gradient 
elution was carried out (Table V-3) with eluent A containing 0.1% TFA (in ultrapure 
water) and eluent B containing 84% CH3CN and 0.08% TFA. EPO has a retention 
time around 15 minutes (Figure V-11). No obvious oxidized specimen was observed 
for the EPO bulk material. Calibration of lipid-free protein samples was established 
with the protein concentration ranging from 3.0µg/ml to 15.0µg/ml.  
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Table V-3.  Gradient elution for RP-HPLC of EPO 
Time/min Eluent A Eluent B Flow rate 
0 80% 20% 
10 40% 60% 
15 40% 60% 
20 0% 100% 
25 80% 20% 
0.5ml/min 
4.3.2. EVALUATION OF DETERGENTS AND ORGANIC SOLVENTS FOR EPO EXTRACTION 
The next step under investigation was to evaluate possibilities for protein 
quantification in the presence of lipids. To simulate the conditions expected during in-
vitro release EPO solutions were spiked with lipid dispersions (with a final lipid 
concentration of 1.5mg/ml) and the recovery of EPO was determined by the 
aforementioned RP-HPLC method and compared to the HPLC-response of lipid-free 
EPO solutions after applying a detergent or an organic solvent. Initial screening of 
the extraction methods was done with a constant EPO concentration of 10µg/ml.  
The ability of several extraction strategies to recover EPO from VPG dispersion is 
summarized in Table V-4. Among the detergents only Triton-X featured an 
acceptable protein recovery of around 90.7 % (as shown in Figure V-12a). In the 
organic solvent group the extraction of the lipids by chloroform resulted in a recovery 
of 84.6 % (Figure V-12b) whereas with hexane and acetonitrile a disastrous protein 
loss was observed. As the extraction involves the generation of water organic solvent 
interfaces proteins tend to adsorbs onto this interfaces which usually accounts for 
protein unfolding and/or aggregation [55, 207-209]. Presumably these processes 
explain the large quantities of EPO lost due to the extraction with hexane. Compared 
to the liposome disruption process caused by Triton-X the recovery of EPO by 
extraction with chloroform was slightly lower. Nevertheless, the extraction of the lipids 
by chloroform and subsequent recovery of EPO from the water phase was chosen for 
further investigations as subsequent injections of Triton X-100 containing samples 
strongly reduced the column efficiency.  
Table V-4. Recovery of EPO determined by RP-HPLC (mean± standard deviation, n = 3 each). For 
protein extraction a VPG dispersion containing 1.5 mg/ml lipid (egg PC, LIPOID E80) and an initial 
protein concentration of  10 µg/ml was treated with several detergents or organic solvents. 
Applied agent for EPO recovery CHCl3 Triton  Tween ODG Hexane AcCN 
Applied concentration per ml 
VPG dispersion 0.3ml 2.5% 0.03% 30mM 0.3ml 0.3ml 
Recovery/% 84.6±5.3 90.7±2.2 43.0±7.6 48.2±12.8 8.7±0.2 0 
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CHCl3
 (a) EPO extracted with Triton X-100, EPO bulk 
was shown as standard. 
(b) EPO extracted with chloroform, EPO 
bulk was showed as standard  
Figure V-12. RP-HPLC of EPO. (a) EPO extracted with Triton, EPO bulk was shown as standard; (b) 
EPO extracted with chloroform, EPO bulk was shown as standard.  
 
4.4. VALIDATION OF THE DEVELOPED QUANTIFICATION METHOD 
4.4.1. CALIBRATION 
The influence of various protein concentrations on the extraction efficacy was 
evaluated. Figure V-13a shows the AUC of extracted EPO by adding chloroform in 
comparison to the calibration curve in the absence of any lipids. Obviously, a good 
correlation was achieved between the detected AUCs of extracted and untreated 
EPO solutions. Based on these data and an acceptable linearity the extraction by 
chloroform was used as the standard method for EPO quantification for the in-vitro 
release studies.  
However, as the release studies will also include investigations on the influence of 
the lipid charge, the extraction efficacy in the presence of negatively and positively 
charged lipids was determined. For that purpose EPO solutions were spiked with 
VPG dispersions based either on the lipid blend of negatively charged DPPA and egg 
PC in a ratio of 1 to 9 or on a mixture of the cationic lipid DOTAP and egg PC in a 
ratio of 8 to 2. For the negatively charged lipid formulation the response curve 
revealed no differences compared to the uncharged lipid formulation (Figure V-13a). 
However, the recovery of EPO from cationic lipid dispersions was dramatically 
reduced (Figure V-13b). This poor extraction efficiency can presumably be explained 
by electrostatic interaction between the positively charged lipid vesicles and the 
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negatively charged protein (EPO has an isoelectric point of 4.2 to 4.6. At pH 7.4, 
EPO is negatively charged.). Furthermore, to confirm this, zeta potential 
measurements were performed and the results are shown in Table V-5.  
Table V-5. Zeta potential measurements. EPO was formulated in PBS buffer with a pH of 7.4.  VPGs 
were dispersed by the same PBS buffer resulting in a lipid content of 1.5mg/ml.   
Samples Zeta potential ζ/mV 
EPO without any lipids, in PBS buffer pH 7.4 -7.8±0.4 
uncharged gel vesicles, dispersed in PBS buffer,  pH 7.4 -3.4±0.7 
negatively charged gel vesicles (Egg PC/ DPPA 9:1) dispersed in PBS buffer, pH 
7.4 -6.0±0.8 
positively charged VPGs (Egg PC/ DOTAP 8:2) dispersed in PBS buffer,  pH 7.4 +14.0±0.9 
EPO + uncharged gel vesicles, redispersed in PBS buffer,  pH 7.4 -2.8±0.4 
EPO + negatively charged gel vesicles (Egg PC/ DPPA 9:1) dispersed in PBS 
buffer,  pH 7.4 -4.5±0.4 
EPO + positively charged gel vesicles (Egg PC/ DOTAP 8:2) dispersed in PBS 
buffer,  pH 7.4 +7.7±0.7 
 
To reduce these interactions various amounts of sodium chloride were added to the 
protein containing VPG formulation before the standard extraction protocol using 
chloroform was carried out. As shown in Figure V-13b the addition of at least 200 mM 
sodium chloride resulted in a suitable response curve similar to that of uncharged 
lipids.  
 
 
 
 
 
 
 
 
 
 
 
                   (a)                                                                (b)   
Figure V-13. Response curve of EPO standard solution in comparison to the recovery after extraction 
from VPG dispersion based on uncharged lipids/charged lipid blends. Extraction was performed with 
CHCl3 either by the standard protocol (a) or after the addition of 200mM sodium chloride (b). 
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4.4.2. INFLUENCE OF CENTRIFUGATION CONDITIONS 
A centrifugation process was involved in the extraction protocol using chloroform. 
Thus it was necessary to evaluate the effect of centrifugation conditions on the 
protein recovery. The samples contain a lipid content of 1.5mg/ml and 10µg/ml of 
EPO. The centrifugation duration was varied from 15 minutes to 30 minutes and the 
centrifugation speed was set to either 1500rpm or 3000rpm. The centrifugation was 
performed at 0°C or 15°C. 
As shown in Table V-6, in general the centrifugation conditions have marginal effect 
on the protein recovery. Low temperature at 0°C was preferred concerning the 
protein instability. Best recovery was achieved when centrifugation was performed at 
3000rpm for 30 minutes. So this condition was applied in the standard extraction 
protocol for EPO extraction.   
Table V-6. EPO recovery: effect of centrifugation conditions (n=3). The samples contain a lipid content 
of 1.5mg/ml and 10µg/ml of EPO. 
Temperature Centrifugation speed 
Recovery of EPO 
(centrifugation for 15mins)
Recovery of EPO 
(centrifugation for 30mins) 
0°C 1500rpm 82.9±1.0% 87.0±0.8% 
15°C 1500rpm 84.4±1.9% 84.4±1.4% 
0°C 3000rpm 89.1±1.3% 90.5±0.7% 
15°C 3000rpm 81.9±0.8% 86.8±2.8% 
4.4.3. INFLUENCE OF CHLOROFORM AMOUNT 
Further investigations were carried out in order to exclude the possibility that adding 
more chloroform might induce the protein aggregation or degradation and 
consequently reduce the protein recovery. An increasing amount of chloroform 
ranging from 0.3ml to 4ml per ml was added to 1ml lipid containing protein samples 
respectively. The samples were centrifuged and the extracted EPO was quantified by 
RP-HPLC as described above. Table V-7 showed that the amount of chloroform had 
little influence on the EPO recovery. It was suggested that the extraction method 
featured the flexibility in dissolving larger amount of lipids if in the release fractions by 
applying more chloroform. For the current study, 0.3ml Chloroform per ml sample 
was preferred in the standard extraction protocol. 
Table V-7.  Protein recovery (n=3): Effect of chloroform amount. The samples contain a lipid content of 
1.5mg/ml and 10µg/ml of EPO.  The protein was extracted by applying various amount of chloroform. 
Volume of chloroform per ml sample 0.3ml 1ml 2ml 4ml 
Recovery of EPO 87.8±1.9% 90.1±2.3% 86.0±2.2% 89.4±2.3%
Chapter V: Development of EPO loaded Vesicular Phospholipid Gels 68
 
4.4.4. INFLUENCE OF LIPID AMOUNT 
It was important to evaluate the robustness of the extraction and quantification 
method against the variation of the lipid content in the samples for the release tests. 
Various amounts of lipids (egg PC) were dispersed into PBS buffer resulting in 
concentrations of 0.5mg/ml, 1.5mg/ml and 5.0mg/ml respectively. These 
concentrations were assumed to be around the concentrations which were expected 
in the release fractions during the release tests. The proteins were extracted from all 
the samples by applying the same standard protocol using 0.3ml/ml chloroform. As a 
result, varying the lipid content in the samples had little influence on the EPO 
recovery (Table V-8). Since the amount of eroded lipids was unknown in the released 
fractions, this result allows concluding that the extraction of EPO from released 
fractions will be fine in the range up to ca. 5mg/ml lipid in the release samples.  
Table V-8.  EPO recovery: Effect of the lipids content (n=3). The samples contain 10µg/ml of EPO.            
Lipid content in the sample 0.5mg/ml 1.5mg/ml 5.0mg/ml 
Recovery of EPO 86.7±1.4% 89.7±2.4% 88.7±2.9% 
4.4.5. RECOVERY OF OXIDIZED PRODUCTS 
In addition, it was also necessary to survey whether denatured EPO could be 
recovered from lipids using the developed extraction protocol and detected by the 
RP-HPLC. EPO solutions were incubated with hydrogen peroxide to generate 
oxidized products. Lipids were dispersed to these oxidized protein containing 
solutions and resulted in a concentration of 1.5mg/ml. The samples were extracted 
and quantified by RP-HPLC. The recoveries of these oxidized products containing 
EPO samples (Table V-9) were comparable to those non-oxidized samples. As a 
conclusion, the extraction method with chloroform and RP-HPLC are capable for the 
quantification of oxidized products containing EPO.  
Table V-9.  Recovery of the oxidized products containing EPO samples (n=3). The samples contain 
1.5mg/ml of lipids.  The protein was extracted by applying chloroform. 
Concentration of 
EPO 
Percentage of the 
oxidized products in 
the samples 
Recovery of the oxidized product containing proteins 
in percentage/%,  
150µg/ml 7.3±0,5% 82,7±4,4% 
30µg/ml 10.4%±0,7% 76,2±3,1% 
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4.5. SUMMARY OF THE QUANTIFICATION METHOD 
It can be expected that EPO is released from the gel matrix both in free form and in 
liposomal form. Therefore it is essential to develop an extraction method that allows 
the quantitative recovery of the protein from the lipid containing samples without 
having detrimental effects on protein integrity. In the work of this chapter, several 
organic solvents and surfactants have been tried out. Using chloroform to extract 
lipids and subsequently recovering EPO from the water phase was found suitable in 
our case. A reverse phase HPLC method with gradient elution was developed for 
quantification of extracted proteins. Calibration of the extracted proteins was 
established with acceptable linearity and moreover it was in comparison to the 
calibration curve of the lipid-free proteins. The developed extraction and 
quantification method featured a high robustness against variations of the lipid as 
well as against variations in the protein amount. It was also possible to recover 
oxidized protein products from lipid containing samples with a comparable recovery. 
Hence it could be stated that the developed method was suitable for protein 
quantification during in-vitro release studies, which made it possible for the further 
investigations on the in vitro release of VPGs.  
5. IN VITRO RELEASE BEHAVIOUR OF EPO LOADED VPGS 
In vitro release behaviour is the most important characteristic for VPGs. So far it has 
been shown in literature that VPGs can serve as sustained release systems for 
various low molecular weight drugs, especially in the field of anticancer treatment 
[11,12] Grohganz [13] has entrapped the small peptide hormone cetrorelix into VPGs: 
in vitro release of the peptide from VPGs ranged from 24 hours to a predicted 
sustained release of over more than 3 months. The release mechanism of VPGs has 
been demonstrated by Tardi [11] using calcein as the model compound: the 
entrapped drug released via erosion of the lipid matrix as well as diffusion out of the 
swollen VPGs. This holds true for the small molecular weight substances. In the case 
of the peptide, it was demonstrated that free diffusion of the peptide through the 
tightly packed lipid matrix could not be expected due to its missing lipophilicity and 
the larger molecular size. Hence it could be assumed that erosion was also the 
dominating factor for protein release from VPGs. It was the aim of our work to reveal 
the protein release behaviour from VPGs and proof the hypothesis. In vitro release 
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tests were performed in flow-through cells (as described in Chapter IV) with PBS 
buffer pH 7.4 at 37°C. The influence of the lipid content and the composition of the 
VPG on the release behavior was evaluated. The released EPO was extracted by the 
developed protocol using chloroform and subsequently quantified by RP-HPLC. To 
investigate the erosion of the matrix, lipid content in the release fractions was 
quantified by an enzymatic assay. Moreover, the protein stability during release was 
examined by SDS-PAGE. The vesicle size of the release fractions was analyzed with 
PCS. Protein adsorption to the release system was also studied.    
5.1. INFLUENCE OF THE LIPID CONTENT 
The influence of lipid concentration on the release of VPGs was the first factor to be 
evaluated. VPGs were prepared with a constant EPO content of 3.8mg/g and 
increasing lipid concentration from 300mg/g to 550 mg/g egg PC (E 80). As it can be 
seen in Figure V-14 increasing the lipid concentration from 300mg/g to 550 mg/g 
decreases the release rate of EPO from the VPGs. From 400mg/g to 500 mg/g lipid 
the system was rather robust and lipid concentration did not have much effect on the 
release kinetics. For instance VPGs consisting of 400mg/g, 450mg/ml and 500 mg/ml 
lipid all delivered about 60% of the incorporated EPO within 280 hours. In contrast, 
VPGs based on 550mg/g lipid released only 40% of the drug and VPGs with 
300mg/ml about 75% of the drug load within this time period.  Importantly, EPO was 
released from all formulations in a linear manner with no burst effect. This trend of 
the influence of the lipid content was in good agreement with the earlier studies on 
the calcein and the peptide CXA.  
The amount of phospholipid content in the release fractions was analyzed by an 
enzymatic assay (LabAssay Phospholipid, Wako, Neuss, Germany). The assay was 
performed in 96-well plates. The adsorption of the reaction product was measured at 
600nm. Figure V-15 showed the lipid release profiles from VPGs based on various 
contents of uncharged egg PC. As a result, low lipid concentration facilitated fast 
erosion of lipids while higher lipid concentration delayed matrix erosion. A closer 
investigation on the release mechanism is discussed later.  
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Figure V-14. Cumulative release of EPO from VPGs based on various concentrations of egg PC 
(LIPOID E80) (Mean± standard deviation, n = 3 each). The protein concentration in all formulations 
was 3.8mg/g. 
 
Figure V-15. Lipid release (Erosion) from VPGs based on various concentrations of egg PC (LIPOID 
E80) (Mean± standard deviation, n = 3 each). The protein concentration in all formulations was 
3.8mg/g. 
5.2. INFLUENCE OF THE LIPID COMPOSITION 
In order to investigate the influence of lipid composition, release tests of two VPG 
formulations with charged lipids (E 80/ DPPA 9:1, E 80/ DOTAP 8:2, respectively, 
total lipid concentration 500mg/g) were performed. A constant protein concentration 
of 3.8 mg/g was used in these formulations. As it can be seen in Figure V-16 the 
negatively charged gel vesicles (Egg PC/ DPPA 9:1) delivered the incorporated 
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protein in a comparable manner to the uncharged formulation whereas the positively 
charged VPGs (Egg PC/ DOTAP 8:2) revealed a strongly accelerated release rate. In 
agreement with protein release the erosion of lipids from VPGs containing positively 
charged DOTAP was faster than from uncharged or negatively charged gel 
formulations (Figure V-17).  
 
                         
Figure  V-16. Influence of lipid charge on the in-vitro release of EPO. The VPGs consist either of pure 
egg PC (LIPOID E80); a mixture of egg PC (LIPOID E80) and DPPA in the ration 9:1 or a mixture of  
egg PC (LIPOID E80) to DOTAP in the ratio 8 to 2. The lipid concentration in all formulations was 
500 mg/ml (mean± standard deviation, n = 3 each). 
  
Figure V-17. Influence of lipid charge on the release of lipid. The VPGs consist either of pure egg PC; 
a mixture of egg PC and DPPA in the ration 9:1 or a mixture of egg PC to DOTAP in the ratio 8 to 2. 
The lipid concentration in all formulations was 500 mg/ml and the concentration of EPO was 3.8mg/g. 
(mean± standard deviation, n = 3 each). 
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However, in contrast the gel rigidity and viscosity measured (Chapter V.2) did not 
show pronounced differences between VPGs containing positively charged lipids and 
uncharged/negatively charged gels. Hence it was assumed that the electrostatic 
interaction between the positively charged lipid vesicles and the release medium 
(PBS buffer pH 7.4) facilitates the erosion as well as the EPO release from the 
system.  
5.3. RELEASE MECHANISM 
In general drug release from VPGs can be explained by two mechanisms: drug 
diffusion out of the lipid matrix and/or erosion of the matrix [11, 51].  
As shown in Figure V-18 (taking VPGs containing 550mg/g lipids and 3.8mg/g EPO 
for example), the correlation between the lipid release (erosion of the phospholipid 
matrix) and the release of EPO was found constantly although the absolute values 
differed in various VPG formulations. Clearly, erosion is the dominant mechanism 
controlling EPO release. This is in agreement with former observations which 
showed that mainly matrix erosion governed the delivery of small molecular weight 
drugs [12, 50, 138, 155] and peptides [51] from VPGs. Moreover, it was found that 
the lipid charge was of dominant importance besides a strong influence of the lipid 
concentration on the matrix erosion. 
 
Figure V-18. Daily release percentage of EPO and lipid (erosion of phospholipid matrix) from VPGs. 
The y axis is the daily released percentage of the total protein/lipid content within VPGs. (VPGs 
contained  550 mg/g egg PC and 3.8 mg/g EPO. (Mean ± SD, n = 3 each) 
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5.4. INTEGRITY OF THE RELEASED PROTEIN FROM VPGS 
EPO was liberated from VPGs in a continuous manner over days, delivering at least 
60% of the incorporated proteins. The remaining protein was not detectable in the 
release medium despite the fact that the matrices were completely eroded after 3 
weeks of incubation.    
Consequently, the stability of proteins released from VPGs (Taking VPGs consisting 
of 400mg/g lipids and 3.8mg/g EPO for example) was examined. The proteins were 
extracted by applying chloroform (as described previously) from release fractions. 
SDS-PAGE was performed with subsequent silver staining.   
As a result, the presence of dimer specimen was evident in all EPO samples (Figure 
V-19). However, the release process of EPO from VPGs did not feature the creation 
of this dimer fraction detected in all release fractions since the dimer was already 
present in the EPO bulk materials (referring to the SE-HPLC of EPO bulk, Figure V-
11a).  
 
 
 
 
 
 
 
  
   
Figure  V-19. EPO stability released from VPGs consisted of 400mg/g lipids and 3.8mg/g EPO. Lane1, 
EPO released after 216hrs; lane 2, EPO released after 168hrs; lane 3, EPO released after 96hrs; lane 
4, EPO released after 48hrs; lane 5, EPO standard solution; lane 6, molecular weight maker. 
 
5.5. PARTICLE SIZE DISTRIBUTION 
The most important morphological characteristic of liposomes and VPGs is the 
vesicle size and distribution. The vesicular morphology has been confirmed by cryo 
electron microscopy of dispersed samples [152]. The other standard method for 
determination of the size distribution of liposomes is PCS.  
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In this work, the vesicle size of the release fractions was analyzed with PCS. The 
results were represented as intensity-weighted averages. As shown in Table V-10, 
the mean particle sizes of all the EPO VPG formulations were in the range up to ca. 
270nm.  
Table V-10. Mean particle size of release fractions from VPGs based on various contents of lipids.      
EPO VPGs Based on 400mg/g lipids 
Based on 
450mg/g lipids 
Based on 
500mg/g lipids 
Based on 
550mg/g lipids 
Particle size of 
release fraction 172nm-205nm 175nm-239nm 156nm-261nm 188nm-271nm 
 
In previous work, Grohganz [13] has determined the particle size of liposome 
dispersions from Cetrorelix loaded VPGs which were formulated by high pressure 
homogenizer. In his work, all the formulations showed a particle size of around 30 - 
50 nm for more than 90% of all the particles. The relatively larger vesicles in our case 
can probably be ascribed to the different preparation technique (In our work, 
formulation of VPGs was performed on DAC) as already observed in the work of 
Massing [147]. However, the EPO loaded VPGs are suitable for application as a 
depot for in situ application. 
6. ADSORPTION STUDY OF EPO 
As shown in Figure V-14 and Figure V-16, protein release levelled off before 
reaching 100% of the total drug load. For PLGA based protein depot systems 
incomplete protein release was often correlated with protein denaturation and/or 
aggregation occurring during system preparation or within the release period or 
during storage [55, 208]. However, as explained above protein aggregation due to 
the manufacturing can be excluded. Protein loss might occur due to adsorption of 
EPO on exposed surfaces since as amphiphilic molecules proteins tend to adsorb on 
interfaces, In order to evaluate adsorption in the release setup EPO solution (10µg/ml) 
alone or spiked with highly diluted VPG dispersions (with a lipid content of 1.5mg/ml) 
was continuously pumped with a flow rate of 1ml/hr through the release system. As it 
can be seen in Figure V-20 already after 12 hours the protein concentration 
decreased by 10µg/ml to 82% for the unspiked and to 93% for the phospholipid 
spiked EPO solution. For the VPGs consisting of 300mg/g lipids and 3.8mg/g EPO, 
75% of the protein was recovered after the total erosion of the matrices. Since EPO 
was expected to release from VPGs both in free form and in liposomally entrapped 
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form, the protein loss caused by unspecific adsorption was in the range from 7% to 
18%. Accordingly, the incomplete protein release was mainly caused by unspecific 
adsorption onto the flow-through release system surfaces.  
Typical means to avoid such adsorption, e.g. addition of surfactants were not applied 
because they would have affected erosion and release heavily by dispersion of the 
VPGs. 
                     
Figure V-20. Adsorption of EPO on the in-vitro release system. The adsorption behaviour of EPO was 
studied in the presence and in the absence of diluted VPG dispersions.  The flow rate was fixed at 
1ml/hr and the cells were incubated at 37°C.  
7. SUMMARY AND CONCLUSION 
In the first part of this section manufacturing strategy based on the dual asymmetric 
centrifugation was developed to produce EPO loaded VPGs. The temperature of the 
preparation process could be controlled with multiple centrifugations and cooling in-
between.  
The obtained VPGs all exhibited rubbery consistency with homogenous morphology 
under visual and microscopic inspection. On the other hand, increasing the lipid 
content in the VPG-formulations resulted in the increased gel rigidity and viscosity.  
SDS-PAGE was performed to analyze the stability of EPO entrapped in VPGs.  
Extraction agents including organic solvents and surfactants were applied to 
eliminate the influence of the lipids. No detrimental effect of the extraction methods 
was found by the SDS-PAGE. Applying chloroform to extract lipids and subsequently 
recover EPO from the aqueous phase was found the most suitable extraction method 
which featured highest protein recovery. Moreover, denatured products of the protein 
could also be recovered from the lipid containing samples and detected by the SDS-
Chapter V: Development of EPO loaded Vesicular Phospholipid Gels 77
 
PAGE. Hence it could be stated the analysis method was established and well 
validated.  SDS-PAGE analysis of EPO extracted from the VPGs matrix revealed no 
aggregates or fragments, and it was concluded that the formulation procedure 
caused no detrimental effect of EPO. 
As the protein stability was not affected by the formulation process the prerequisite 
for a successful sustained release system based on lipids was fulfilled and further 
investigations on the in-vitro release studies were encouraged. However, a major 
obstacle was found in the protein quantification from the release fractions since the 
presence of lipids had strong interference on the routine analysis methods (e.g. 
HPLC, photometry). Therefore it was essential to develop an extraction method that 
allowed the quantitative recovery of the protein from the liposome fraction without 
having detrimental effects on the protein integrity. As for quantification, RP-HPLC 
was found to have more advantages in our case than SE-HPLC in robustness and 
flexibility in choosing the extraction agents. Among the organic solvents and 
surfactants tried out, applying chloroform for extraction of the lipids and subsequent 
recovering of EPO from the water phase was found most suitable. Calibration of 
extracted EPO from lipids was established with acceptable linearity. In the case of 
lipids containing egg PC or negatively charged lipid blends, good correlations were 
achieved between the detected AUCs of extracted and untreated lipid-free EPO 
solutions. However, due to the electrostatic interaction between the positively 
charged lipid vesicles and the negatively charged protein, the recovery of EPO from 
cationic lipid dispersions was dramatically reduced. Hence, the extraction protocol 
was modified by addition of at least 200 mM NaCl to reduce the interaction and 
consequently resulted in a suitable response curve similar to that of uncharged lipids. 
In addition, the influence of the centrifugation conditions on the protein recovery was 
evaluated to achieve an optimised process. Importantly for the release tests, 
variations of the lipid amount as well as variations in the protein amount had little 
effect on the EPO recovery. It was also possible to recover oxidized protein products 
from lipid containing samples with a comparable recovery. With the developed 
quantification method of EPO in lipid containing samples, it was possible for the 
further investigations on the in vitro release of VPGs.  
The release profile could be tailored by varying the lipid content within VPGs 
formulations. Irrespective of the investigated formulation all VPGs delivered the 
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protein over prolonged periods of time at close to linear kinetics without any burst 
effect. For instance formulations based on 300mg/g lipid delivered 83% EPO after 
280 hours while gels based on 550mg/g lipid liberated 64% within 400 hours. Beside 
the lipid content, the lipid charge also had a strong influence on the release behavior. 
Incorporating 20% of positively charged lipids (DOTAP) into VPGs resulted in a 
strongly accelerated release rate while adding the 10% of negatively charged lipids 
(DPPA) delivered the incorporated protein in a comparable manner to the uncharged 
formulation. It was assumed that the erosion of the VPG matrix was facilitated due to 
the ionic interaction between the lipid vesicle and the buffer solution in the case of 
the addition of positively charged lipids. The desired release kinetics can easily be 
achieved by adjusting the lipid content or the lipid charge. From the parallelism of 
release and erosion kinetics found for all formulations it was concluded that erosion 
rather than diffusion was the dominant release controlling mechanism for these 
macromolecule-loaded VPGs.  
Importantly, SDS-PAGE analysis of EPO extracted from VPGs’ release fractions 
revealed no further aggregates or fragments beside the denatured products that 
already existed in the protein bulk solutions. Hence the in vitro process featured no 
detrimental effect on the protein incorporated within VPGs detected by SDS-PAGE. 
The vesicle size of the liposomes released from VPGs was majorly in the range up to 
300nm .This result encouraged the expectation that a large number of protein drugs 
can be transferred into stable liposomes when using VPGs as a depot. 
In the final section of this chapter, the protein adsorption onto the release system 
was investigated since incomplete release was observed for the in vitro release tests.    
As a result, the protein got 7% lost after 12 hours in presence of lipids while much 
more protein loss (18%) was observed without liposomal entrapment. Since the 
protein was released from VPGs both in free form and in liposome form, the 
adsorption of EPO in the release fractions was in the range from 7% to 18%. This 
unspecific adsorption to the release system mainly contributed to the incomplete 
release of EPO from the matrices and should be corrected from the results to reveal 
the real situation of in vivo application of the VPGs. 
Thus it was assumed the unspecific adsorption led to the incomplete protein release 
from VPGs. However, surfactant was not used since it might affect erosion and 
release by dispersion of the VPGs. 
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As conclusion, a sustained release of EPO from VPGs over several hundred hours 
was observed depending on the formulations. The release of EPO from VPGs is 
dependant on the erosion of the lipid matrix. Varying the lipid content and 
composition can modify the erosion and the EPO release profile. Moreover, the 
protein released from VPGs is expected both in free form and in liposomally 
entrapped form. These two parts could be differentiated by using asymmetric flow 
Field Flow Fractionation (AFFF) technique in future work.  
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CHAPTER VI: VPGS FOR GROWTH FACTOR DELIVERY 
Growth factors contribute to tissue regeneration at various stages of cell proliferation 
and differentiation [210-211]. Although many studies using growth factors have been 
carried out, limited success has been achieved due to their very short half-life time in 
vivo to retain the biological activity. Thus, many different controlled release devices 
have been optimized for controlled delivery of the growth factors. Choi [212] has 
reported a sustained release of G-CSF over a week in vitro by using PLGA based 
nanoparticles. Hydrogels based on polyethylene glycol or other copolymers  have 
been investigated for delivering insulin-like growth factor (IGF-1) [213] and vascular 
endothelial growth factor (VEGF) [214]. A combination of PLGA microspheres 
embedded in a PLGA matrix has been used for rapid delivery of VEGF from the 
PLGA matrix followed by a sustained release of platelet derived growth factor (PDGF) 
from the embedded microspheres [215]. This combination delivery of multiple growth 
factors has shown improved growth of stable blood vessels around tissue 
engineering constructs. Gelatin based hydrogels were used for the immobilization 
and controlled release of human recombinant basic fibroblast growth factor (bFGF) 
and G-CSF. The co-delivery of the bFGF and G-CSF highly increased endothelial 
branch point formation than the delivery of either growth factor alone [216].  
The aim of this chapter is to develop the VPGs with loading of growth factors. 
Various VPG-formulations of granulocyte colony-simulating factor (G-CSF) were 
prepared and characterized with the established methods. In vitro release behavior 
was evaluated to address the potential of the system for the delivery the growth 
factors. In vivo experiments would be carried out using rats as animal model. VPGs 
prepared with various doses of G-CSF, bFGF and a combination of the two growth 
factors would be applied in the rupture of the tendon to offer a sustained release of 
proteins. The therapeutic effect for the implantation of VPGs would be evaluated.  In 
order to study the pharmacokinetics, ELISA was performed to develop a 
quantification method of G-CSF in the serum.     
1. PREPARATION OF G-CSF LOADED VPGS 
The G-CSF stock solution used here has a concentration of 4.0mg/ml in 10mM 
acetate buffer pH 3.9 containing 0.004% Tween and 5% sorbitol. Egg 
phosphatidylcholine (E80) were supplied from LIPOID. G-CSF VPGs were 
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formulated in DAC following the procedure described in the method section. In brief,  
the protein solution was added to the lipids. The mixture was homogenized in DAC 
by multiple runs of 1.5-minutes (to a total mixing time of 45 minutes) at a process 
speed of 3500 rpm. The samples were cooled at 2-8°C at interrupts (after 6-10 runs) 
to control the system temperature below 40°C.  Several formulations were prepared 
to evaluate the influence of the lipid and protein content on the release behaviour. 
The lipid content was varied between 400mg/g and 550mg/g. The concentrations of 
G-CSF were varied from 2.2mg/ml to 8.4mg/ml.   
2. TEXTURE ANALYSIS AND RHEOLOGY TEST OF G-CSF VPGS 
The Texture analyser (TA.XT plus, Stable Micro Systems, UK) recorded the forces 
(Figure VI-1a) which occured when the probe (4mm in diameter) was pushed with a 
speed of 0.5mm/s into the tested VPGs. The gel strength of VPGs was represented 
as the maximal force value. The rheology behaviour of MAB VPGs was studied by a 
rotational viscometer (Physica MCR 100, Anton Paar) at 25°C. The shear viscosity 
was provided versus shear rate ranging from 10-1 and 100-1 (up and down curve, 
Figure VI-1b).  
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Figure VI-1. (a) Texture analysis of G-CSF loaded VPGs: recorded force trace when the probe (4mm 
in diameter) was pushed with a speed of 0.5mm/s into the tested VPGs. VPGs were based on 
450mg/g lipids and 2.2mg/g G-CSF. (b) Rheological behaviour of VPGs. VPGs were based on 
450mg/g lipids and 4mg/g G-CSF. 
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The influence of the lipid content in VPG-formulations on both the gel strength and 
viscosity was investigated. VPGs were prepared by various lipid contents ranging 
from 400mg/g to 490mg/g. A constant G-CSF concentration of 4mg/g was used in all 
the formulations. Increased gel strength was found by incorporating more lipids within 
VPGs (Figure VI-2a). The maximal force of VPGs based on 400mg/g lipids was 
16.4g, while the value of VPGs consisted of 490mg/g lipids was 52.6g. As for the 
rheological behaviour of VPGs, the viscosity was compared at the same shear rate of 
37.9s-1. As shown in Figure VI-2b, increasing the lipid content also resulted in 
increased viscosity.  
   
                              (a)                                                                                       (b) 
Figure VI-2. (a) Gel strength (mean±SD, n=3) of G-CSF loaded VPGs. VPGs were prepared by 
various contents of lipids (as indicated in the figure) and a constant G-CSF concentration of 4mg/g. (B) 
Viscosity (mean±SD, n=3) of G-CSF loaded VPGs. VPGs were prepared by various contents of lipids 
(as indicated in the figure) and a constant G-CSF concentration of 4mg/g. 
 
The influence of the G-CSF content within VPG-formulations on both the gel strength 
and viscosity was also investigated. VPGs were prepared by varying the protein 
contents from 2.2mg/g to 8.4mg/g. A constant lipid concentration of 450mg/g was 
used in all the formulations. As shown in Figure VI-3a, VPGs based on 2.2mg/g G-
CSF had a gel strength value of 28.4g while VPGs containing 4.0mg/g G-CSF got a 
similar value of 27.1g. When the lipid content was further increased to 8.4mg/g, the 
gel strength was much higher (49.4g). However, the viscosity got little influenced by 
changing the protein content in this concentration range taken the standard deviation 
into consideration (Figure VI-3b). In accordance with the results of texture analysis, 
the viscosity (13.3 Pa.s) of VPGs based on 4.0mg/g G-CSF was slightly lower than 
that of VPGs based on 2.2mg/g.  
Comparing G-CSF VPGs with EPO VPGs, the gel strength and viscosity of G-CSF 
VPGs were lower than those of EPO VPGs which were based on the same content 
of lipids (EPO was formulated with 20mM PBS buffer while G-CSF was formulated 
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with 10mM acetate buffer). Further experiments were performed and it was found 
that the buffer ingredients in the protein solutions have strong influence on the gel 
strength and viscosity. Therefore the difference in the gel texture was attributed to be 
the different buffers used in the different protein samples. 
 
                                         (a)                                                                    (b) 
Figure VI-3. (a) Gel strength (mean±SD, n=3) of G-CSF loaded VPGs. VPGs were prepared by 
various contents of G-CSF (as indicated in the figure) and a constant lipid concentration of 450mg/g. 
(b) Viscosity (mean±SD, n=3) of G-CSF loaded VPGs. VPGs were prepared by various contents of G-
CSF (as indicated in the figure) and a constant lipid concentration of 450mg/g. 
 
3. EVALUATION OF G-CSF STABILITY BY SDS-PAGE 
The integrity of G-CSF was analyzed by non-reducing SDS-PAGE with subsequent 
silver staining. In brief: the electrophoresis was performed on the Bis-Tris Pre-Cast 
Gel (Invitrogen, Groningen, Netherlands) in the MES running buffer (Invitrogen).  
Without applying an extraction process, the analysis of G-CSF VPGs (redispersed in 
PBS buffer pH 7.4 resulting in a protein concentration of 100ug/ml) was strongly 
interfered by the presence of lipids (Figure VI-4a). Hence organic solvents and 
surfactants including chloroform, dichloromethane, ethanol and Triton X-100, were 
tried out to dissolve the lipids. As surface active molecules, proteins tend to adsorb at 
water/organic solvent interfaces. Since this adsorption step can induce protein 
instability [55, 217], the influence of the extraction agents on the protein stability was 
evaluated as the start point. It was found that adding ethanol to the G-CSF in 
absence of any lipids resulted in low protein recovery (as indicated by the band 
intensity). Beside the acceptable recoveries, no aggregation or fragmentation fraction 
was observed when other extraction agents were applied to the G-CSF without lipids 
(Figure. VI-4b). Then these extraction agents except ethanol were applied for the 
extraction of G-CSF from VPGs. As shown in Figure VI-4c, the dissolution of the 
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lipids by adding Triton X-100 resulted in the highest recovery of G-CSF without any 
detection of degradation products. Though the methods using chloroform and 
dichloromethane revealed lower extraction efficiencies, none of these methods 
featured aggregation or fragmentation of G-CSF. Accordingly, the formulation 
process to entrap G-CSF within VPGs suggested no detrimental effect on the protein 
stability.  
   
 
                       (a)                                                  (b)                                                         (c) 
Figure VI-4.  Influence of the formulation process on the GCSF stability, by SDS-PAGE, silver staining.  
(a): lane 1, molecular weight marker; lane 2, G-CSF standard; lane 3, G-CSF VPGs’ dispersions 
without applying extraction process.  
(b): lane 1, G-CSF solution (in absence of lipids) with adding Triton X-100; lane 2, G-CSF solution (in 
absence of lipids) with adding dichloromethane; lane 3, G-CSF solution (in absence of lipids) with 
adding chloroform; lane 4, G-CSF solution (in absence of lipids) with adding ethanol; lane 5, G-CSF 
standard; lane 6, molecular weight marker.  
(c): lane 1 G-CSF VPGs, the protein was extracted by applying Triton X-100; lane 2, G-CSF VPGs, 
the protein was extracted by applying dichloromethane; lane 3, G-CSF VPGs, the protein was 
extracted by applying chloroform; lane 4, G-CSF standard;  lane 5, molecular weight marker.      
4. CHARACTERISATION OF THE SECONDARY PROTEIN STRUCTURE WITHIN VPGS 
FTIR-spectroscopy has been suggested to analyze the secondary structure of 
proteins embedded within controlled release devices [218-220]. However, vibration of 
the matrix materials in the spectrum was observed, which might have interference on 
the spectra of the embedded proteins [219]. Van de Weert [219] has tried out to 
correct the spectra of lysozyme embedded within PLGA microspheres by the spectra 
of the blank PLGA microspheres. However, it was found that the background from 
the blank could not be completely removed because of the baseline slopes and 
distorted peak shapes especially in the carbonyl stretch vibration of PLGA. Moreover, 
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the different adsorption characteristics of protein–loaded microspheres were also 
suggested to restrict the subtraction of the spectrum of blank PLGA microspheres 
[219]. In the work of Herrmann [100], the same problem was observed for the IFN-α 
embedded in a lipid extrudate. The variations of the subtraction factor either involved 
an over-subtraction or an under-subtraction of the lipid contributions, leading to 
negative or positive features between 1700 and 1800 cm-1. 
In this context, FTIR with the ATR-technique was used for the analysis of G-CSF 
either formulated in the buffer (10mM acetate buffer pH 3.9) or embedded within 
VPGs.  
 
                                                 (a)                                                                   (b) 
Figure VI-5: ATR-spectrum, (a) G-CSF in the buffer solution; (b) G-CSF VPGs (without subtraction) 
based on 450mg/g lipids and 4mg/g G-CSF and placebo VPGs based on 450mg/g lipds.  
As illustrated in Figure VI-5a, the spectra recorded by the ATR-technique revealed a 
protein signal in the amid l/amid II region for the G-CSF in buffer solution.  
The potential of FTIR to characterize the secondary structure of proteins embedded 
within VPGs was investigated subsequently. G-CSF VPGs were freshly prepared 
with 450mg/g lipids and 4mg/g G-CSF. As shown in Figure VI-5b, the spectrum of G-
CSF VPGs was influenced by the background from placebo VPGs. Yang [220] 
suggested a flat baseline in the region at 1730 - 1710 cm-1as criterion for successful 
background subtraction. However, it was not possible to fulfil this request with the G-
CSF loaded VPGs studied here.  
In addition, several extraction methods were applied to eliminate the influence of the 
matrix background. However, lipids could not be removed clearly, and the left lipids 
still got strong interference. Hence we have no access to use FTIR to examine the 
protein stability in the study.  
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5. QUANTIFICATION METHOD FOR RELEASED G-CSF  
A quantification and extraction method was needed for MAB analysis from lipid 
containing samples. Since the released amount of VPGs at each time interval was 
unknown, the quantification method should feature a high robustness against 
variations of the lipids as well as against variations in the protein amount which make 
this method suitable for protein quantification during in-vitro release studies. The 
fluorescamine assay and reverse phase HPLC method were assessed in the 
following.  
5.1. THE FLUORESCAMINE ASSAY 
Anderson [221] has used a fluorescamine assay to detect microgram quantities of 
GM-CSF in presence of dimyristoyl phosphatidyl choline (DMPC). Accordingly, the 
assay was performed for the quantification of G-CSF from the liposome fractions. A 
modified process using the 96 well-microplate as described by Lorenzen [194] was 
performed. Briefly, 150µl of the protein containing samples (in PBS buffer pH 7.4) 
and standards were pipetted into microplate wells (Nunc MaxiSorp™, Roskilde, 
Denmark). Fluorescamine was dissolved in acetone resulting in a concentration of 
3mg/ml. The microplate was placed on a microplate shaker and 50µl of the 
fluorescamine solution was added to each well. After shaking for a minute, the 
fluorescence was determined by using an excitation wavelength of 400nm 
(bandwidth: 20nm), and an emission wavelength of 460nm (bandwidth: 20nm). 
Placebo VPGs were dispersed with PBS buffer pH 7.4 resulting in lipid 
concentrations from 0.5mg/ml to 5mg/ml. To simulate the conditions expected during 
in-vitro release G-CSF solutions (10µg/ml) were spiked with diluted VPG dispersions 
and the recovery of G-CSF was determined and compared to the results of lipid-free 
G-CSF solutions by the assay. As shown in Table VI-1. The results of the assay were 
strongly influenced by the presence of various contents of lipids. Thus it could be 
stated the assay appeared not suitable in our case. 
Table VI-1. Recovery of G-CSF from liposome containing samples, by the fluorescamine assay, n=8 
Lipid concentration 0.5mg/g lipids 1.5mg/g lipids 5.0mg/g lipids 
G-CSF recovery 142±13% 159±24% 243±37% 
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5.2. RP-HPLC METHOD 
From the experiences in developing the quantification method of EPO, reverse phase 
HPLC appeared reasonable for G-CSF quantification in the samples containing 
liposomes. The method was developed with a ProSwiftTM RP-2H column (4.6*50mm, 
Dionex). Gradient elution was performed as shown in Table VI-2. The eluent A 
consisted of 0.12% TFA in destilled water, and the eluent B consisted of 90% CH3CN 
(in destilled water) and 0.1% TFA. The UV detector was operated at 215nm. The 
injection volume was 100µl. 
Table VI-2. Gradient elution for RP-HPLC of G-CSF 
Time/min 0 5 10 25 30 35 40 45 
Eluent A% 100 80 60 60 40 20 0 100 
Eluent B% 0 20 40 40 60 80 100 0 
Flow rate 1.5ml/min 
 
G-CSF had a retention time around 28minutes (Figure VI-6). The calibration curve 
was generated with the protein concentrations ranging from 2.5µg/ml to 20.0µg/ml for 
the G-CSF solutions in absence of lipids (Figure VI-7).  
 
Figure VI-6. RP-HPLC chromatogram of G-CSF 
standard, 5µg/ml 
 
Figure VI-7. Calibration of G-CSF standard, 
concentrations of G-CSF ranged from 2.5µg/ml 
to 20.0µg/ml, R2=0.990 
 
 
 
 
5.3. EXTRACTION METHOD 
To determine the concentration of G-CSF in the release fractions, an extraction 
method is necessary for the dissolution of the lipids and extraction of the protein. The 
extraction method should allow the quantitative recovery of the protein from the 
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liposome fractions without having detrimental effects on the protein integrity. To 
simulate the conditions expected during in-vitro release G-CSF solutions were spiked 
with diluted VPG dispersions and the recovery of G-CSF was determined and 
compared to the HPLC-response of lipid-free G-CSF solutions after applying a 
detergent or an organic solvent. For the initial screening of the extraction methods, 
the samples were prepared with a G-CSF concentration of 10µg/ml and a lipid 
content of 1.5mg/ml. 
5.3.1. METHOD DEVELOPMENT  
In Chapter V it was shown that applying chloroform for the dissolution of lipids 
resulted in good recovery of EPO. Thus as a start point, chloroform (0.3ml per ml 
sample) was applied for extraction of G-CSF from lipids containing samples. The 
protein was recovered from the supernatant and subsequently quantified by the 
aforementioned RP-HPLC method. As shown in Figure VI-8a, a low protein recovery 
of 22.5±2.0% was observed for G-CSF extracted by applying chloroform. Thus other 
extraction methods had to be assessed.   
In previous work, Grohganz [204] used Triton X-100 for the dissolution of liposomes 
and extraction of the decapeptide cetrorelix from VPGs. Accordingly, 5% Triton X-
100 was applied for G-CSF extraction. As shown in Figure VI-8b, Triton X-100 has 
generated multiple peaks which could not be totally separated from the protein peak. 
This phenomenon was already observed in the application of Triton X-100 for EPO 
extraction. In addition, a fluorescence detector (Excitation wavelength: 280nm, 
Emission wavelength: 340nm) was also used aimed to eliminate the influence of the 
Triton X-100. However, similar results were obtained which made the extraction 
method with applying Triton X-100 not suitable in this case. 
Methanol has been used  to dissolve lipids in the G-CSF liposome samples prior to 
HPLC analysis [222]. Hence, this method was also assessed in our work. 1ml 
methanol was applied to extract G-CSF from the lipid (1.5mg/ml) containing samples. 
However, our challenge here is the variation of the lipid content as well as the 
variation of the protein content in the released samples.  
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      (a)                                                                               (b) 
Figure VI-8.  RP-HPLC chromatograms of G-CSF, (a) extracted G-CSF by applying chloroform, G-
CSF standard was shown as reference, (b) G-CSF by applying Triton X-100 for dissolving the lipids, 
G-CSF standard was shown as reference. 
Unfortunately, it was observed that the recovery of G-CSF was influenced by the 
original protein content in the samples when methanol was applied for lipid 
dissolution (Table VI-3). At lower protein concentrations the protein recoveries were 
implausibly high, which was probably caused by the baseline noise. In comparison 
about 48% was recovered from 10µg/ml G-CSF. However, the dilution effect of 
methanol has to be taken into account since methanol is miscible with the buffer 
solution. Regardless of this point, the method using methanol for extraction appeared 
not suitable for the quantification of released G-CSF from VPGs.  
Table VI-3. Recovery of G-CSF from liposome containing samples, methanol was added to dissolve 
the lipids, n=3 
Concentration G-CSF 2.5µg/ml 5.0µg/ml 7.5µg/ml 10µg/ml 
G-CSF recovery±SD% 336.7±40.4% 95.9±-9.0% 58.9±1.9% 48.2±8.6% 
 
When chloroform was added to the G-CSF samples, the recovery of G-CSF was only 
about 22.5% for the lipids (1.5mg/ml) containing samples, whereas it was 
interestingly found about 100% of the protein was recovered in absence of lipids. Our 
hypothesis was that the low recovery of G-CSF could be caused by the interaction 
between the protein and the lipids. Due to the interaction a part of the proteins were 
transported to the organic phase with the lipids, which consequently resulted in low 
protein content recovered from the aqueous phase. Some trials were made aimed to 
reduce the interaction: The pH of the solution was adjusted to change the protein 
charge (G-CSF has a pI of 6.1 [223], The zeta potential in various buffer conditions 
was shown in Table VI-4.). Chloroform was added for lipid extraction and the 
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recovered protein was quantified by the developed RP-HPLC method. As shown in 
Table VI-4, the recovery of the G-CSF was even worse at either a pH of 3.0 or pH 
10.0. Thus varying the charge of the protein failed to improve the extraction efficiency 
of the method. 
Table VI-4. G-CSF recovery: influence of the protein charge, the protein was extracted by applying 
chloroform. 
G-CSF Sample 
G-CSF in liposome 
containing samples, pH 
7.4. 
G-CSF in liposome 
containing samples, pH 
3.0. 
G-CSF in liposome 
containing samples, pH 
10.0. 
Concentration 10 µg/ml 
Zeta potential ζ/mV -4.4±0.3 4.4±0.3 -20.8±1.0 
Recovery±SD% 22.5±2.0% 10.3±5.8% 7.6±12.5% 
 
However, low protein recovery by applying chloroform might also be induced by the 
protein instability occurred at the interface [209, 224] since the presence of lipids 
might create an improved interface between the protein and the organic solvent. 
Consequently some trials were made based on the report that adding a high amount 
of sucrose could improve the stability of the protein [225].  Accordingly, sucrose was 
added to the samples, and the G-CSF was extracted by applying chloroform and 
quantified by RP-HPLC. As a result, the addition of sucrose could not efficiently 
improve the protein recovery (Table VI-5) whereas resulted in high viscosity of the 
samples which might harm the HPLC column.  
Table VI-5. G-CSF recovery: the addition of sucrose on the recovery of G-CSF. The protein was 
extracted by applying chloroform and subsequently quantified by RP-HPLC. 
Concentration of sucrose 0 50mM 250mM 1M 2M 
Concentration of G-CSF 10µg/ml 
Recovery±SD% 22.5±2.0% 14.7±5.8% 17.5±2.2% 34.3±2.0% 28.0±5.0% 
5.3.2. VALIDATION OF THE FINAL EXTRACTION METHOD WITH N,N-DIMETHYLFORMAMID 
N,N-Dimethylformamid (DMF) is a water-miscible organic solvent which has been 
used in the fluorescamine assay for protein-lipid isolation process. The function of the 
organic solvent was reported to suppress the influence of the residual lipids allowing 
direct comparison of samples with and without lipids [226]. Accordingly, 0.4ml DMF 
was added to 1ml G-CSF solutions (in PBS buffer) in presence of 1.5mg/ml lipids. 
After centrifugation (3000rpm for 30mins, at 15°C), the lipid was precipitated and the 
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protein was recovered from the solution. The protein was quantified by the developed 
RP-HPLC method.  
As a result of the RP-HPLC analysis, the extraction by applying DMF at a pH 
environment of 7.4 featured the creation of oxidized G-CSF species whereas only 
monomeric protein with good recovery was observed at a pH of 3.5 (Figure VI-9). 
However, it was not surprising to find that the extraction effect was better at a low pH 
environment when G-CSF was exposed to organic solvent as CHI [223] had found 
out that G-CSF was more stable in a buffer solution of pH 3.5 rather than of pH 7.4.    
 
Figure VI-9. RP-HPLC of G-CSF, the protein was extracted from liposome containing samples (lipid 
concentration: 1.5mg/ml) by applying DMF. (a), G-CSF standard, 10µg/ml; (b), G-CSF extracted from 
liposome containing samples (PBS buffer pH 3.5); (c), G-CSF extracted from lipid containing samples 
(PBS buffer pH 7.4) 
The extraction method with DMF was further evaluated at low pH. The recovery of G-
CSF extracted by applying DMF from the lipid containing samples was calculated to 
be 91.4% at a pH of 3.5. Further investigations showed that in the pH range from 3.0 
to 3.8, the protein recovery maintained relatively stable above 90% (Table VI-6). For 
the consideration of the in vitro release tests which were performed with PBS buffer 
pH 7.4, the release fractions needed a pH adjustment to 3.5 prior to the addition of 
DMF for extraction.  
Table VI-6. Recovery of G-CSF: influence of the pH values of the PBS solution, the pH ranged from 
3.0 to 3.8. The lipid content was 1.5mg/ml and the protein content was 10µg/ml in all the samples; 
DMF was used for protein extraction. 
pH of the sample 3.0 3.2 3.5 3.8 
G-CSF recovery±SD% 98.8±1.4% 96.1±-3.5% 91.4±1.9% 92.5±5.6% 
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Further investigations were carried out to see whether the extraction efficiency of G-
CSF by using DMF was influenced by the lipid content within the samples. The lipid 
contents were varied between 0.5mg/ml and 5mg/ml (This concentration range was 
assumed to be around the lipid concentration in the release fractions).The protein 
concentration in all the samples was 10µg/ml. It was found that a lower protein 
recovery of 68% was obtained for the samples containing the lowest lipid content 
(0.5mg/ml). In comparison, there was a plateau of the extraction efficiency at a level 
of more than 90% for all the other samples containing a lipid content of more than 
1.5mg/ml (Figure VI-10). This phenomenon can be explained in a way that the 
presence of sufficient amount of lipids can reduce the exposure of G-CSF to the 
organic solvent and consequently reduce the protein loss due to the addition of DMF.  
In this case, an extra amount of 1.5mg lipid (per ml sample) should be necessarily 
added to the release samples to achieve a high and repeatable protein recovery for 
the quantification aim.  
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Figure VI-10. Recovery of the G-CSF: influence of the lipid content within the samples. The lipid 
content was varied from 0.5mg/ml to 5mg/ml; the protein content was 10µg/ml in all the samples; DMF 
was used for protein extraction. 
In summary, the quantification method for G-CSF in the release fractions was fixed 
as followings: (1) 1.5mg/ml lipid (from VPG-disperions) is added to the release 
fractions. (2) The pH of the samples is adjusted to 3.5. (3) 0.4ml/ml DMF is added 
and the lipids are precipitated after centrifugation (3000rpm for 30mins, at 15°C). (4) 
G-CSF is recovered from the aqueous solution and subsequently quantified by the 
RP- HPLC.  
Figure VI-11 shows the AUCs of G-CSF with this method in comparison to the 
calibration curve in the absence of any lipids (The calibrations were established with 
protein concentrations ranging from 2.5µg/ml to 20µg/ml).  The extraction method by 
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applying DMF was used as standard method for G-CSF quantification for the in-vitro 
release studies.  
                             
Figure VI-11. Response curve of G-CSF standard in comparison to the protein samples recovered 
after extraction from liposome containing samples. The lipids were precipitated by adding DMF. 
6. IN VITRO RELEASE OF G-CSF FROM VPGS  
In vitro release tests were conducted within flow through cells at 37°C as described in 
the method section. PBS buffer pH 7.4 (20mM) was used as acceptor medium. The 
released G-CSF from VPGs was extracted by applying DMF and quantified by RP-
HPLC. The release data are presented as the average of triplicates.  
6.1. INFLUENCE OF THE LIPID CONTENT 
The influence of the lipid content on the release behavior of G-CSF VPGs was first 
investigated. VPGs were prepared with various lipid (egg PC, LIPOID E80) contents 
ranging from 400mg/g to 490mg/g (Table IV-7). The concentration of G-CSF was 
4mg/g in all these formulations. The pH of release fractions were adjusted to 3.5 by 
adding hydrogen chloride for analysis if not otherwise stated. 
Table IV-7. Formulations of G-CSF VPGs based on various contents of lipids. 
 Lipid Concentration G-CSF Concentration 
G-CSF VPGs_1 400mg/g Egg PC (Lipoid E80) 
G-CSF VPGs_2 450mg/g Egg PC (Lipoid E80) 
G-CSF VPGs_3 490mg/g Egg PC (Lipoid E80) 
4mg/g 
 
As it can seen in Figure IV-12, G-CSF VPGs based on 400mg/g lipids delivered 63% 
of the total entrapped proteins over 408hrs while VPGs containing 450mg/g lipids 
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released 43% and VPGs with 490mg/g lipids released 35% within the same period. 
Increasing the lipid content from 400mg/g to 450 mg/g decreased the release rate of 
G-CSF from the VPGs. In comparison, the release behavior of the systems was little 
influenced when the lipid content was increased from 450mg/g to 490 mg/g. 
Moreover, it was observed that G-CSF was released from all formulations in a close 
to linear manner without initial burst.  
 
Figure VI-12. Cumulative release of G-CSF from VPGs based on various concentrations of lipids (egg 
PC, LIPOID E80) (Mean± standard deviation, n = 3 each).  
6.2. INFLUENCE OF THE G-CSF CONTENT 
In Grohganz’s work, the release behaviour of the decapeptide cetrorelix from VPGs 
was found also dependant on the content of the peptide entrapped within VPGs [51].  
Accordingly, the influence of the G-CSF content on the release behaviour of the 
system was investigated. VPGs were prepared with various concentrations of G-CSF 
as shown in Table VI-8. The lipid content in all these VPG-formulations was 450mg/g 
(egg PC, LIPOID E80). 
Table VI-8. Formulations of G-CSF VPGs based on various contents of proteins 
 Lipid Concentration G-CSF Concentration (in the final formulations) 
G-CSF VPGs_2 4.0mg/ml 
G-CSF VPGs_4 
450mg/g Egg PC (Lipoid E80)
8.4mg/ml 
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In comparison to VPGs based on 4.0mg/g G-CSF which delivered 43% of the 
incorporated proteins, the formulations containing 8.4mg/g G-CSF showed a far 
slower release from which about 11% of the total entrapped G-CSF was released 
over 600hrs (Figure VI-13). This finding was in agreement with the work on the 
decapeptide cetrorelix that increasing the content of the peptide within VPGs could 
result in reduced release rate.  This behaviour may also be described as drug–drug 
and drug–lipid interactions, which in turn increase the overall stiffness of the 
VPGs[51] (as also indicated by the texture analysis of G-CSF VPGs in Figure VI-3a), 
thus slowing down the erosion of the lipid matrix and leading to a slower release of 
G-CSF.  
 
Figure VI-13. Cumulative release of G-CSF from VPGs based on various concentrations of G-CSF 
(Mean± standard deviation, n = 3 each). The lipid concentration in the formulations was 450mg/g.  
6.3. DAILY RELEASE AMOUNT  
The releases from various VPG-formulations were calculated and are summarized in 
Table VI-9. It was confirmed the VPG system showed no initial burst for the G-CSF 
release. From 450mg/g to 490 mg/g lipid the system was rather robust and the lipid 
concentration did not have much effect on the release kinetics. However, by 
increasing the lipid content from 400mg/g to 450mg/g the initial protein release and 
daily release amount were both reduced while increasing the content of G-CSF from 
4.0mg/g to 8.4mg/g also decreased the release rate. For the effect of the protein 
content on the release behavior, our hypothesis was made that G-CSF plays a role 
as glue in-between the liposome vesicles within the matrix and consequently 
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increasing the protein content results in delayed erosion due to the enhanced 
structure which was also indicated in the gel strength as shown in Figure VI-3a. In 
summary, it can be stated that desired release profiles of G-CSF loaded VPGs could 
be achieved by varying either the lipid content or the protein content within VPGs. 
Moreover, the obtained results have revealed the possibility for the development of 
formulations for sustained delivery of G-CSF through local application.  
 
Table VI-9. Daily release of G-CSF from 1g VPGs based on various compositions. 
Formulation G-CSF VPGs_1 
G-CSF 
VPGs_2 
G-CSF 
VPGs_3 
G-CSF 
VPGs_4 
Lipid content 400mg/g 450mg/g 490mg/g 450mg/g 
G-CSF content 4.0mg/g 4.0mg/g 4.0mg/g 8.4mg/g 
Initial release (Day 1) 64μg 32μg 43μg 49μg 
Daily release amount 56μg-388μg 32μg-204μg 32μg-150μg 25μg- 76μg 
Average release amount per 
day 149μg 88μg 89μg 43μg 
Daily release percentage of 
the incorporated protein/% 3.7% 2.2% 2.2% 0.5% 
 
6.4. INVESTIGATIONS ON THE IMCOMPLETE PROTEIN RELEASE 
For all the G-CSF loaded VPG-formulations investigated above, the protein release 
leveled off before reaching 100% of the incorporated amount.  
However, RP -HPLC did not indicate the existence of denatured protein materials in 
the release media (Figure VI-14). 
 
Figure VI-14. Chromatograms of GCSF. (1) G-CSF, DMF applied to dissolve lipids (2) G-CSF from 
release fractions, DMF applied to dissolve lipids. 
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Moreover, the stability of G-CSF (15µg/ml, in simulation to the concentration of G-
CSF in the release fractions) at 37°C within buffer solutions was also investigated. It 
was found that G-CSF has a massive loss (63%) after 8 days incubation under a 
condition of 20mM PBS buffer pH 7.4 while 90% of G-CSF has left in a PBS buffer 
pH of 3.5 (Figure VI-15). No peak for the oxidized products was observed by the RP-
HPLC. 
Accordingly, the G-CSF bulk solutions used for VPGs’ preparation were formulated 
with the low pH (3.5) and the presence of 5% sorbit. In the situation of in vitro release 
tests, PBS buffer pH 7.4 was used as acceptor medium. As G-CSF was theoretically 
entrapped within as well as in-between the lipid vesicles, it was easy to image that 
the part of G-CSF entrapped in-between the vesicles would be exposed to the 
massive volume of PBS release buffer pH 7.4 (which did not compromise the protein 
stability) along with the erosion process.  Thus concerning the stability issue of G-
CSF itself under the physical conditions, it was not surprising to find the incomplete 
release of G-CSF from the VPGs. 
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 Figure VI-15. G-CSF stability in various buffer conditions, at 37°C, 15µg/ml. 
Since the release tests were conducted with PBS buffer pH 7.4 at 37°C, it was not 
surprising to find incomplete release of the G-CSF from VPGs concerning the protein 
stability under the release conditions. 
As it can be also seen from Figure 16, the addition of 5% sorbitol or 1M sucrose 
appeared to improve the stability of G-CSF at pH 7.4. Based on these results and the 
previous report that the stability of G-CSF could be improved at pH 7.4 in presence of 
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sucrose [223], G-CSF VPGs were prepared by incorporating sucrose (the formulation 
is shown in Table VI-10) and the release tests were performed subsequently.   
 
Table VI-10. Addition of sucrose into the VPGs,  
 Lipid Content G-CSF Content (in the final formulations) Sucrose Content 
G-CSF VPGs_3 - 
G-CSF VPGs_5 
490mg/g Egg PC (Lipoid E80) 4.0mg/ml 
0.16g 
 
As it can be seen the VPGs containing sucrose delivered the incorporated G-CSF in 
a comparable manner to the VPGs without sucrose. Namely the addition of sucrose 
could not significantly improve the degree of G-CSF release from the systems 
(Figure VI-16).  It was assumed that the mass of sucrose entrapped within VPGs was 
insufficient to function considering the large volume of the release buffer in the entire 
release tests. 
 
Figure VI-16. Cumulative release of G-CSF from VPGs with and without sucrose (Mean ± standard 
deviation, n = 3 each). The lipid concentration in the formulations was 490mg/g, and the protein 
concentration was 4.0mg/g. 
 
7. IN VIVO EXPERIMENTS 
7.1. PROVIDING BACK GROUNDS 
Ruptures of the rotator cuff, in the supraspinatus muscles in particular, are among 
the most common degenerative injuries. They mainly occur in older age as 
degenerative diseases and are associated with pain and movement restrictions. 
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Untreated ruptures are deemed as a form of pre-arthrosis and therefore require an 
optimal treatment to prevent long-term damage to the shoulder osteoarthritis [227-
228].  
Growth factors represent one of the most important roles involved in tendon healing 
[229]. Chan [229-230] has demonstrated that the basic fibroblast growth factor (bFGF) 
is active in simulation of cellular proliferation and collagen III expression. G-CSF is 
shown to be capable in mobilizing cells [231-232]. In vivo use of the growth factors 
has shown some promise in recent years. Recent studies have suggested that by 
using two or more growth factors in combination may in fact promote mature vessel 
formation. [215-216]. However, a major challenge of the use of growth factors in vivo 
is the delivery of the therapeutic molecules to the target cells in a specific and 
sustained manner [210, 216, 233].  
To achieve continuous therapeutic effect, various carriers have been investigated for 
the delivery of growth factors. These include gelatine hydrogels [234], collagen [235], 
and chitosan-based fleeces [236]. Pieper [237] has reported the loading of bFGF to 
cross-linked collagenous matrices with covalently attached heparin sulfate for 
subcutaneous implantation. For this system in vitro release was reported over 30 
days. In vivo evaluation in rats has revealed an intense and prolonged tissue 
response and considerably promoted generation of new tissue. Application of the 
FGF entrapped chitosan hydrogel was found to significantly induce wound 
contraction and accelerate wound closure in mice [238]. No generally acknowledged 
dosing scheme has been established for the long-term application of the growth 
factors but the following data might be helpful for the estimation of therapeutical 
relevant doses: In the work of Pieper [237], loading 1260 μg/g matrix of bFGF 
resulted in an average release of 12ng/day during the in vitro release over 30 days. 
Ono [239] has reported that applying 1-10μg/day of bFGF both alone and in 
combination with collagen matrix was effective in wound contraction using a 
simulated in vivo delayed healing type model. Richa [240] has used 10 μg/kg/day of 
G-CSF for stem cell mobilization in humans. Single injections of 5μg/kg or 250 μg/kg 
of G-CSF were given to examine the pharmacological action of G-CSF in mice [241]. 
The biocompatibility and biodegradability of phospholipid based delivery systems 
have been widely demonstrated in previous works [242-246]. 
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In this context, VPGs were loaded with growth factors including G-CSF and bFGF. 
Their implantation possesses a new and promising approach for the improved 
healing of the tendon and the angiogenic stimulation.  Due to the specific 
characteristic of the VPG-system, a continuous release of the growth factors in situ 
with therapeutically relevant levels could be expected. 
7.2. EXPERIMENTAL SET-UP 
The in vivo evaluation of growth factor loaded VPGs will be performed using Sprague 
Dawley rats as the animal model (This work will be carried out by the Technical 
University Munich, Sport-orthopedics). In rats the structure of the shoulder girdle is 
similar to that of humans. Moreover, they have also proved as experimental animals 
in the study of the muscle-tendon pathology at the shoulder joint [247-248].  
The tendon is separated from the shoulder muscle of the rats (Figure 17a). Growth 
factors (G-CSF and/or bFGF) are then applied in a continuous manner. This can be 
achieved either by infusion of the protein solutions using the osmotic pumps (model 
2004, ALZET) or by the sustained release of proteins from VPGs which contain 
liposomal fractions. The therapeutic effect (e.g. histology) and pharmacokinetics of 
the protein will be evaluated.    
 
 
 
 
 
 
 
 (a)                                        (b)                                            (c) 
 
Figure VI-17. (a) Rupture of tendons in rats. (b) Cross section of osmotic pump, model 2004, ALZET. 
(c) Application of VPGs based on 450mg/g lipids and various concentrations of growth factors. 
The ALZET pumps (Figure 17b) operate because of an osmotic pressure difference 
between a compartment within the pump, called the salt sleeve, and the tissue 
environment in which the pump is implanted. These mini osmotic pumps can deliver 
a variety of solutions including protein solutions at zero-order rates for periods up to 4 
weeks [249]. The volume delivery rate of the pump was proved to be 0.28±0.01μl/hr 
by using methylene blue (at 590nm) for the pumps Model 2004 (lot.No.10172-07) 
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used in our study. Different dosing rates can be achieved by varying the 
concentration of agent in the solution or suspension used to fill the pump reservoir 
[249]. The filling volume was calculated from the net weight of the loading solutions, 
and in our case it was determined to be 251.8±6.0μl in average.  
In our work, the desired dose infused daily from the pumps was 5μg/day for G-CSF 
while for bFGF was 0.5μg/day to maintain the therapeutic effect. As shown in Table 
VI-11, G-CSF was diluted from the bulk materials with the acetate buffer pH 3.9. 
bFGF lyophilized powder was obtained from PROSPEC. It was reconstituted with 
PBS buffer and 0.1% BSA [250]. A combination of the two proteins was also 
preparation in acetate buffer. The protein solutions were filled into the pumps and 
delivered for the animal experiment. 
Table VI-11. Formulations of the growth factor solutions for the osmotic pumps.  
 G-CSF bFGF G-CSF und bFGF 
Concentration 834 µg/ml 83.4 µg/ml G-CSF (834µg/ml) and bFGF (83.4µg/ml) 
Dose pro 24h 5µg 0.5µg 5µg G-CSF and 0.5µg bFGF 
Formulation 
10 mM acetate buffer pH 3.9 
0.004% Tween 
5% sorbitol 
10 mM PBS pH 7.4 
0.1% BSA 
10 mM acetate buffer pH 3.9 
0.004% Tween 
5% sorbitol 
As described in the introduction section, VPGs can be easily prepared under sterile 
conditions. The lipid based system has good biocompatibility [242-246] and will 
dissolve after a defined period itself based on the observation of in-vitro release tests 
in our work. Furthermore, in vitro release tests have showed that VPGs loaded with 
G-CSF could deliver the protein with therapeutically relative dose over a defined 
period of up to 4 weeks.  
Table VI-12. Formulations of VPGs, loaded with various contents of growth factors 
Protein G-CSF 
Buffer in protein solutions 
10 mM acetate buffer pH 3.9 
0.004% Tween 
5% sorbitol 
Protein concentration per ml VPGs 200µg 2mg 
Lipid content per ml VPGs 450mg/g 
Expected release amount pro 24h 1µg 10µg 
Concerning the texture of the gels, VPGs based on 450mg/g lipids (egg PC, LIPOID 
E80) were chosen for the in vivo tests. The protein solutions (or buffer solutions) will 
be added to be sterile phospholipids in the sample containers (25ml, PP) under the 
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laminar flow. Aseptic production is achieved using the hermetically sealed sample 
vials. The prepared gels will be transferred into 1ml syringes (B.Braun Melsungen AG, 
Germany) under the aseptic conditions. 0.2ml of VPGs will be implanted to the 
rupture of the tendons in each of the rats (10 rats for each group). Placebo VPGs 
(based on 450mg/g lipids) will first be applied as control group and to evaluate the 
biocompatibility of the gels as well. The potentially therapeutically relevant 
formulations were planned as shown in Table VI-12. Various protein concentrations 
were entrapped within VPGs to achieve different doses. The serum samples will be 
taken from the rats after implantation of the gels at planned intervals, and the 
concentration of G-CSF will be quantified with the developed method of ELISA for the 
pharmacokinetics study. 
7.3. ELISA OF HUMAN G-CSF 
In order to investigate the pharmacokinetics of G-CSF from VPGs, the rat serum will 
be collected at predetermined intervals. An ELISA was developed as quantification 
method for G-CSF in serum.  
As a start point, the cross-reactivity of the ELISA assay was evaluated. To simulate 
the conditions from the animal tests, G-CSF was spiked with placebo rat serum. 
Three ELISA kits have been assessed. As for the RayBio Human G-CSF ELISA, the 
placebo serum samples got a high OD background (2.477±0.746) which indicated 
cross-reactivity with the assay, and no correlation could be established for the serum 
spiked samples.  
Another ELISA kit (Human G-CSF Instant ELISA, Bender) was also evaluated. The 
working procedure of the assay was simplified as the detection antibody and 
streptavidin-HRP (color reagent) beside the coating antibody were readily included in 
the assay plate so that the binding starts simply by adding the samples or destilled 
water. A correlation (R2=0.971) could be established for the protein stock solutions 
(Figure VI-18). However, the serum samples appeared to have strong cross-reactivity 
with the assay as the placebo serum alone got strong background signals. 
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Figure VI-18. Response curve of Human G-CSF stock solution, by Instant Human G-CSF ELISA 
(Bender) n=3. 
The Quantikine G-CSF Immunoassay (DCS50, R&D Systems) contains E. coli-
expressed recombinant human G-CSF and antibodies raised against the protein. It 
has demonstrated accurate quantification of the recombinant human G-CSF without 
measurable cross-reactivity with mouse serum[251].  
The optical density was determined at 490nm and subtracted from the readings at 
650nm for correction. It was recommended in the manual that the log transformation 
of the data could result in better linearity. Correlation was established for the G-CSF 
stock solutions with concentrations ranging from 78pg/ml to 1250pg/ml (Figure VI-19).  
 
Figure VI-19. Response curve of Human G-CSF stock solution, Quantikine Human G-CSF ELISA, n=3 
Importantly, placebo serum samples showed little background (Table VI-13). To 
evaluate the influence of the serum spiking, the G-CSF bulk was spiked with serum 
in two different levels resulting in the same protein concentration (625pg/ml). The 
result showed the recoveries of G-CSF from spiking were both around 78% (Table 
12), which could be acceptable for the study. Moreover, the spiking ratio has shown 
little influence on the result which is promising for the quantification of released G-
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CSF since the protein-serum ratio is uncertain in the serum samples from the animal 
experiments.  
Table VI-13.  ELISA of Human G-CSF spiked with serum samples: influence of the serum spiking.  
Sample Optical density Recovery/% 
Serum Blank 0.072±0.010 - 
G-CSF stock, 625pg/ml 1.232±0.136  
G-CSF spiked with serum in a ratio of 1:1, 
625pg/ml in the final solution 0.966±0.043 78.4% 
G-CSF spiked with serum in a ratio of 1:4, 
625pg/ml in the final solution 0.968±0.126 78.5% 
 
The calibration of G-CSF spiked with serum samples (in a ratio of 1:1) was 
established as shown in Figure VI-20. Good correlation was established for the 
response curve of the stock materials and the serum spiked samples. Thus based on 
the obtained results, this Quantikine Human G-CSF ELISA was found suitable for the 
quantification of G-CSF in the rat serum. However, currently no pharmacokinetics 
results were obtained because the animal studies have been postponed due to the 
fact that the authorization by the clinical committee has been delayed. 
 
 
Figure VI-20. Response curve of Human G-CSF spiked with rat serum in a ratio of 1:1, Quantikine 
Human G-CSF ELISA, n=3 
8. CONCLUSION 
In this chapter, VPGs are used for the delivery of growth factors. Various 
formulations of G-CSF VPGs were prepared and characterized by the texture 
analysis and rheological tests. Suitable gel strength and viscosity for the aim of easy 
application and sustained release could be achieved by adjusting the lipid content 
and the protein content within the matrices.  
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No detrimental effect of G-CSF was found of the preparation process in dual 
asymmetric centrifuge analyzed by SDS-PAGE. FTIR was not assessable for the 
analysis of G-CSF within VPGs.   
For the quantification of G-CSF from liposome containing samples, a reverse-phase 
HPLC method was developed. Several extraction methods were assessed according 
to the literatures and previous work. When chloroform was applied to the G-CSF in 
absence of any lipids, the protein was 100% recovered from the aqueous solution. 
However, it was found that the presence of lipids highly reduced the protein recovery 
from liposome containing samples when chloroform was applied for lipid extraction. 
Thus it was assumed that interaction existed between the lipids and the proteins.  
Accordingly, N,N-Dimethylformamid was used for the protein-lipid isolation. The lipids 
were precipated and G-CSF was recovered from the aqueous solution. The 
extraction method works under a buffer condition of pH 3.5 whereas there were 
oxidized products observed for G-CSF exposed to DMF at pH 7.4 which was 
associated with the fact that G-CSF has better stability in an acidic environment [225]. 
A correlation was established between the extracted protein and the standard. Thus, 
the method was applied as the standard for quantification of G-CSF in the release 
fractions. 
Generally, the in-vitro release studies demonstrated the potential of VPGs for 
sustained delivery of G-CSF. It was observed that G-CSF was released from all 
formulations in a linear manner following the zero-order kinetics. Increasing the lipid 
content from 400mg/g to 450mg/g resulted in slower release rate. However, the 
VPG-system appeared robust when the lipid content was changed from 450mg/g to 
490mg/g (For VPGs based on 400mg/g lipids and 4.0mg/g G-CSF 63% of the total 
entrapped protein was delivered over 408hrs whereas VPGs based on 450mg/g 
lipids delivered 43% and VPGs with 490mg/g lipids delivered 35% within the same 
period.). To investigate the influence of the loading amount of proteins, VPGs were 
also prepared with a higher protein concentration (8.4mg/g). As a result, higher 
protein loading resulted in a much slower release of 11% within the same period. 
Concerning the determined gel strength and rheology, the VPGs with loading of 
8.4mg/g G-CSF had a higher gel strength and viscosity (see Figure VI-3) compared 
with the VPGs containing 4.0mg/g G-CSF. It was assumed that the delayed release 
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of G-CSF was attributed to the enhanced gel properties due to the interaction 
between the drug and drug as well as the interaction between the drug and lipids.  
The incomplete protein release was attributed to the instability of G-CSF under the 
release conditions (PBS buffer pH 7.4, 37°C). More than 60% of G-CSF was lost 
after 8 days (216hrs) incubation at 37°C. Though the addition of sucrose or sorbitol 
was proved to improve the stability of G-CSF at pH 7.4, no obvious improvement in 
the protein recovery from the release of VPGs containing sucrose was observed. 
Comparing with the massive volume of the release buffer, the amount of sucrose 
within VPGs was too little to function. However, it was not possible to incorporate a 
large amount of sucrose into the matrices.  
Concerning the in vivo tests, the experiment was set up based on the fact that the 
lipid based VPG-system possesses excellent biocompatibility [50, 123] and the 
growth factors were shown healing effect of wounds in recent research [229].  In 
collaboration with Sport-orthopedics of Technical University Munich, the experiment 
was performed using rats as animal model. The basic fibroblast growth factor (bFGF), 
granulocyte colony-simulating factor (G-CSF), and a combination of both will be 
applied for the rupture of tendons. VPGs with the loading of these growth factors 
were expected to release the entrapped protein in a sustained manner after 
implantation based on the results of the in vitro release. On the other hand, osmotic 
pumps were used to offer a stable infusion of the protein solutions over a period of 28 
days for the matters of comparison. The healing effect (e.g. histology) and the 
pharmacokinetics of the protein released from VPGs will be evaluated. The 
Quantikine G-CSF Immunoassay was validated for the quantification of G-CSF in the 
serum samples. No cross-reactivity of the assay was observed with the rat serum. 
However, the experiment was still ongoing since the animal studies have been 
postponed due to the fact that the authorization by the clinical committee has been 
delayed. The related results would be included later in a publication.  
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CHAPTER VII: MAB LOADED VPGS  
Our data so-far indicated that the advantageous use of VPGs can be extended to 
protein drugs. In Chapter V and Chapter VI, cytokines which possess a molecular 
weight below 40kDa were used as model proteins. However, considering the growing 
value of the global therapeutic monoclonal antibody (MAB) market an increasing 
demand for improved delivery of these large multidomain proteins arose. With more 
than 400 ongoing studies targeting a broad range of diseases MAB therapeutics will 
surely dominate the new approvals of biotech drugs [252]. 
Nevertheless, only limited work has been conducted in the field of controlled and/or 
local release of MAB. Today most approved MAB therapeutics are formulated for 
intraveneous infusion (i.v.) or repeated subcutaneous injection (s.c.) requiring large 
quantities of drug for systemic distribution [253-254]. Due to the relatively high costs 
of both the drug itself and the way of administration antibody therapy is comparatively 
expensive. In contrast, the direct local controlled release of antibodies at the intended 
site of action (e.g. in knee joints, at a tumour site, at the eyes, and other topical 
application sites) would allow a spatial control over antibody distribution and thus 
lower dosing requirements. In addition, the typical benefits of controlled release 
formulations such as improved patient compliance reduced systemic exposure would 
be associated with this way of administration.  
As for proteins in general controlled delivery of antibodies requires sophisticated 
formulation strategies to meet the demands of instable and complex bio-
macromolecular drugs. So far only polymers were exploited as carriers for controlled 
release devices lacking either biodegradation, maintenance of antibody stability or 
sufficient release kinetics [2, 4, 254].  
Based on the investigations on VPGs for cytokine delivery these lipid-based 
formulations appear suitable to form a new delivery platform for monoclonal 
antibodies. Therefore, the main object of the study in this Chapter will be a careful 
evaluation of the benefits and boundaries of VPG-based controlled antibody delivery. 
To fulfil a broad range of needs for various indications an ideal delivery system 
should permit tailoring of antibody dose and release kinetics. Therefore, within the 
context of this study various formulation strategies will be investigated to modify the 
release kinetics.  
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1. PREPARATION OF MAB LOADED VPGS 
1.1. CONCENTRATING MAB BULK 
A high protein concentration was necessary for the preparation of MAB VPGs 
considering the therapeutically relevant doses. MAB stock solution (17mg/ml) was 
concentrated by ultrafiltration with Vivaspin tubes (100KDa, 20ml). The concentration 
of MAB was determined with UV photometry at 280nm using the extinction 
coefficiency (1.499ml/mgXcm). SE-HPLC was performed to check the stability of the 
protein after the concentrating process. As shown in Figure. VII-1, the MAB monomer 
was maintained the same before and after the up-concentrating, namely no 
detrimental effect was induced by the ultrafiltration process.  Besides, the percentage 
of protein dimer and fragments were slightly reduced in the concentrated protein 
samples (Table VII-1).   
Table VII-1. SE-HPLC results of MAB bulk and concentrated samples. mean±SD, n=3 
 Monomer% Dimer/% Fragments/% 
MAB Bulk 94.63±0.15%  4.4±0.09%  0.97±0.09% 
MAB concentrated 96.40±0.13%  2.75±0.05%  0.79±0.09% 
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Figure VII-1. SE-HPLC of MAB. (a) bulk solution, unconcentrated, 1.55mg/ml; (b) concentrated MAB 
solution,  0.67mg/ml (100 times diluted).  
1.2. FORMULATION OF MAB LOADED VPGS 
In general, the preparation of MAB VPGs followed the procedure described in the 
method section. MAB was formulated with 50 mM phosphate buffer pH 6.4, 
containing 150mM sodium chloride and 0.1% BSA. The phospholipid used here was 
egg phosphatidylcholine (E80, LIPOID). Homogenization of the mixture was 
performed by means of the dual asymmetric centrifugation in a cylindric container of 
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25 ml total volume. Multiple runs of 1.5-minutes were added up to a total mixing time 
of 45 mins at a process speed of 3500 rpm. The samples were cooled at 2-8°C at 
interrupts to control the system temperature.  
A number of different VPGs were produced in order to evaluate the influence of VPG 
composition on the release properties (Table VII-2).The content of phospholipid was 
varied between 350 and 450 mg/g. A variety of MAB concentrations was investigated 
ranging from 9.4 mg/g (in the final VPGs formulations) for basic research to 37.4 
mg/g for therapeutically relevant levels. 
Table VII-2. Formulation of MAB VPGs 
(a) Influence of the lipid concentration                          (b) Influence of the protein concentration 
Formulation MAB VPGs_1
MAB 
VPGs_2 
MAB 
VPGs_3
Lipid 
content 350mg/g 400mg/g 450mg/g
MAB 
content 9.4mg/g 
Formulation MAB VPGs_3
MAB 
VPGs_4 
MAB 
VPGs_5 
Lipid 
content 450mg/g 
MAB 
content 9.4mg/g 17.6mg/g 37.4mg/g 
2. TEXTURE ANALYSIS AND RHEOLOGY 
The texture analyser (TA.XT plus, Stable Micro Systems, UK) recorded the forces 
(Figure VII-2a) which occured when the probe (4mm in diameter) was pushed into 
the tested VPGs. The gel strength of VPGs was represented as the maximal force 
value according to the “Bloom test” method. The rheology behavior of MAB VPGs 
was studied by a rotational viscometer (Physica MCR 100, Anton Paar) at 25°C. The 
shear viscosity was provided versus shear rate ranging from 10-1 and 100-1 (Figure 
VII-2b).  
As shown in Figure VII-3a, the gel strength increased with the lipid content when the 
content of MAB was kept constant (9.4mg/g) within VPGs. The maximal force 
reached a value of 64.2g for VPGs containing 500mg/g lipids, whereas VPGs 
containing 350mg/g had a value of 8.1g. Figure VII-3b showed the gel strength of 
VPGs containing 17.6mg/g MAB (with a value of 40.3g) was a little higher than the 
VPGs containing 9.4mg/g MAB (with a value of 36.7g). However, it was surprisingly 
found that the gel strength value of VPGs containing 37.4mg/g MAB was much lower 
than the other two formulations. Our explanation was that the presence of very high 
content of proteins may reduce the gel strength whereas the gel strength increases 
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with the protein concentration in a low concentration range (less than 17.6mg/g in the 
case of MAB). 
 
up+down curve 
  (a)                                                                               (b)                                 
 
Figure VII-2. (a) Texture analysis of MAB loaded VPGs: recorded force trace when the probe (4mm in 
diameter) was pushed with a speed of 0.5mm/s into the tested VPGs. (VPGs containing 400mg/g 
lipids and 9.4mg/g MAB) (b) Rheological behaviour of VPGs. Gel strength (VPGs containing  450mg/g 
lipids and 37.4mg/g MAB). 
As shown in Figure VII-3a, the gel strength increased with the lipid content when the 
content of MAB was kept constant (9.4mg/g) within VPGs. The maximal force 
reached a value of 64.2g for VPGs containing 500mg/g lipids, whereas VPGs 
containing 350mg/g had a value of 8.1g. Figure VII-3b showed the gel strength of 
VPGs containing 17.6mg/g MAB (with a value of 40.3g) was a little higher than the 
VPGs containing 9.4mg/g MAB (with a value of 36.7g). However, it was surprisingly 
found that the gel strength value of VPGs containing 37.4mg/g MAB was much lower 
than the other two formulations. It was assumed that the gel strength and viscosity 
could reach a peak value at an optimized drug-lipid ratio due to the drug-drug and 
drug-lipid interaction. Non-linear trend could be expected for the influence of the 
protein content on the gel strength and viscosity. In a low protein concentration range, 
the gel strength increases with increasing the protein content within the matrices 
whereas the gels got less stiff at a much higher protein content.  
The viscosity of various VPG formulations was compared at the shear rate of 37.9s-1. 
When the lipid content was increased from 350mg/g to 500mg/g, the viscosity of the 
gels increased from 0.6Pa.s to 21.6Pa.s (Figure VII-4a). Increasing the content of 
Chapter VII: MAB loaded VPGs 111
 
MAB resulted in decreased viscosity of VPGs (Figure VII-4b). However, the influence 
is not dramatic concerning the deviations.  
  
                                  (a)                                                                         (b)  
Figure VII-3. Gel strength (mean±SD, n=3) of mAb loaded VPGs. (a) Influence of the lipid content, 
VPGs were based on 9.4mg/g mAb IgG; (b) Influence of the protein content, VPGs were based on 
450mg/g lipids. 
As a conclusion, the gel strength and viscosity of VPGs both increased when the lipid 
content increased, whereas the gel strength and viscosity were of low values when 
there was a high content of MAB incorporated within VPGs.   
 
(a) (b)  
Figure VII-4. Viscosity of mAb VPGs (mean±SD, n=3). (a) influence of the lipid content, VPGs were 
based on 9.4mg/g mAb IgG; (b) Influence of the protein content, VPGs were based on 450mg/g lipids. 
3. EVALUATION OF MAB STABILITY BY SDS-PAGE 
SDS-PAGE was conducted to examine the stability of MAB entrapped into VPGs. 
Non-reducing SDS-PAGE analysis was performed with subsequent silver staining. 
0.05g freshly prepared VPGs (500mg/g lipids) were accurately weighed and 
redispersed in 4ml PBS buffer (40mM, pH 7.4). The concentration of the MAB in the 
VPG-redispersions was around 100µg/ml. In order to eliminate (or minimize) the 
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influence of lipids on the results of SDS-PAGE, various agents including chloroform, 
5% Triton X-100, and 5% SDS, have been tried out to dissolve the lipids and extract 
the antibody. 0.3ml/ml chloroform was added to dissolve the lipids. The MAB was 
recovered in the supernatant aqueous solution after centrifugation at 3000rpm for 
30mins. Chloroform was also added to MAB standard solutions to investigate the 
influence of the organic solvent itself on the protein integrity. On the other hand, 5% 
Triton or 5% SDS was added to the lipid containing solutions. The surfactant 
containing samples were incubated at 37°C for 30mins respectively before running of 
the SDS-PAGE. 
The results were shown in Figure VII-5. The MAB solutions with the addition of 
chloroform (lane 3/8) showed exactly the same bands as the standard solutions 
(100µg/ml, lane 2/7), which indicates that adding chloroform causes no instability of 
the antibody. When chloroform was used to extract the protein from VPGs, no 
difference was observed for the extracted MAB (lane 4/9) from the standard (lane 
2/7). Moreover, judged on the stained density the extraction recovery of MAB by 
adding chloroform was high. In the case of adding Triton to dissolve liposomes, band 
shrifts (lane 5/10) were observed which might be probably induced by interaction 
between the proteins and Triton. By adding SDS, we observed more pronounced 
aggregations and fragments (lane 6/11).  
                        
 
 
 
 
 
 
 
 
Figure VII-5. SDS-PAGE analysis of MAB integrity: 
 
 
 
 
 
Lane 1, molecular weight marker 
Lane 2/7, MAB standard 
Lane 3/8, MAB with adding chloroform 
Lane 4/9, MAB VPGs extracted by adding chloroform 
Lane 5/10, MAB VPGs extracted by adding 5% Triton X-100 
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Hence it can be stated that: (1) Adding chloroform for extraction causes no instability 
of the MAB; (2) Aggregate and fragment fractions beside the monomer can also be 
extracted by adding chloroform; (3)  The formulation process to entrap MAB into 
VPGs by dual asymmetric centrifugation has no influence on the protein stability. In 
summary, the SDS-PAGE results provide evidence that the formulation technology of 
VPGs is applicable for MABs, and adding chloroform is suitable to extract MAB for 
SDS-PAGE analysis. 
4. QUANTIFICATION METHOD FOR  MAB IN PRESENCE OF LIPIDS  
Quantification and extraction method were needed for MAB analysis from lipid 
containing samples. Since the released amount of VPGs at each time interval was 
unknown, the quantification method should feature a high robustness against 
variations of the lipids as well as against variations in the protein amount which make 
this method suitable for protein quantification during in-vitro release studies. CBQCA 
assay and micro BCA protein assay were tried out to quantify MAB instead of the 
HPLC method due to the detection limit and sensitivity of the SEC column.  
4.1. CBQCA ASSAY 
CBQCA Protein Quantitation Kit (Molecular Probe, Invitrogen) provides a rapid and 
highly sensitive method for the quantitation of proteins in solution. The kit utilizes the 
ATTO-TAG CBQCA reagent (3-(4-carboxybenzoyl) quinoline-2-carboxaldehyde) 
originally developed as a chromatographic derivatization reagent for amines. This 
reagent has also proven extremely useful for quantitating amines in solution, 
including the accessible amines in proteins. Importantly, it was reported by using this 
assay lipoproteins and other lipid associated proteins could be assayed without any 
manipulation to extract lipids [255].  
4.1.1. CALIBRATION  
A calibration curve for MAB without lipids was generated in the concentration range 
between 0.74 µg/ml and 44.40 µg/ml. BSA was assayed as reference. A series of 
lipid containing MAB samples were prepared with a lipid content of 5mg/ml. In order 
to minimize the influence of lipids in the samples on the protein analysis, 0.3 ml/ml 
chloroform was added to extract the lipids before the assay. Fluorescence 
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measurements were performed with 96-well (white) micro-plates (Nalge NUNC, 
Denmark) and FLUOstar Omega multifunctional micro-plate reader (BMG LABTECH, 
Germany). The excitation wavelength was set to 485nm, and the emission was 
measured at 580nm (The choice of excitation and emission wavelengths was limited 
by the device filters). 
For each calibration, PBS buffer (40mM) pH 7.4 was assayed as blank and used for 
background correcting. As shown in Figure VII-6: There was good calibration line 
established for BSA as the reference standard (R2 = 0.994). For MAB without lipids, 
similar response curve was obtained despite that the linearity was poor (R2 = 0.963) 
which was probably caused by operating errors (Large deviations might occur in 
handling with 5µl and 10µl sample volumes).  
 
Figure VII-6. Calibrations of the proteins by CBQCA Assay. BSA was used as the reference standard. 
Lipid free MAB and MAB extracted from lipids were assayed to develop the method. 
4.1.2. INFLUENCE OF THE LIPID CONTENT  
As described previously in the method development of EPO and G-CSF 
quantification, the influence of the lipid content on the assay was investigated since 
the released amount of VPGs at each time interval was unknown. Various amounts 
of lipids were dispersed into PBS buffer resulting in concentrations ranging from 
0.5mg/ml to 5.0mg/ml. The concentration of MAB was 7.4µg/ml in all the samples. 
The lipids were extracted by applying 0.3 ml/ml chloroform and the proteins were 
recovered from the aqueous supernatant.  
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Figure VII-7. Influence of lipid content on the protein recovery. The lipid concentration within the 
samples was varied between 0mg/ml and 5mg/ml. The protein concentration was determined by the 
CBQCA assay. The results were represented by the fluorescence density as shown for the left axis, 
n=9. The protein recovery was calculated as compared to the original protein concentration and shown 
for the right axis. 
Unfortunately, it was found that the lipid content had influence on the results of the 
assay (Figure VII-7). When the lipid content was more than 1.5mg/ml, the 
fluorescence density was much higher than expected. We have applied chloroform to 
remove a major part of the lipids. However, it was assumed there were a small part 
of lipids remained in the supernatant due to the interaction between the protein and 
lipids. The presence of lipids obviously disturbs the assay. However, this 
phenomenon was undesirable in our case since the lipid content was uncertain for 
the release samples and it might consequently led to bad repeatability in the MAB 
quantification from the release samples. Moreover, the CBQCA assay was hard to 
handle due to the small sample volumes (5µl-10µl) and the very toxic substances e.g. 
potassium cyanide used for reaction. Therefore, the CBQCA assay appeared not 
suitable for the need of quantification of MAB for the release tests.  
4.2. MICRO BCA ASSAY 
4.2.1. THE METHOD 
The principle of the micro BCA assay is that colored products are formed when the 
working reagent (Cu2+) is reduced by protein in an alkaline environment. This water 
soluble complex exhibits a strong absorbance at 562nm that is linear with increasing 
protein concentrations.  
The procedure for microplate mode follows the instructions provided by the 
manufacture of the test reagents. Briefly, the working reagent is added to sample 
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solutions in the microplates. The mixture is incubated at 37°C for 2hrs. The optical 
density is measured at 562nm after the mixture is cooled down to room temperature.   
Lipids are known to cause high background in the assay. Therefore, an extraction 
method is necessary to remove lipids and recover protein before the assay is applied. 
Some often used organic solvents and surfactants, including Triton, DMF, Tween 
have interference with the assay. Adding SDS can not efficiently eliminate the 
influence of the lipids [256-258]. Based on the experience from EPO extraction, 
chloroform has tried out as the start point.   
4.2.2. CALIBRATION OF THE STANDARD 
BSA was used as a standard reference to validate the assay. Calibration of MAB 
standard solutions was established with concentrations in the range from 0.5µg/ml to 
20µg/ml (Figure VII-8).  
 
Figure VII-8. Calibration of MAB standard solutions, BSA was used as reference, n=6. 
In general, the OD values of MAB were slightly higher than the reference BSA. Good 
linearity and repeatability were achieved for both proteins. Therefore this assay was 
applicable for quantification of MAB. Further investigations were carried out for in 
presence of lipids.   
4.2.3. EXTRACTION METHOD WITH CHLOROFORM 
4.2.3.1. CALIBRATION 
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A series of lipid containing samples was prepared with a constant lipid concentration 
of 1.5mg/ml and various MAB concentrations between 0 and 20µg/ml. 0.3 ml/ml 
chloroform was added to dissolve the lipids. The antibody was recovered in the upper 
aqueous solutions and quantified by the micro BCA assay. As shown in Figure VII-9, 
good linearity and acceptable repeatability were achieved for the extracted MAB. A 
good correlation was established for the lipid-free MAB and the extracted samples. 
The recovery of the extraction method by applying chloroform was calculated 72% by 
using the slopes of the two calibration curves. 
 
Figure VII-9. Calibration of extracted MAB samples, MAB standard solution was used as reference, 
linear fit, n=12.  
4.2.3.2. INFLUENCE OF LIPID CONTENT ON THE MAB RECOVERY 
The influence of the lipid content on the recovery of MAB was investigated by using 
the micro BCA assay in combination with the extraction method. Various amounts of 
lipids were dispersed into PBS buffer resulting in concentrations ranging from 
0.5mg/ml to 5.0mg/ml. The concentration of MAB was 5µg/ml in all the samples. As 
shown in Figure VII-10, the recovery of MAB was stable (91.7%~97.9%) when the 
lipid content was between 0 and 1.5mg/ml. However, the recovery was much higher 
(138.9%) than expected when the lipid content was increased further to 5.0mg/ml. It 
was consequently assumed that a part of lipids might remain in the aqueous solution 
and cause additional optical density when the amount was high enough. Hence, 
further investigation was carried out aimed to eliminate the influence by adding more 
chloroform (applying 1ml or 3ml chloroform per ml sample) to dissolve the lipids. 
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Figure VII-10. Influence of the lipid content on the MAB recovery, micro BCA assay, MAB 
concentration: 5µg/ml, 0.3ml/ml chloroform was added to dissolve the lipids.  
 
4.2.3.3. INFLUENCE OF CHLOROFORM  AMOUNT 
A series of MAB samples (MAB concentration: 5µg/ml) were prepared with lipid 
content varying from 0.5mg/ml to 5mg/ml. Various amounts of chloroform (0.3ml/ml, 
1ml/ml, and 3ml/ml) were applied to dissolve the lipids within the samples.  As shown 
in Figure VII-11, the amount of chloroform applied in the range between 0.3ml/ml and 
3ml/ml got marginal effect on the assay results. Namely, adding more chloroform was 
not efficient to dissolve the rest part of lipids in the aqueous solution. Therefore, it 
was a must to find another method to remove the lipids which caused the 
interference. A protein precipitation method by using sodium deoxycholate was tried 
out for the next step.     
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Figure VII-11. Influence of the chloroform content on the MAB recovery, micro BCA assay, MAB 
concentration: 5µg/ml.  
4.2.4. ADDING SODIUM DEOXYCHOLATE  
Sodium deoxycholate (DOC) is a kind of water soluble ionic detergent, commonly 
used for membrane protein and lipid isolation. In order to eliminate the influence of 
lipids, DOC was added before adding chloroform aimed to reduce the interaction 
between the protein and lipids. 0.01ml 1.5% sodium deoxycholate was added to 1ml 
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lipid containing MAB samples. After incubating at 37°C for 20mins, 1ml/ml chloroform 
was added to dissolve the lipids. The protein remained in the aqueous phase. 
Samples from the upper solution were assayed by the micro BCA assay. 
As a start point, the influence of adding DOC and chloroform on the protein recovery 
in absence of lipids was first evaluated. 79% of the MAB were recovered from lipid 
extraction at the low concentration of 2.5µg/ml whereas 95% were recovered at the 
high concentration of 20µg/ml. This phenomenon was similar to the situation of 
applying chloroform alone for EPO extraction.  
A series of samples were prepared with various lipid contents ranging from 0.5mg/ml 
to 5mg/ml. The MAB concentration was 5µg/ml in all the samples. DOC and 
chloroform were applied and the protein was recovered from the aqueous solution. 
The supernatant was assayed after centrifugation process.   
For the samples containing 0.5mg/ml lipids protein recovery was 115.7% whereas 
the protein recovery was around 100% for the samples containing 1.5mg/ml or 
5.0mg/ml lipids (Figure VII-12). However, compared with the other methods it could 
be stated the lipid content got less interference on the recovery of MAB extracted 
from lipids when DOC and chloroform were applied, which encouraged further 
investigations. 
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Figure VII-12. Influence of the lipid content on the protein recovery, DOC and chloroform were applied 
for extraction. n=12  
MAB solutions of known concentrations (2.5 – 20μg/mL) in presence of 5.0mg/ml 
lipids were used to generate the calibration curve (Figure VII-13). The AUCs of 
extracted MAB by adding DOC and chloroform were in comparison to the calibration 
curve in the absence of any lipids. Obviously, a good correlation was achieved 
between the detected AUCs of extracted and untreated MAB solutions. Based on 
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these data and an acceptable linearity the extraction by adding DOC and chloroform 
appeared suitable for MAB quantification for the in-vitro release studies.  
 
Figure VII-13. Calibration of MAB standard and extracted MAB from lipid containing samples, 
extraction was performed by adding DOC and chloroform, n=12. 
4.2.5. SUMMARY OF THE QUANTIFICATION METHOD 
The major criteria to develop the quantification method of the MAB for the in vitro 
release tests is the robustness against the variation of the lipid and protein content in 
the release fractions. For the CBQCA assay, the presence of lipids showed great 
interference on the fluorescence output. Different calibration curve of extracted MAB 
from lipid containing samples was observed from the lipid-free samples. Alternatively, 
a commonly used protein assay - micro BCA assay was used for the quantification of 
MAB. Calibration of the MAB standard was first established with good linearity and 
repeatability. Applying chloroform alone for MAB extraction could not eliminate the 
influence of the lipids when there was a large amount of lipids in the samples. It was 
assumed that there was interaction between the MAB and lipids. Therefore, DOC 
was used for the protein and lipid isolation before adding chloroform for extraction.  
As a result, the influence of the lipids was minimized. The calibration was established 
for the extracted MAB in simulation to the MAB standard samples in absence of lipids. 
In summary it could be stated that the micro BCA assay in combination with the 
developed extraction method using DOC and chloroform, suitable for the 
determination of MAB in the release fractions, was developed and validated for the 
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quantification of MAB in presence of liposomes taking the variation of lipid and 
protein amount into account. 
5. STABILITY STUDY OF MAB AT 37°C 
The influence of the manufacturing process on the integrity of MAB was studied by 
extracting the protein from VPGs and subsequent analysis by SDS-PAGE. As shown 
in Figure VII-5 similar bands were observed to the MAB standard. Encouraged by 
these results the question arose whether this excellent stability could also be 
maintained at elevated temperature during in-vitro release. To simulate the 
conditions during in-vitro release VPG formulations based on 450mg/g lipids and 
9.4mg/g MAB were incubated at 37°C in Eppendorf tubes. At predetermined points of 
time the samples were taken out and the protein was extracted by applying DOC and 
chloroform (as described above). For matters of comparison MAB solutions with a 
concentration of 9.4mg/g in PBS buffer (40mM) was incubated at 37°C.   
The recovery from the gel formulation was comparable with that observed with the 
liquid formulation (Figure VII-14). Both got little protein loss (less than 10%) after 14 
days incubation at 37°C.  
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Figure VII-14. Stability of MAB with a VPG formulation based on 450mg/g lipids and 9.4mg/g MAB 
compared to the protein stability in PBS buffer. Both the liquid and the gel formulation were incubated 
at 37°C (mean± standard deviation, n = 3 each).  
 
Beside the quantitative analysis of MAB during the incubation, SDS-PAGE was 
performed (as described previously see Chapter VII.3) to reveal the stability of the 
proteins at 37°C.  
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Figure VII-15. SDS-PAGE analysis of MAB stability incubated at 37°C:  (a) solution of MAB in PBS 
buffer pH 7.4, 9.4mg/ml. (b) MAB VPGs based on 450mg/g lipids and 9.4mg/g. The protein was 
extracted by applying chloroform.  
 
For both the MAB solutions (Figure VII-15a) and the MAB extracted from VPGs 
(Figure VII-15b), the band pattern observed from the incubated samples was the 
same as for the protein bulk materials. Therefore it could be stated the solution of 
MAB (PBS buffer pH 7.4) had good stability at 37°C. Also a good stability of MAB 
incorporated within the VPGs was revealed: compared to the protein standard no 
pronounced aggregation or degradation products showed up during the whole 
incubation period at 37°C.  
   (a)                                                        
Lane 1, MAB solution after 14 days incubation 
Lane 2, MAB solution after 12 days incubation 
Lane 3, MAB solution after 10 days incubation  
Lane 4, MAB solution after 8 days incubation 
Lane 5, MAB solution after 6 days incubation  
Lane 6, MAB solution after 4 days incubation 
Lane 7, MAB solution after 2 days incubation 
Lane 8, MAB solution after 1 days incubation 
Lane 9, MAB standard solution 
Lane 10, molecular weight  maker 
 
     (b)                                                          
Lane 1, MAB VPGs after 14 days incubation 
Lane 2, MAB VPGs after 12 days incubation 
Lane 3, MAB VPGs after 10 days incubation  
Lane 4, MAB VPGs after 8 days incubation 
Lane 5, MAB VPGs after 6 days incubation  
Lane 6, MAB VPGs after 4 days incubation 
Lane 7, MAB VPGs after 2 days incubation 
Lane 8, MAB VPGs after 1 days incubation 
Lane 9, MAB standard solution 
Lane 10, molecular weight  maker 
 
(a) 
(b) 
Chapter VII: MAB loaded VPGs 123
 
6. ADSORPTION OF MAB TO THE RELEASE SYSTEM 
It was observed for the EPO VPGs that protein release leveled off before reaching 
100% of the total protein incorporated. It was found that incomplete release of EPO 
from VPGs was mainly caused by unspecific adsorption onto the flow-through 
release system surfaces. Therefore, the adsorption of MAB to the release system 
was first evaluated before performing the in vitro release tests of MAB VPGs. The 
MAB solution (in PBS buffer pH 7.4) with a concentration of 10µg/ml was pumped 
through the release set with a flow rate of 1ml/hr over a time period of 11hrs. In 
contrast to the results of EPO, no adsorption of MAB was observed to the release 
system (Figure VII-16), which made it possible to expect 100% release of the total 
MAB incorporated into VPGs.   
 
Figure VII-16. Adsorption of MAB onto the in-vitro release system. The solution of MAB with a 
concentration of 10µg/ml was pumped through the release system with a flow rate of 1ml/hr. The 
system was incubated at 37°C. 
7. IN VITRO RELEASE BEHAVIOUR OF MAB (IGG) LOADED VPGS 
7.1. INFLUENCE OF THE LIPID CONTENT 
In vitro release tests of MAB VPGs were conducted at 37°C within flow through cells 
as described previously. PBS buffer (40mM) pH 7.4 was used as acceptor medium. 
The flow rate was set to 1ml/hr controlled by the syringe pump.  
VPGs were prepared with various lipid contents (Table VII-1a). The lipid content 
ranged from 350mg/g to 450mg/g. The MAB content within VPGs was 9.4mg/g in 
these formulations. In general, the influence of the lipid content on the release 
behavior was not pronounced (Figure VII-17). VPGs based on 350mg/g delivered 
89% of the total MAB loaded into VPGs over 600hrs (25 days), whereas VPGs 
Chapter VII: MAB loaded VPGs 124
 
containing 400mg/g released 90% over 750hrs (over 31 days) and VPGs based on 
450mg/g lipids released 100% over 1000hrs (over 41 days). Moreover, the initial 
release rate of VPGs based on 350mg/g lipids was much higher (ca. 16%). A close to 
zero-order release kinetics was observed for VPGs based on 400mg/g and 450mg/g 
lipids.  
 
Figure VII-17. Cumulative release of MAB from VPGs based on various contents of lipids (Mean± 
standard deviation, n = 3 each). The protein concentration in all formulations was 9.4mg/g. 
 
7.2. INFLUENCE OF THE MAB CONTENT 
In order to investigate the influence of the MAB content in VPGs on the release 
profiles, VPGs were prepared with various MAB content ranging from 9.4mg/g to 
37.4mg/g (Table VII-1b), while the lipid content was 450mg/g in all the formulations. 
For the three formulations, total release of entrapped MAB from VPGs was achieved 
over 1000hrs (over 41 days, Figure VII-18). In general, the MAB content within VPGs 
showed little influence on the release behavior. However, it was interestingly 
observed that there was a fast release phase for the VPGs based on 37.4mg/g MAB 
in the time period between 700hrs and 900hrs, which was probably caused by the 
accelerated erosion due to the lack of stiffness in the later phase of the release.   
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Figure VII-18. Cumulative release MAB from VPGs based on various contents of MAB (Mean± 
standard deviation, n = 3 each). The lipid concentration in all formulations was 450mg/g. 
 
7.3. QUANTIFICATION OF PHOSPHATIDYLCHOLINE CONTENT  
The LabAssay Phospholipid (Wako, Neuss, Germany) was used to quantify the 
phospholipid content in the release fractions based on the method described 
previously. The assay was performed by measuring the absorption at 600 nm. In 
Figure VII-19 it was shown that the release of lipids from various VPG formulations. 
Faster lipid erosion was observed for the VPGs based on 350mg/g lipids. Besides, 
the other formulations showed similar erosion profiles. Comparing the release 
profiles of MAB from VPGs (Figure VII-17 and Figure VII-18), it was found that the 
lipid erosion was in parallel with the protein release (Figure VII-20 showed the VPGs 
containing 37.4mg/g MAB and 450mg/g lipids for example). It could consequently be 
stated that erosion is the dominant mechanism controlling the release of MAB from 
VPGs, which is in agreement with former observations in the EPO release. 
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Figure VII-19a. Cumulative release amount of phospholipid from VPGs based on various lipid contents. 
(Mean± standard deviation, n = 3 each).  
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Figure VII-19b. Cumulative release amount of phospholipid from VPGs based on various MAB 
contents. (Mean± standard deviation, n = 3 each).  
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Figure VII-20. Daily releasae percentage of MAB and lipid from VPGs based on 450mg/g lipids and 
37.4mg/g MAB. (Mean± standard deviation, n = 3 each).  
Chapter VII: MAB loaded VPGs 127
 
7.4. SDS-PAGE OF THE RELEASED PROTEINS FROM VPGS 
The quality of released MAB from VPGs (Taking VPGs based on 450mg/g lipids and 
37.4mg/g EPO for example; only limited samples can be analyzed due to the low 
protein concentration in the release fractions.) was examined with SDS-PAGE. The 
proteins were extracted by adding DOC and chloroform subsequently (as described 
above) from release fractions. Non-reducing SDS-APGE were performed with silver 
staining. 50µl of extracted protein solutions were diluted into 100µl with Tris-buffer pH 
6.8 containing 2 % SDS. Electrophoresis was performed in a 7% Tris-acetate/SDS 
running buffer (Invitrogen). 
MAB recovered from release fractions of VPGs showed fraction bands similar to the 
MAB standard (Figure VII-21) despite that some fragment species in the standard 
were not detectable in the release samples (Some fragmentation fractions might be 
removed in the concentrating process). However, the release procedure of VPGs did 
not feature the creation of further aggregation or fragmentation species.  
                                   
 
 
 
 
                       Lane 1/2, MAB release after 216hr 
Lane 3/4, MAB release after 264hr 
Lane 5/6, MAB release after 192hr 
Lane 7, MAB standard solution 
Lane 8, molecular weight marker 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure VII-21. MAB stability from release samples of VPGs based on 450mg/g lipids and 37.4mg/g 
MAB. SDS-PAGE with silver staining.  
8. SUMMARY AND DISCUSSION 
In Chapter V and Chapter VI, EPO and G-CSF have been loaded into VPGs 
respectively. In vitro release tests showed the potential of VPGs for sustained 
delivery of these cytokines. Based on the previous work, the suitability of VPGs as 
the delivery system for the monoclonal antibody was evaluated. Various MAB VPG 
formulations were development which allowed an almost complete and sustained 
release of the entrapped antibody. 
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Initially, VPGs were prepared with various lipid and MAB contents. The obtained 
formulations were characterized by texture analyzer and rheometer. Increasing the 
lipid content could increase both of the gel strength and viscosity whereas 
incorporating more protein resulted in slightly decreased gel viscosity.  
Again, the influence of the formulation process on the stability of the entrapped 
proteins was evaluated. Taken the experiences from previous work, chloroform and 
several surfactants were tried out for MAB extraction. The extracted MAB by applying 
chloroform showed the same bands with the standard samples. It was consequently 
concluded that MAB maintained stable within VPGs after formulation process in DAC, 
which fulfilled the prerequisite for a successful sustained release system.  
For quantification of MAB in the release fractions from VPGs, CBQCA and micro 
BCA assay were tried out. However, the release samples could not be directly 
assayed since the lipids thereof got strong interference on the assay output. 
Moreover, the screening of extraction agents was limited for the both assays since 
some mostly used surfactants or organic (e.g. Triton X-100) were not compatible. 
Thus chloroform appeared the first choice for the MAB extraction in this case. 
Despite that the CBQCA assay was reported to work well in presence of lipids [255], 
it was found the results of the assay were influenced by the lipid content in the 
samples even though a major part of the lipids had been removed by applying 
chloroform. Besides, poor linearity and repeatability were observed for the CBQCA 
assay. As for the micro BCA assay, the protein recovery was also affected by the 
lipid content at a high concentration if adding chloroform alone for extraction. 
However, it was also found adding more chloroform could not efficiently change the 
extraction efficiency. Finally the extraction method was improved by using a 
surfactant – sodium deoxycholate before chloroform was added. The effect of the 
DOC (sodium deoxycholate) was assumed to reduce the interaction between the 
MAB and the lipids, and thus more lipids could be extracted to the organic phase by 
adding chloroform subsequently. The quantification method was established for the 
extracted MAB from lipid containing samples. A good correlation was generated for 
the results of the lipid containing and lipid-free samples. Based on the developed 
method, it was possible to quantify the MAB from VPGs or from VPGs’ release 
fractions.   
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Protein denaturation and/or aggregation were found occurring within the release 
period or during storage for PLGA based protein depot systems, which consequently 
correlated with the incomplete protein release [55, 208]. Thus, the stability of MAB 
within VPGs was examined after incubation at 37°C to simulate the conditions during 
the in vitro release tests. As a result, the stability of MAB from VPGs was comparable 
to the MAB solutions, for both of which little protein was lost after 14 days incubation 
at 37°C. SDS-PAGE also confirmed that MAB maintained the stability both in 
solutions and in VPGs. It could be stated that the encapsulation of MAB within the 
lipid matrix did not feature the creation of protein instabilities under the conditions 
during in vitro release tests.  
However, protein loss can also be induced by adsorption on exposed surfaces as 
amphiphilic molecule proteins tend to adsorb on interfaces. In the case of MAB, it 
was found that there was no protein lost after pumping the MAB solutions through the 
release set over a time period of 11hrs. Thus the unspecific adsorption of MAB could 
be excluded. Based on the promising results of the adsorption and stability study, it 
was expected 100% protein recovery could be achieved from the in vitro release 
tests.  
Then the in vitro release tests of various MAB VPG formulations were carried out. In 
general, the lipid content as well as the protein content incorporated into VPGs had 
no dramatic influence on the release profiles. All the formulations showed sustained 
release of MAB from VPGs over at least 600hrs: VPGs based on 350mg/g delivered 
89% of the total MAB within VPGs over 600hrs, whereas the other VPGs containing 
400mg/g or 450mg/g lipids released 90% over 750hrs. A close to zero-order release 
kinetics was observed for all the formulations. Linear fit was made for the release 
curves. Judged on the slope, it was found increasing either the lipid content or the 
MAB content could slight decrease the release rate. Moreover, it was shown that the 
initial release and daily release amount of MAB from VPGs could be modified by 
varying the compositions of the VPGs. In addition, SDS-PAGE analysis revealed that 
the stability was maintained of MAB released from VPGs. Therefore it can be stated 
that the VPG formulations feature the flexibility for therapeutically applications 
besides the fulfilled protein stability issues. 
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In addition, the release of lipids was found in line with MAB release. Thus erosion 
was proved to be the dominant mechanism controlling the MAB release from the lipid 
matrix which was in agreement with the results of EPO VPGs. 
In a summary, it can be concluded that the VPGs possess a great potential as an 
alternative approach to formulate depot delivery systems for MAB. The protein 
instability problems which always hampered the development of the other sustained 
release systems were solved by using VPGs. The MAB maintained the stability 
during system preparation, as well as within the release period. Moreover, the 
release profiles can be easily modified to achieve desired kinetics. 
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CHAPTER VIII: FINAL SUMMARY 
Within the scope of the present thesis, it was aimed to evaluate the potential of 
vesicular phospholipid gels as local depot system for protein delivery. Focus was 
also necessarily put on the development of suitable quantification methods for 
various proteins in presence of lipids to meet the requirement of the in vitro release 
tests.  
In Chapter I, the protein release systems are introduced in general. Background of 
the application of pharmaceutical proteins is first presented. Controlled release 
systems for protein delivery are reviewed into aspects of the polymeric systems and 
the lipid based systems.  The success and major limit of the polymer based PLGA 
and hydrogel systems are stated.  On the other hand, the increasing interest is 
revealed in the development of protein release devices based on lipidic materials. 
The principles of the lipid based systems and several promising features are 
presented. A close overview is focused on the novel lipid based systems: lipid 
implants, multivesicular liposomes, and vesicular phospholipid gels. The 
manufacturing technique and the related application are illustrated in details. 
The objectives of the thesis are summarized in Chapter II. Chapter III lists the 
materials and methods that are employed in the present work, where three different 
protein drugs are used: erythropoietin (EPO), granulocyte colony stimulating factor 
(G-CSF), and monoclonal antibody immunoglobulin G (MAB IgG) 
In Chapter IV, grounds are provided using FITC-Dextran as a macromolecular model 
for protein delivery from vesicular phospholipid gels. The high pressure 
homogenization and dual asymmetric centrifugation (DAC) technique were utilized 
for the production of VPGs. DAC appeared a suitable device for the lab-scale 
preparation of VPGs. The release system was set up with flow through cells for the in 
vitro release tests as described by Tardi[11]. Sustained release of FITC-Dextran from 
various VPG formulations was observed from ca. 50hrs up to more than 288hrs with 
zero-order kinetics. Incorporating higher amounts of lipids resulted in more delayed 
drug release. Importantly, the suitability of VPGs for the delivery of macromolecular 
compounds was demonstrated in this Chapter.  
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In the following chapters, three protein models (EPO (Chapter V), G-CSF (Chapter 
VI), and MAB (Chapter VII)) were loaded into the VPG matrices using the DAC 
method. The preparation protocol established by Massing [147] was optimized by 
including cooling steps in-between the multiple DAC runs to control the system 
temperature. Under microscopic observation, densely packed vesicle structures were 
observed for the prepared VPGs. Texture analysis and rheological test were 
performed to determine the gel characters, including the gel strength and viscosity, 
which might potentially influence the release behaviour of the system. It was found 
that the gel strength and viscosity increased with increasing the lipid content within 
the VPGs. The gel strength and viscosity were also influenced by varying the loading 
amount of proteins and changing the lipid compositions within the matrices. Moreover, 
the buffer ingredients contributed to the various values of the gel strength and 
viscosity of the VPGs containing the same content of lipids but various kinds of 
proteins. 
SDS-PAGE was performed to examine the influence of the formulation process by 
using DAC on the stability of various proteins. The presence of the matrix material-
lipids has shown influence on the protein bands of the electrophoresis results. Thus 
various extraction protocols for each protein were assessed aimed to eliminate the 
influence of the lipids. A case-by-case study was necessarily performed to exclude 
the influence of the addition of the extraction agents due to the different characters of 
various proteins. In general, EPO, G-CSF, and MAB all maintained the integrity 
within the matrices after the loading process.  
In vitro release tests of VPGs loaded with various proteins were performed using the 
established in vitro release system.  To determine the concentration of the released 
protein from VPGs, a quantification method for each protein was needed in presence 
of unknown contents of lipids.  For EPO (Chapter V), the addition of chloroform to 
dissolve the lipids was applied to the release fractions prior to the RP-HPLC 
quantification of EPO. The quantification in combination with the extraction protocol 
showed robustness against the variation of the protein concentration as well as the 
variation of the lipid content and lipid composition within the release samples. 
Sustained release of EPO was observed from various VPG-formulations over a time 
period of 280hours to over 400hrs. A close to zero-order kinetic was found without 
initial burst. Increasing the lipid content from 300mg/g to 550mg/g resulted in delayed 
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release of EPO from VPGs whereas the lipid content had little effect on the release 
profiles in the range from 400mg/g to 500mg/g. Furthermore, the lipid charge also 
had strong influence on the release behavior. Incorporating 20% of positively 
charged lipids (DOTAP) into VPGs resulted in a strongly accelerated release rate 
while adding 10% of negatively charged lipids (DPPA) delivered the incorporated 
protein in a comparable manner to the uncharged formulation. The lipid content 
released from VPGs was determined to study the matrix erosion which was found to 
be the dominant mechanism in controlling the EPO release from the matrices. The in 
vitro released EPO was analyzed with SDS-PAGE and was found to be unchanged 
as compared to standard materials. The release fractions were shown containing free 
EPO and EPO liposomes (in the range up to 300nm).  
For the quantification of G-CSF (Chapter VI), a RP-HPLC method was developed 
where N,N-Dimethylformamid was used to precipitate the lipids in the release 
samples. The extraction method worked under the conditions of low pH value (pH 3.5) 
which favoured the stability of G-CSF.  The in vitro release tests have demonstrated 
the potential of VPGs for sustained delivery of growth factors. A sustained release of 
G-CSF from various VPG-formulations was observed following zero-order kinetic too. 
Increasing the lipid content within the matrices resulted in slower release rate. About 
63% of the total entrapped G-CSF was delivered from the VPGs containing 400mg/g 
lipids and 4.0mg/g G-CSF over 408hrs (17 days) whereas VPGs containing 450mg/g 
lipids delivered 43% and VPGs containing 490mg/g lipids delivered 35% within the 
same period. Moreover, VPGs containing a higher content of G-CSF (8.4mg/g) 
revealed a slower release of 11% within 408hrs (17 days). However, the in vitro 
release conditions (pH 7.4, at 37°C) did not favor the stability of G-CSF, which 
contributed to the incomplete release of G-CSF from VPGs. To reveal the suitability 
of VPGs for the local application, G-CSF loaded VPGs will now be implanted to the 
rupture of tendons in vivo. The experiment will be performed using rats as animal 
model. The healing effect (e.g. histology) and the pharmacokinetics of the G-CSF 
VPGs will be evaluated. ELISA (Quantikine G-CSF Immunoassay) was developed for 
the quantification of G-CSF in the serum samples. However, the in vivo studies can 
not be included into this thesis since the authorization by the clinical committee had 
been delayed.  
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The study on the EPO VPGs and G-CSF VPGs has shown the potential of the 
system for the delivery of cytokines. In order to investigate the feasibility of the VPGs, 
the monoclonal antibody (MAB) loaded VPGs were developed and evaluated in the 
Chapter VII. A micro BCA assay was used for the determination of MAB content in 
the VPGs’ release fractions. Sodium deoxycholate was added to eliminate the 
influence of lipids within the samples prior to the assay.  The release profiles of MAB 
from VPGs were little influenced by the lipid and protein content within the 
formulations. Sustained release of MAB was observed over 1000hrs (42days) 
following zero-order kinetics. Again, it was shown that erosion was the dominating 
mechanism controlling the protein release from VPGs. In addition, the protein 
integrity was maintained in the release fractions analyzed by SDS-PAGE.  
In summary, the development of VPGs can be considered as the most promising 
strategy for sustained local protein delivery. Accordingly, major achievements were 
reached in the context: First, the manufacture process was shown to be suitable for 
the production of VPGs with loading of proteins. Second, the suitability of the lipid 
based VPG system was revealed in vitro for the sustained delivery of various kinds of 
proteins. A long term release (over a couple of weeks) was observed following the 
zero-order kinetics. As conclusion, the knowledge obtained so far should enable to 
transfer the developed system to a variety of other pharmaceutical proteins. 
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